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Stellingen behorende bij het proefschrift : 
 
Radiofrequency catheter ablation in atrial arrhythmias: Insights into 
pre-procedural evaluation and procedural guidance 
 
1. Comprehensive evaluation of left atrial remodeling allows identification of patients with a 
high likelihood to maintain sinus rhythm after radiofrequency catheter ablation of atrial 
fibrillation. (This thesis) 
2. Left atrial size, pulmonary vein anatomy, natriuretic peptide levels, left atrial fibrosis and 
total atrial conduction time are predictors of atrial fibrillation recurrence after 
radiofrequency catheter ablation. (This thesis) 
3. Integration of intracardiac echocardiography and multi-slice computed tomography 
combines the advantages of a real-time imaging modality and high resolution three-
dimensional imaging. (This thesis) 
4. 
congenital heart disease by visualizing the complex cardiac anatomy in its relation to the 
position of the ablation catheter. (This thesis) 
5. The high lifetime risk for AF underscores the important public health burden posed by AF. 
(Lloyd-Jones et al, Circulation. 2004 Aug 31;110(9):1042-6) 
6. Catheter ablation is currently recommended in patients with symptomatic atrial fibrillation 
unresponsive or intolerant to at least one Class 1 or 3 antiarrhythmic drug. (Calkins et al, 
Europace. 2012 Apr;14(4):528-606) 
7. In the last decade the number of ablation procedures performed to treat atrial fibrillation 
has nearly doubled, however the success rate does not seem to have improved. (Cappato 
et al, Circ Arrhythm Electrophysiol. 2010 Feb;3(1):32-8) 
8. A careful assessment of the risks and benefits should be made for each patient considered 
for radiofrequency catheter ablation for atrial fibrillation. (Calkins et al, Europace. 2012 
Apr;14(4):528-606) 
9. I have no special talent. I am only passionately curious. (Albert Einstein, 1879-1955) 
10. Time you enjoy wasting was not wasted.  (John Lennon, 1940-1980) 
11. The only true wisdom is in knowing you know nothing. (Socrates, 469 BC-399 BC) 
12. If a problem is fixable, then there is no need to worry. If it's not fixable, then there is no help 
in worrying. (Dalai Lama, 1935-present) 
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General Introduction and Outline of the Thesis 
Radiofrequency catheter ablation (RFCA) has become an important treatment 
option in the management of supraventricular arrhythmias such as 
atrioventricular (nodal) re-entry tachycardia, atrial tachycardia, atrial flutter and 
atrial fibrillation (AF). Particularly in the management of AF the number of RFCA 
procedures performed is growing rapidly.1 Three-dimensional 
electroanatomical mapping combined with non-invasive imaging is currently a 
state of the art technique to guide RFCA for complex arrhythmias such as AF 
ablation, providing information on anatomical landmarks and arrhythmogenic 
substrate with higher accuracy and with less radiation exposure than 
fluoroscopy or conventional catheter based mapping. Importantly, accurate 
characterization of the arrhythmogenic substrate and the underlying 
mechanisms of the arrhythmia as well as visualization of anatomical landmarks 
are pivotal to optimize the results of RFCA.2 Comprehensive pre-procedural 
evaluation may help to identify the appropriate substrate as well as to identify 
patients with a high likelihood to benefit from a RFCA procedure. 
 
Pre-procedural Evaluation of Patients undergoing Radiofrequency 
Catheter Ablation for Atrial Fibrillation 
Atrial fibrillation is the most common sustained cardiac arrhythmia in the 
developed world, with an estimated prevalence of 1-2 %.3 Atrial fibrillation is 
associated with an increased risk for thromboembolic complications (e.g. 
stroke), congestive heart failure, hospitalisation and mortality.3-5 As a result of 
the global population aging, the prevalence of AF is expected to at least 
double in the next 50 years. Consequentially, AF poses a major problem to 
society in terms of medical, social and economic expenses.  
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 Management of AF is targeted at the prevention of AF related 
complications (e.g. stroke, tachycardiomyopathy) and at the reduction of AF 
related symptoms.3 Prevention of complications is based on antithrombotic 
therapy, reduction of ventricular response rate and adequate treatment of 
concomitant cardiac disease. Although these therapies may already reduce 
symptoms, additional restoration of the sinus rhythm can result in further relief 
of symptoms. Sinus rhythm can be restored by cardioversion, antiarrhythmic 
medication and/or ablation therapy. Radiofrequency catheter ablation for AF is 
currently reserved for patients with symptomatic AF, refractory or intolerant to 
at least one Class 1 or 3 anti-arrhythmic drugs.2 
The success of surgical treatment of AF in the early 1990s has led to an 
interest in the field of interventional cardiology to reproduce these results by 
creating a set of lesions similar to the surgical procedures using RFCA.2 These 
approaches were based on the theoretical model by Moe et al. that a critical 
number of AF wavelets was needed to sustain AF.6 The lesions set were 
designed to limit the number of circulating wavelets thereby avoiding the 
development and maintenance of AF. In the later 90s, Haïssaguerre et al. made 
the landmark observation that AF could be spontaneously initiated by ectopic 
beats originating from the pulmonary veins and that subsequent ablation of 
these ectopic foci could successfully cure patients.7 These observations rapidly 
increased the increased interest in RFCA for AF and directed the attention to 
the pulmonary vein region. Currently, RFCA for AF is a rapidly evolving 
treatment modality that gains popularity.1 A large variety of ablation strategies 
have evolved, however the pulmonary vein region remains the cornerstone of 
most RFCA procedures.1,2 However, with a reported success rate of 66-89 %, not 
all patients benefit from RFCA for AF.1,2 In addition, RFCA for AF is associated 
with a small but relevant risk for serious complications (e.g. tamponade, stroke, 
General Introduction and outline of the thesis 
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atrio-esophageal fistula).1  To improve the outcome of RFCA for AF and avoid 
unnecessary procedure related risks a proper patient selection is mandatory. 
The current Heart Rhythm Society/European Heart Rhythm 
Association/European Cardiac Arrhythmia Society expert consensus statement 
on catheter and surgical ablation of AF, recommends careful assessment of the 
risks and benefits of RFCA in each patient.2 Ideally, the likelihood of sinus 
rhythm maintenance after RFCA should be estimated based on clinical 
characteristics, imaging studies and biochemical results. Risk factors for AF 
recurrence after RFCA are non-paroxysmal AF (persistent or longstanding), 
sleep apnea syndrome/obesity, left atrial enlargement, increased age, 
hypertension, concomitant structural heart disease and a high extent of left 
atrial fibrosis.8-12 However, the evidence demonstrating the accuracy of these 
risk factors to properly identify patients with a high probability of maintaining 
sinus rhythm after RFCA is limited. Therefore additional markers, for example 
new markers derived from imaging technique or biochemical analyses, are 
needed to improve the patient selection. 
 
Echocardiography 
Atrial fibrillation causes electrical and structural changes to the atria which play 
an important role in the perpetuation and progression of the arrhythmia.13,14 
This process is referred to as atrial remodeling. A large extent of atrial 
remodeling is associated with a limited efficacy of RFCA for AF.11 Therefore, pre-
procedural assessment of the extent of atrial remodeling could be used to 
identify patients with a high risk for AF recurrence after RFCA. Measurement of 
left atrial size is the most common used method to estimate the extent of atrial 
remodeling. Left atrial size is an independent predictor of AF in the general 
population as well as a well-recognized risk factor for AF recurrence after 
RFCA.9,15-17 However as a selection criterion the clinical applicability of left atrial 
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size is limited. Recently the use of contrast-enhanced magnetic resonance 
imaging to visualize, localize and measure atrial fibrosis in patients with AF was 
demonstrated.18,19 However, despite the promising results, contrast-enhanced 
magnetic resonance imaging is not widely available in clinical practice and 
therefore alternative and better available methods to assess atrial remodeling 
are needed. In this regard, novel echocardiographic techniques provide 
information about atrial remodeling additional to left atrial dimensions, such as 
left atrial function (e.g. tissue Doppler imaging derived left atrial strain) and 
myocardial tissue properties (e.g. calibrated integrated backscatter derived left 
atrial fibrotic content and tissue Doppler imaging derived electromechanical 
delay [PA-TDI]). 
Left atrial strain is an echocardiographic technique to assess the active 
contraction and relaxation of the atrial myocardium. In contrast to 
conventional methods to assess left atrial function (i.e. calculated from phasic 
volumes), left atrial strain is less dependent on loading conditions and provides 
information of the regional function of the myocardium. Kuppahally and 
coworkers demonstrated that left atrial strain and strain rate (assessed with 
speckle tracking echocardiography) correlated with the amount of left atrial 
fibrosis (assessed with contrast-enhanced magnetic resonance imaging) in 
patients with AF: patients with large areas of fibrosis had more impaired left 
atrial strain and strain rate.20 In addition, these parameters have been 
associated with the burden of AF and with the outcomes of RFCA. In a recent 
study including 148 patients undergoing RFCA for AF, baseline left atrial strain 
was an independent determinant of favorable left atrial reverse remodeling at 
follow-up.21 
Integrated backscatter is an echocardiographic technique that allows 
non-invasive characterization of cardiac tissue and may provide an alternative 
tool to estimate left atrial fibrosis and thereby atrial substrate remodeling.22-24 
General Introduction and outline of the thesis 
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Calibrated integrated backscatter is based on the quantification of ultrasound 
energy reflected by scattering elements inside the myocardium. Integrated 
backscatter can be measured using two-dimensional echocardiographic gray-
scale images and provides a global estimate of the fibrotic content of the left 
atrial wall.  
The total atrial conduction time is determined by atrial size and conduction 
velocity and is thereby a marker of both electrical and structural remodeling of 
the atria. Echocardiographic assessment of the total atrial conduction time 
using tissue Doppler imaging (PA-TDI duration) may allow a more 
comprehensive estimation of the extent of atrial remodeling than left atrial size 
alone. The PA-TDI duration is measured as the time delay between the onset of 
the P- -wave on the tissue 
Doppler tracing of the left atrial lateral wall (Figure 1).25 The PA-TDI duration 
has been validated against P-wave duration on signal-averaged 
electrocardiography and has previously been used to identify patients with an 
atrial substrate vulnerable to develop AF.26-28  
 
Multi-slice computed tomography 
Multi-slice computed tomography (MSCT) is nowadays commonly acquired 
prior to RFCA for AF to plan and guide the ablation procedure.2 MSCT contains 
information about pulmonary vein anatomy, pulmonary vein dimensions and 
the presence and extent of coronary artery disease. Potentially, pulmonary vein 
anatomy and dimensions could be of influence on the efficacy or RFCA lesion 
placement and the presence of coronary artery disease could have a negative 
impact on the efficacy of pulmonary vein isolation. Moreover, MSCT allows a 
more comprehensive evaluation of left atrial dimensions than two-dimensional 
echocardiography.29 Potentially, this information could be used to improve the 
patient selection for RFCA for AF. 
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Figure 1. Measurement of the total atrial conduction time (PA-TDI duration). A fixed 9x9 pixel region of 
interest (yellow) was positioned in the left atrial lateral wall on a tissue Doppler recording to obtain a tracing 
of the mechanical activation in this area (yellow tracing). A simultaneously acquired registration of surface 
electrocardiogram lead II (blue tracing) was displayed underneath the tissue Doppler tracing. The PA-TDI 
duration (arrow) was assessed by measuring the time interval between the onset of the P-wave in lead II and 
-wave on the tissue Doppler tracing. 
 
Natriuretic peptides 
Natriuretic peptides are hormones released from the atria and/or ventricles in 
response to volume or pressure overload and result in natriuresis.30 Atrial 
natriuretic peptide is secreted primarily from the atria whereas B-type 
natriuretic peptide is primarily released from the ventricles.30 It has been well 
recognized that in patients with AF, natriuretic peptide levels are elevated.31,32 
However it remain unclear whether this is solely caused by the presence of AF 
or reflects an underlying cardiac condition.33 Elevated natriuretic peptides have 
been identified as a predictor of new-onset AF in the general population and 
have been related to a higher risk for AF recurrence after RFCA.34-36 Potentially, 
natriuretic peptide levels can provide information about underlying cardiac 
General Introduction and outline of the thesis 
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conditions that limit the efficacy of RFCA for AF and could therefore be a 
valuable addition.  
 
Imaging to facilitate Radiofrequency Catheter Ablation of complex 
Atrial Arrhythmias 
As RFCA procedures become more complex, the need for adequate 
visualization of cardiac and surrounding structures increases.2 Currently, most 
RFCA procedures are guided by fluoroscopy, allowing real-time visualization of 
intracardiac catheters. However, fluoroscopy does not allow visualization of 
anatomical structures such as the pulmonary veins and causes radiation 
exposure to both patient and operator. Alternatively, electroanatomical 
mapping systems have been developed that allow non-fluoroscopic navigation 
and can create a three-dimensional reconstruction of the cardiac anatomy 
using point-by-point contact mapping. Similar to fluoroscopy, 
electroanatomical mapping does not allow visualization of all cardiac 
structures and surrounding anatomy. 
 MSCT allows detailed visualization of the cardiac anatomy and can be 
integrated with an electroanatomical mapping system to facilitate RFCA 
procedures.37 By performing a segmentation and registration process, a three-
dimensional shell of the cardiac anatomy can be merged with the 
electroanatomical map of the heart thereby combining the advantages of non-
fluoroscopic navigation with the anatomical information of MSCT. However, 
the validity of using this approach is highly dependent on the accuracy of the 
registration process.38,39 Differences in fluid status, heart rhythm and heart rate 
between the time of MSCT acquisition and the RFCA procedure potentially 




Intracardiac echocardiography allows real-time visualization of 
important cardiac structures and can be used to guide lesion placement during 
RFCA.40 In left-sided procedures (i.e. AF procedures or left atrial tachycardia), 
intracardiac echocardiography can be used to facilitate a safe transseptal 
puncture. Moreover, intracardiac echocardiography can be used to monitor 
and titrate energy delivery and allows for early detection of complications (e.g. 
thrombus formation on catheters or sheats, pericardial effusion).40,41 However, 
intracardiac echocardiography provides two-dimensional images and lacks the 
3-dimensional information that can be acquired using MSCT. 
Ideally, RFCA procedures are guided by an imaging modality that 
provides real-time 3-dimensional visualization of the intracardiac catheters in 
relation to both cardiac and surrounding anatomy with low radiation exposure 
to patient and operator. In practice, such an imaging modality is not yet 
available. However, several mapping and fluoroscopy systems are being 
developed that allow integration of several imaging modalities.42-44 An 
integrated approach using a combination of imaging modalities (e.g. 
fluoroscopy, electroanatomical mapping, MSCT and/or intracardiac anatomy) 
allows the operator to combine the advantages of these different techniques 
(Figure 2). The optimal combination has not yet been established but most 
likely depends on the type of patient, the operators experience and the 
availability of each imaging technique. 
 
Outline of the Thesis 
The objectives of this thesis were (1) to study the incremental value of new 
diagnostic markers on the pre-procedural evaluation of patients undergoing 
RFCA for AF and (2) to study the role of imaging to facilitate RFCA for complex 
atrial arrhythmias. 
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Figure 2. Example of integration of different imaging modalities to facilitate radiofrequency catheter 
ablation of complex atrial arrhythmia. The integration of electroanatomical mapping, intracardiac 
echocardiography and multi-slice computed tomography combines non-fluoroscopic navigation, real-time 
visualization of important cardiac structures and highly detailed three-dimensional anatomical information 
that can be used to guide the ablation procedure. 
 
 In part I, the impact of echocardiography, MSCT and biochemical 
markers on the efficacy of RFCA for AF is discussed. First, Chapter 1 reviews the 
limitations of left atrial size as a criterion to select patients with a high 
likelihood to maintain sinus rhythm after RFCA for AF. Then Chapter 2 focusses 
on the impact of left atrial fibrosis, assessed using echocardiography derived 
calibrated integrated backscatter, on the efficacy of RFCA for AF. Importantly, 
the interaction of left atrial size and atrial fibrosis on the efficacy of RFCA for AF 
is discussed. In Chapter 3 the impact of the total atrial conduction time (PA-TDI 
duration) on the efficacy of RFCA for AF is studied. Similar to the chapter 2, a 
comparison with left atrial size was made and discrepancies between left atrial 
size and PA-TDI duration were highlighted. In Chapter 4 the impact of 
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coronary artery disease on MSCT on the efficacy of RFCA for AF is discussed. 
Chapter 5 focusses on the impact of pulmonary vein anatomy and dimensions 
on the efficacy of RFCA for AF. Furthermore, this chapter evaluates the 
incremental value of 3-dimensional evaluation of left atrial dimensions on 
MSCT compared to left atrial size on echocardiography. Finally, Chapter 6 
evaluates the prognostic value of atrial natriuretic peptide and B-type 
natriuretic peptide to predict AF recurrence after RFCA. In addition, a 
comprehensive echocardiographic evaluation of atrial volumes, ventricular 
volumes and ventricular systolic and diastolic function was performed. The 
prognostic impact of serum natriuretic peptide levels was studied in relation to 
these echocardiographic parameters. 
 In part II, the use of intracardiac echocardiography, MSCT and 
electroanatomical mapping to facilitate RFCA for complex atrial arrhythmias is 
discussed. Chapter 7 comprises a review of the use of intracardiac 
echocardiography during electrophysiological and other interventional 
procedures. Chapter 8 further advances on the role of integration imaging to 
guide RFCA for AF and Chapter 9 describes the integration of intracardiac 
echocardiography and electroanatomical mapping to successfully treat a 
patient with recurrent atrial tachycardia after a Senning operation for 
transposition of the great arteries. Finally, Chapter 10 describes the use of 
electroanatomical mapping to facilitate RFCA of an atrioventricular nodal re-
entry tachycardia in a patient who previously underwent a Mustard operation 
for transposition of the great arteries. In addition, the anatomical situation 
following the Mustard operation and its implications to perform RFCA are 
discussed. 
 
General Introduction and outline of the thesis 
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Radiofrequency catheter ablation (RFCA) is a curative treatment option for 
patients with atrial fibrillation (AF). However, this treatment modality is 
associated with a considerable recurrence rate and a small risk for serious 
complications.1 To improve the success rate and to avoid unnecessary 
procedure-related risks in patients with a high likelihood of AF recurrence, 
proper patient selection is mandatory. According to the Heart Rhythm 
Society/European Heart Rhythm Association/European Cardiac Arrhythmia 
Society expert consensus statement, considerations in the selection of patient 
for AF ablation should include: severity of symptoms, age, duration of AF, and 
left atrial (LA) diameter.2 However, as an alternative to LA diameter, a more 
of patients with a high likelihood of maintaining sinus rhythm after RFCA.  
Abecasis et al.3 prospectively investigated the use of LA volume 
assessed by multi-slice computed tomography (MSCT) as a predictor of 
successful ablation for AF. Ninety-nine consecutive patients undergoing 
circumferential pulmonary vein ablation were studied. A pre-procedural MSCT 
examination was performed in all patients and LA volume was measured using 
semi-automatic software to detect the endocardial borders. The authors 
demonstrated that an increase in the LA volume on MSCT was related to 
increased risk for AF recurrence after RFCA. Using ROC curve analysis, a cut-off 
value of 145 mL for LA volume was identified to provide the best predictive 
value for recurrent AF after RFCA.  
LA enlargement is considered an important risk factor for AF. In the 
Framingham Heart Study, LA enlargement was found to be an independent 
predictor of new onset AF in the general population.4 Moreover, LA 
enlargement has been identified as a risk factor for AF recurrence after RFCA. In 
a group of 148 patients, Berruezo et al.5 demonstrated that the anterior
posterior LA diameter was an independent predictor of AF recurrence after 
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RFCA. This finding was confirmed by Shin et al.6 who demonstrated the 
predictive value of LA volume for AF recurrence after RFCA in a group of 68 
patients. Significantly dilated atria are generally thought to be associated with 
a high degree of atrial remodelling which limits the efficacy of RFCA. As a 
consequence, many clinical trials on RFCA for AF have restricted their 
enrolment to patients with an LA anterior posterior diameter of <50 55 mm. 
However, when using LA enlargement as a patient selection criterion, it should 
be noted that the LA anterior posterior diameter is not the most accurate 
7 Owing to constraints of the thoracic cavity, 
LA enlargement is often asymmetric and oriented predominantly in superior
inferior and medial lateral direction. Therefore, the application of the anterior
posterior diameter to select patients eligible for RFCA may be limited. This was 
demonstrated by Abecasis et al. who showed that LA volume on MSCT was 
related to the outcome of RFCA, whereas the LA anterior posterior diameter 
on transthoracic echocardiography was not.3 The most likely explanation for 
this finding is that three-dimensional imaging modalities like MSCT provide a 
-dimensional 
echocardiography and therefore have a higher prognostic value for the 
outcome after RFCA.7 Accordingly, a similar prognostic value is expected when 
using other three-dimensional imaging modalities to assess the LA size such as 
three-dimensional echocardiography. Importantly, MSCT is associated with a 
considerable amount of radiation exposure which limits its applicability as a 
patient selection tool. Alternatively, three-dimensional echocardiography 
allows the accurate assessment of cardiac volumes without radiation exposure 
and can also be used to monitor functional improvement or reverse 
remodelling of the atria after RFCA.8,9 In contrast to MSCT, three-dimensional 
echocardiography does not provide information about the pulmonary vein 
anatomy, which is essential for safety of RFCA. Magnetic resonance imaging 
LA size to predict successful RFCA for AF 
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provides information about the pulmonary vein anatomy and allows the 
accurate assessment of LA volume without radiation exposure.10 However, the 
use of magnetic resonance imaging is limited by its limited availability and 
high costs.  
In conclusion, as demonstrated by Abecasis et al.,3 accurate assessment 
of LA volume using a three-dimensional imaging modality is essential for 
improvement of patient selection for RFCA of AF. Three-dimensional imaging 
-
dimensional imaging and has a higher prognostic value for outcome after 
RFCA. The available three-dimensional imaging modalities include MSCT, 
magnetic resonance imaging, and three-dimensional echocardiography. 
Importantly, each of these imaging modalities has its own advantages and 
limitations. Nevertheless, all can be used to accurately assess LA size, which 
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Background: Left atrial (LA) dilatation is an important risk factor for recurrence 
of atrial fibrillation (AF) after radiofrequency catheter ablation (RFCA). However 
the clinical application to select patients eligible for RFCA according to LA size 
is limited. Additional pre-procedural assessment of LA fibrosis could improve 
patient selection for RFCA.  
Objective: To investigate the impact of LA size and LA fibrosis on the outcome 
of RFCA for AF. 
Methods: One-hundred-seventy consecutive patients undergoing RFCA for AF 
were studied. Left atrial size was assessed by measuring maximum LA volume 
index on echocardiography. LA wall ultrasound reflectivity was assessed by 
measuring echocardiography derived calibrated integrated backscatter (IBS) as 
a surrogate of LA fibrosis.  
Results: After 12 ± 3 months follow-up, 103 patients (61%) had maintained 
sinus rhythm and 67 patients (39%) had recurrence of AF. Univariate Cox 
analyses identified LA wall ultrasound reflectivity, as well as LA size and type of 
AF, as predictors of AF recurrence after RFCA. Importantly, multivariate 
analyses showed that LA ultrasound reflectivity remained as strong predictor 
after correction for LA size and type of AF. Moreover, LA wall ultrasound 
reflectivity provided an incremental value in predicting outcome of RFCA over 
LA size and type of AF (increment in global Chi-square 61.6, p<0.001). 
Conclusion: Assessment of LA fibrosis using two-dimensional 
echocardiography derived calibrated IBS can be useful to predict AF recurrence 
after RFCA. Combined assessment of LA fibrosis and LA size improves the 
identification of patients with a high likelihood for a successful ablation. 





Radiofrequency catheter ablation (RFCA) is a curative treatment option for 
patients with symptomatic drug-refractory atrial fibrillation (AF).1 However, 
RFCA is associated with a considerable recurrence rate.2 To improve the 
outcome of RFCA proper patient selection is mandatory. 
Left atrial (LA) enlargement and LA fibrosis are two of the mainstay 
processes involved in atrial remodeling. LA size is a well recognized risk factor 
for AF recurrence after RFCA.3-5 Previous studies have demonstrated that in 
patients with severe atrial dilatation, the risk for AF recurrence after RFCA is 
high.3-5 However, in patients with mild-to-moderate LA enlargement, the AF 
recurrence rates are still significant and, therefore, the predictive value of LA 
size is reduced. In addition, LA fibrosis has been related to high probability of 
AF recurrence after RFCA.6 Non-invasive evaluation of the extent of atrial 
remodeling by assessment of LA fibrosis additional to LA size could be used to 
improve patient selection for AF ablation.  
 Two-dimensional echocardiography derived integrated backscatter 
(IBS) allows non-invasive tissue characterization based on tissue ultrasound 
reflectivity and may provide a good surrogate of myocardial fibrosis.7,8 
Recently, calibrated IBS has been demonstrated to provide a reliable 
assessment of LA fibrosis.9  
The aim of this study was to investigate the impact of LA wall ultrasound 
reflectivity assessed with calibrated IBS (as a surrogate of LA fibrosis) on the 
outcome of RFCA for AF. In addition, the relative merits of LA size and LA wall 





Patient population and evaluation 
One-hundred-and-seventy patients undergoing RFCA for AF were studied. 
Before the ablation, all patients underwent transthoracic echocardiography to 
assess LA size, left ventricular (LV) systolic function and to exclude valvular 
heart disease. In addition, IBS analysis was performed to estimate LA wall 
ultrasound reflectivity as a surrogate of LA fibrosis. After the ablation, all 
patients were evaluated at the outpatient clinic during a 12-month follow-up 
period. Routine electrocardiogram (ECG) recordings were acquired each visit 
and 24-hour Holter registrations were scheduled after 3, 6 and 12 months 
follow-up. All medications were continued for at least 3 months. Afterwards, 
anti-arrhythmic drugs were discontinued at the discretion of the physician. 
After a blanking period of 3 months, recurrence of AF was defined as any 




Two-dimensional transthoracic echocardiography was performed using a 
commercially available ultrasound system (Vivid 7, General Electric Vingmed, 
Milwaukee, WI), equipped with a 3.5-MHz transducer. All patients were imaged 
in left lateral decubitus position. Two-dimensional and color Doppler data were 
obtained in the parasternal short- and long-axis views and the apical 2- and 4-
chamber views, adjusting gain settings and depth. All images were ECG-
triggered and stored in cineloop format for off-line analyses (EchoPac 108.1.5, 
General Electric Medical Systems, Horten, Norway). Maximum LA volume was 
obtained from the apical 4- and 2-
indexed to body surface area.10 Left ventricular ejection fraction was calculated 
Impact LA fibrosis and LA size on outcome RFCA for AF 
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from the standard apical 2- and 4-chamber views by Sim
according to the American Society of Echocardiography guidelines.10 
 
Calibrated integrated backscatter 
Integrated backscatter is an echocardiographic parameter based on two-
dimensional gray-scale images which measures the myocardial ultrasound 
reflectivity and can be used to estimate myocardial fibrosis.11-13 Integrated 
backscatter is expressed in decibels (dB) and, conventionally, cardiac structures 
with no fibrotic content have a low ultrasound reflectivity and are coded with 
negative IBS values (e.g. blood pool) whereas cardiac structures with a high 
content of fibrosis have a high ultrasound reflectivity and IBS values near 0 dB 
(e.g. pericardium). Normal myocardium has an intermediate IBS value which 
increases as the content of fibrosis increases.8 In the present study, fibrosis of 
the LA was evaluated by measuring calibrated IBS of the LA wall. For this 
purpose, two-dimensional gray-scale images were obtained from the 
parasternal long-axis view, with frame rates between 80 and 120 frames/s. 
Three cardiac cycles were stored in cine-loop format for offline analysis 
(EchoPAC 108.1.5, General Electric Medical Systems). A fixed 2 x 3 mm region of 
interest was positioned in the LA posterior wall, excluding epicardial specular 
reflections. In addition, the 2 x 3 mm region of interest placed at the 
pericardium provided the reference value of ultrasound reflectivity to estimate 
the calibrated IBS value of the LA. Calibrated IBS of the LA was calculated by 
subtracting the IBS value of the pericardium from the IBS value of the posterior 
LA wall. Accordingly, higher values (i.e. less negative values) of calibrated IBS 
correspond to a larger extent of atrial fibrosis. All IBS values were measured 




Radiofrequency catheter ablation  
The ablation was aimed at creating circular lesions around the left and right 
pulmonary vein ostia. All patients received intravenous heparin to maintain an 
activated clotting time of 300-400 s. Intracardiac echocardiography was used to 
exclude a cardiac thrombus and to guide the transseptal puncture. A non-
fluoroscopic electroanatomical mapping system with multi-slice computed 
tomography integration was used to guide the ablation procedure (CARTO 
XPTM, CartomergeTM, Biosense Webster, Diamond Bar, CA, USA). Mapping and 
ablation was performed using a 4-mm quadripolar open-loop irrigated 
mapping/ablation catheter (7Fr NavistarTM, Biosense Webster). Radiofrequency 
current was applied at 30-35 W with a maximum temperature of 45°C and an 
irrigation flow of 20 ml/min until a bipolar voltage of <0.1 mV was achieved, 
with a maximum of 60 s per point. Pulmonary vein isolation was confirmed by 
recording entrance block during sinus rhythm or pacing in the coronary sinus.14  
 
Statistical analysis 
All variables were tested for a normal distribution with the Kolmogorov-
Smirnov test. Continuous variables with a normal distribution are presented as 
mean ± SD -test. Continuous variables 
with a non-normal distribution are presented as median (25th-75th percentile) 
and statistical comparisons were performed with the Mann-Whitney U-test. 
Categorical variables are presented as number (percentage) and were 
compared with the chi-square test. Univariate and multivariate Cox 
proportional hazard analyses were performed to investigate the relation 
between calibrated IBS of the LA and risk for AF recurrence after catheter 
ablation. Variables with a p<0.05 in the univariate analyses were included in the 
multivariate analysis which was performed using an 
incremental value of calibrated IBS of the LA over baseline clinical and 
Impact LA fibrosis and LA size on outcome RFCA for AF 
 
 39 
echocardiographic characteristics to assess the risk for AF recurrence was 
studied by calculating the improvement in global chi-square. Finally, to test the 
reproducibility of the calibrated IBS measurements, 20 patients were randomly 
selected to evaluate the inter- and intra-observer variability. The 
measurements of calibrated IBS of the LA posterior wall were repeated by the 
same observer in a blinded-fashion and at a separate time (1 week later). To 
evaluate inter-observer variability, a second independent observer re-analyzed 
the same dataset. Intra- and inter-observer reproducibility were calculated with 
the Bland-Altman analysis and the intraclass correlation coefficient. Good 
In addition, the test-retest 
variability of measurement of echocardiographic calibrated IBS was assessed in 
20 patients. Two echocardiograms were performed within 24 hours in each 
patient and the data were analyzed by the same observer. All statistical 
analyses were performed with SPSS software (version 16.0, SPSS Inc., Chicago, 
IL, USA). A value of p<0.05 was considered statistically significant. 
 
Results 
Patient characteristics  
A total of 170 consecutive patients were included (131 men, mean age 56±9 
years), representing an ongoing clinical registry.15 AF was paroxysmal in 121 
patients and persistent in 49 patients according to current guidelines 
definitions.16 Median duration of AF was 48 months (interquartile range: 24-96) 
and the mean number of anti-arrhythmic drugs used was 3.3 ± 1.3 per patient. 
No patient had previously undergone RFCA for AF. The mean LA volume index 
was 42.5 ± 15.4 ml/m2, the mean LA diameter was 42 ± 6 mm and the mean LV 
ejection fraction was 58 ± 5%. No significant valvular heart disease was 
observed in any patient. Finally, the mean calibrated IBS of the LA was -18.0 ± 
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5.1 dB (Table 1). The intra- and inter-observer reproducibility for calibrated IBS 
measurements were good with small bias and tight limits of agreement (0.93 ± 
1.8 dB and 0.12 ± 3.3 dB, respectively) and good intraclass correlation 
coefficients (0.91 and 0.82, respectively). The test-retest variability for calibrated 
IBS was 1.07 ± 1.9 dB with an intraclass correlation coefficient of 0.92. 
 
Table 1. Baseline patient characteristics 
Patients (n) 170 
Age (years) 55.9±9.0 
Male gender, n (%) 131 (77) 
Body Surface Area (m2) 2.11±0.20 
Type of AF  
Paroxysmal, n (%) 121 (71) 
Persistent, n (%) 49 (29) 
Duration of AF (months) 48 (24-96) 
Number of failed antiarrhythmic drugs (n) 3.3±1.3 
Hypertension, n (%) 76 (45) 
Hypercholesterolemia, n (%) 51 (30) 
Coronary artery disease, n (%) 9 (5) 
Beta blocker, n (%) 54 (32) 
Class 1 or 3 antiarrhythmic drug, n (%) 132 (78) 
ACE inhibitor/angiotensin receptor blocker, n (%) 86 (51) 
Diuretic, n (%) 27 (16) 
LA volume index (ml/m2) 42.5 ±15.4 
LV ejection fraction (%) 58 ± 5 
Calibrated IBS LA (dB) -18.0±5.1 
AF = atrial fibrillation, ACE = angiotensin-converting enzyme, IBS = integrated backscatter, LA = left atrium, 
LV = left ventricular.  
 
Outcome after radiofrequency catheter ablation 
After a mean follow-up of 12 ± 3 months, 103 patients (61%) maintained sinus 
rhythm, whereas 67 patients (39%) had recurrence of AF. In 22 patients (13%) a 
repeat procedure was performed due to early recurrence of AF. In the 
recurrence group a higher prevalence of persistent AF was found compared to 
Impact LA fibrosis and LA size on outcome RFCA for AF 
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the non-recurrence group (16 [16%] versus 33 [49%], p<0.001). Moreover, in 
the recurrence group the mean LA volume index and LA diameter were 
significantly larger compared to the non-recurrence group (46.0 ± 16.9 ml/m2 
versus 40.2 ± 14.1 ml/m2 [p=0.016] and 44 ± 6 mm versus 41 ± 5 mm [p<0.001], 
respectively). Patients with persistent AF had significantly higher values (i.e. 
less negative) of calibrated IBS of the LA than patients with paroxysmal AF (-
16.8 ± 4.7 dB versus -18.4 ± 5.2 dB, p=0.049). 
To study the relation between LA size, LA calibrated IBS and outcome 
after RFCA, the study population was divided i
value (42.5 ml/m2) as cut-off point. Similarly, the population was divided into 
cording to 
calibrated IBS value of the posterior LA wall, using the mean value (-18.0 dB) as 
cut-off point. 
The relation between LA enlargement and calibrated IBS of the LA is 
calibr -
19.4 ± 5.0 dB versus -16.5 ± 4.7 dB, p<0.001). Importantly, a wide range of 
that a small LA may still contain a large extent of fibrosis content (Figure 1). 
P
(Figure 2, panel A). When both LA size and LA fibrosis were taken into account, 





-recurrence vs. 38% non-recurrence, 
p<0.001) (Figure 2, panel B). 
Figure 1. Relation between left atrial (LA) size and calibrated 
oportion 
wide range of calibrated IBS values of the LA, but with a mean value significantly higher (i.e. less negative) as 
compared to the group  





Figure 2. Outcome of radiofrequency catheter ablation (RFCA) according to left atrial (LA) size (panel A) and 
ml/m2 
integrated backscatter (IBS) of the LA <- -
lihood of atrial fibrillation (AF) recurrences after RFCA was lower 
 
 
Finally, Figure 3 shows the relation between the occurrence of AF 
recurrence after RFCA and calibrated IBS and LA volume index. Patients who 
remained in sinus rhythm had significantly lower values of calibrated IBS (i.e. 
more negative) (-20.6 ± 3.7 dB vs. -13.9 ± 4.0 dB; p<0.001) and smaller LA 
volume index (40.2 ± 14.1 ml/m2 vs. 46.0 ± 16.9 ml/m2, p<0.001) than patients 
who had AF recurrences after RFCA. Interestingly, most patients with a value of 
calibrated IBS >-13.9 dB showed AF recurrence at follow-up. In contrast, there 
was a significant overlap between LA volume index values of patients who 
presented with AF recurrences and patients who remained in sinus rhythm and 
no LA volume cut-off value could be derived to differentiate these two groups 
of patients. Therefore, calibrated IBS may be a more accurate parameter to 





Figure 3. Calibrated integrated backscatter (IBS) of the left atrium (LA) and LA volume index in relation to 
outcome of radiofrequency catheter ablation. Patients who had atrial fibrillation recurrence after RFCA had 
significantly higher values of calibrated IBS of the LA (panel A) and LA volume index (panel B) at baseline 
than patients who remained in sinus rhythm. 
 
Clinical and echocardiographic risk factors for AF recurrence 
Univariate and multivariate Cox proportional hazard analyses were performed 
to evaluate the relation between calibrated IBS of the LA (in combination with 
other baseline clinical and echocardiographic variables) and the risk for AF 
recurrence after RFCA. Univariate analyses showed that increased calibrated 
IBS of the LA (i.e. less negative values) was related to a higher risk for AF 
recurrence after ablation, as were the presence of persistent AF and 
enlargement of the LA volume index (Table 2). Multivariate analysis showed 
that calibrated IBS of the LA was an independent predictor of AF recurrence 
(HR: 2.796 per 5 dB, 95% CI: 2.168-3.605, p<0.001). Moreover, addition of 
calibrated IBS of the LA to a Cox model including LA volume index and type of 
AF resulted in a significant improvement in the prediction value for AF 
recurrence after RFCA (indicated by a significant improvement in global chi-
square value: 61.6, p<0.001) (Figure 4).  
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Table 2. Univariate Cox regression analysis of AF recurrence  
 HR 95% CI P-value 
Clinical characteristics    
Age (per year) 1.005 0.977-1.033 0.74 
Male gender (yes/no) 0.873 0.503-1.514   0.87 
AF duration (per month)   1.008 0.959-1.059 0.76 
Number of failed antiarrhythmic drugs (per drug) 1.058 0.886-1.262 0.54 
Persistent AF (yes/no) 3.264 2.015-5.285 <0.001 
Hypertension (yes/no) 1.063 0.658-1.717 0.80 
Hypercholesterolemia (yes/no) 1.406 0.856-2.308 0.18 
Coronary artery disease (yes/no) 0.217 0.030-1.564 0.13 
    
Echocardiographic characteristics    
Calibrated IBS LA (per 5 dB) 2.670 2.119-3.363 <0.001 
LA volume index (per ml/m2) 1.023 1.006-1.039 0.007 
LV ejection fraction (per %) 0.971 0.920-1.024 0.28 
AF = atrial fibrillation, IBS = integrated backscatter, LA = left atrium, LV = left ventricular. 
 
 
Figure 4. Incremental prognostic value of calibrated integrated backscatter (IBS) of the left atrium (LA). Bar 
graph illustrating the improvement in global chi-square value by the addition of calibrated IBS of the LA to a 





The main findings of the present study were that LA enlargement was related 
to an increased risk for AF recurrence. More important, a high value of LA 
calibrated IBS as a surrogate of large extent of LA fibrosis was associated with 
poor outcome after RFCA. Finally, this study demonstrated that the combined 
assessment of LA calibrated IBS and LA size improved the identification of 
patients with a high likelihood for a successful ablation. 
 
Atrial remodeling and outcome: LA size 
Atrial fibrillation causes electrical and structural remodeling of the atria which 
play an important role in the perpetuation and progression of the 
arrhythmia.17,18 More importantly, atrial remodeling is associated with a limited 
efficacy of RFCA for AF.6 Pre-procedural evaluation of the extent of atrial 
remodeling can be used to improve patient selection for RFCA.  
Atrial dilatation is associated with atrial remodeling.19 LA size has been 
shown to be an important risk factor for AF recurrence after RFCA.3,4 In a group 
of 148 patients, Berruezo et al. demonstrated that a large anterior-posterior LA 
diameter was related to a high risk for AF recurrence after RFCA.3 This was 
confirmed by Shin et al. who demonstrated that LA volume was an 
independent predictor of AF recurrence.4 However, the clinical value of LA size 
to select patients for RFCA may be limited. Whereas patients with severely 
patients with mild-to-moderate LA enlargement show a varying response to 
RFCA. Accordingly, extensive research has been performed to obtain additional 
parameters to better predict the outcome of RFCA for AF. 
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Atrial remodeling and outcome: LA fibrosis 
Atrial fibrosis has been proposed as one of the processes involved in atrial 
remodeling.20 Moreover, the presence of LA fibrosis is a risk factor for AF 
recurrence after RFCA.6 In 700 patients undergoing RFCA for AF, Verma et al. 
evaluated the extent of LA fibrosis by invasive voltage mapping of the left 
atrium. The presence of areas with low voltage in the LA (i.e. LA fibrosis) were 
an independent predictor AF recurrence after RFCA.6 However, ideally the 
assessment of LA fibrosis would be performed using a non-invasive and widely 
available imaging technique prior to the RFCA procedure. Calibrated IBS 
analysis allows non-invasive tissue characterization based on the quantification 
of ultrasound energy reflected by scattering elements inside the 
myocardium.8,11-13 Recently, assessment of LA fibrosis using calibrated IBS has 
been validated by Wang et al. in a group of 74 patients undergoing coronary 
artery bypass surgery.9 The authors found a good correlation between 
calibrated IBS value of the LA and the extent of collagen inside the LA 
appendage. Similarly, in the present study two-dimensional transthoracic 
echocardiography derived calibrated IBS was used to assess LA fibrosis. 
Patients with large LA size had higher values of calibrated IBS than patients 
with a small LA size. However, a large variation existed in the values of LA 
calibrated IBS in relation to LA size, and a considerable proportion of patients 
with a small LA had a high values of LA calibrated IBS suggesting a large 
amount of fibrosis. Notably, patients with small LA and high values of LA 
calibrated IBS had a significant percentage of AF recurrences at follow-up. 
Indeed, LA wall ultrasound reflectivity was a strong independent predictor of 
AF recurrences after RFCA and had an incremental value over LA size. 
Consequently, assessment of LA calibrated IBS in addition to LA size may 
improve the selection of patients eligible for RFCA for AF, thereby increasing 
the procedural success rate.  
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 The assessment of macroscopic LA fibrosis with contrast-enhanced 
magnetic resonance imaging (CE-MRI) has been recently demonstrated. 21,22 
The high spatial resolution of CE-MRI permits exact localization of areas of 
macroscopic fibrosis within the LA wall. However, CE-MRI is not widely 
available and, in patients with renal dysfunction, the use of contrast may be not 
recommended.23 In contrast, calibrated IBS provides a surrogate of fibrosis 
content of the LA wall. This analysis is performed on two-dimensional 
echocardiographic data and no contrast media is needed. Importantly, the 
present study shows that in combination with assessment of the LA size, 
calibrated IBS of the LA can be a valuable tool to identify patients with a high 
likelihood to have AF recurrence after RFCA. 
 
Clinical implications 
The present study demonstrated that pre-procedural assessment of LA fibrosis 
using calibrated IBS analyses can be useful to predict the outcome of RFCA for 
AF. LA fibrosis can be readily evaluated with this non-invasive imaging 
technique. Particularly in combination with measurement of LA size, pre-
procedural assessment of LA fibrosis improves identification of patients with a 
high likelihood to maintain sinus rhythm after RFCA. Furthermore, this study 
extended the evidence that persistent AF is a risk factor for AF recurrence after 
RFCA. However, the present study also demonstrated that assessment of LA 
fibrosis with calibrated IBS improved patient selection compared to established 
risk factors as persistent AF and LA size. Consequently, an improved patient 
selection could result in a higher success rate of RFCA for AF. Alternatively, this 
information could be used to better inform patients about their likelihood to 
maintain sinus rhythm after RFCA. 
 




Left atrial fibrosis can be inhomogeneous in patients with AF.21,22 The inclusion 
LA fibrosis (e.g. electroanatomical voltage maps or late-gadolinium enhanced 
magnetic resonance imaging) would have strengthened our conclusions. 
Nevertheless, current studies have demonstrated a strong relationship 
between the measurement of IBS in a single area of the LA and the fibrosis 
content quantified by histology.9 In addition, calibrated IBS analyses are 
dependent on the settings used during image acquisition (e.g. ultrasound 
frequency, focus, depth, etc).  
 
Conclusion 
Assessment of LA fibrosis using two-dimensional echocardiography derived 
calibrated IBS can be useful to select patients for RFCA for AF. Combined 
assessment of LA fibrosis and LA size improves the identification of patients 
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Background: Total atrial activation time has been identified as an independent 
predictor of new-onset atrial fibrillation (AF). Echocardiographic assessment of 
PA-TDI duration provides an estimation of total atrial conduction time. The aim 
of this study was to investigate the prognostic value of total atrial conduction 
time to predict AF recurrence after radiofrequency catheter ablation (RFCA). 
Methods: In 213 patients undergoing RFCA for symptomatic drug-refractory 
paroxysmal AF, the total atrial conduction time was estimated by measuring 
the time delay between the onset of the P-wave in lead II of the surface ECG 
-wave on the tissue Doppler tracing of the left atrial lateral wall 
(PA-TDI duration). After RFCA, all patients were evaluated on a systematic basis 
at the outpatient clinic. 
Results: After a mean follow-up of 13 ± 3 months, 74 patients (35%) had 
recurrent AF whereas 139 patients (65%) maintained sinus rhythm. Left atrial 
maximum volume index and PA-TDI duration were identified as independent 
predictors of AF recurrence after RFCA. However, receiver-operator 
characteristics curve analyses demonstrated that PA-TDI duration had a 
superior accuracy to predict AF recurrence compared to left atrial maximum 
volume index (area under the curve 0.765 vs. 0.561, respectively). 
Conclusion: Assessment of total atrial conduction time using tissue Doppler 
imaging can be used to predict AF recurrence after RFCA.  
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Introduction 
Atrial fibrillation (AF) causes electrical and structural changes to the atria which 
play an important role in the perpetuation and progression of the arrhythmia.1,2 
This process is referred to as atrial remodelling. A large extent of atrial 
remodelling is associated with a limited efficacy of radiofrequency catheter 
ablation (RFCA) for AF.3 Therefore, pre-procedural assessment of the extent of 
atrial remodelling could be used to identify patients with a high risk for AF 
recurrence after RFCA. 
 Currently, the most common used method to estimate the extent of 
atrial remodelling is the measurement of the left atrial (LA) size. Left atrial size is 
an independent predictor of new onset AF in the general population and has 
been identified as a predictor of AF recurrence after RFCA.4-7 However, the 
clinical applicability of LA size to identify patients with a high likelihood to 
maintain sinus rhythm after RFCA for AF is limited. Therefore, additional 
markers of atrial remodelling are needed to improve patient selection. 
 Total atrial conduction time has been proposed as a marker of atrial 
remodelling. In contrast to LA size, total atrial conduction time reflects the 
extent of both electrical and structural remodelling of the atria. Recently, a 
novel echocardiographic parameter based on tissue Doppler imaging (TDI) has 
been introduced to assess the total atrial conduction time: the PA-TDI 
duration.8 Potentially, this new parameter provides a more accurate 
assessment of the presence and extent of atrial remodelling than conventional 
echocardiographic parameters. The aim of this study was to investigate the 






Patient population and evaluation 
The patient population consisted of a group of consecutive patients with 
symptomatic drug-refractory paroxysmal AF, undergoing RFCA. Atrial 
fibrillation was classified as paroxysmal when episodes were generally self-
terminating and lasted no longer than 7 days, according to the European 
Society of Cardiology guidelines definitions.9 Prior to the procedure, all patients 
underwent a comprehensive transthoracic echocardiographic examination to 
assess LA size and function, left ventricular (LV) function, and to exclude 
structural heart disease. In addition, a novel echocardiographic parameter was 
assessed to estimate the total atrial conduction time (PA-TDI duration). The PA-
TDI duration is measured using TDI during sinus rhythm. Therefore, patients 
who were in atrial fibrillation during echocardiography were excluded from the 
analysis. After the ablation, all patients were evaluated on a systematic basis at 
the outpatient clinic during a 12 months follow-up period. Electrocardiogram 
(ECG) recordings were acquired each visit and 24-hour Holter registrations 
were scheduled after 3, 6 and 12 months follow-up. Importantly, all patients 
were encouraged to immediately obtain an ECG registration when 
experiencing palpitations. All medications were continued for at least 3 
months. Afterwards, anti-arrhythmic drugs were discontinued at the discretion 
of the physician. After a blanking period of 3 months, recurrence of AF was 
defined as any recording of AF on ECG or an episode longer than 30 s on 24-
hour Holter registration. 
 
Standard echocardiography 
Two-dimensional transthoracic echocardiography was performed using a 
commercially available ultrasound system (Vivid 7, General Electric Vingmed, 
Milwaukee, WI), equipped with a 3.5-MHz transducer at a depth of 16 cm. All 
Total atrial conduction time to predict recurrence of AF  after RFCA 
 57 
patients were imaged in left lateral decubitus position. Two-dimensional and 
color Doppler data were obtained in the parasternal short- and long-axis views 
and the apical 2- and 4-chamber views. All images were ECG-triggered and 
stored in cineloop format for off-line analyses (EchoPac 108.1.5, General Electric 
Medical Systems, Horten, Norway). Left atrial volumes were obtained from the 
10 Left atrial 
volumes were measured at two phases of the cardiac cycle: LA maximum 
volume at the end-systolic phase (just before mitral valve opening) and LA 
minimum volume at the end-diastolic phase (just before mitral valve closure). 
The LA function was derived from the LA volumes by calculating the total LA 
emptying fraction according to the following formula: total LA emptying 
fraction = ([LA maximum volume  LA minimum volume]/LA maximum 
volume) x 100%. Left ventricular ejection fraction was calculated from the 
standard apical 2- and 4- rding to 
the American Society of Echocardiography guidelines.10 Left ventricular 
diastolic function was evaluated using pulsed-wave Doppler recordings of the 
mitral valve inflow pattern (E-wave, A-wave, deceleration time of the E-wave) 
-wave). In 
addition, the diastolic function grade was classified as either normal, grade 1 
(impaired relaxation), grade 2 (pseudonormalization) or grade 3 (restrictive 
filling pattern) as recommended by current guidelines.11  
 
Atrial tissue Doppler imaging 
The PA-TDI duration is a novel echocardiographic parameter which can be 
used to estimate the total atrial conduction time.8 Color-coded TDI images of 
the LA were obtained from the apical 4-chamber view during end-expiration, 
with the sector size and depth optimized for the highest frame rates possible 
(>115 frames/s). The ultrasound beam was carefully aligned to keep the 
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incidence angle as small as possible. To assess the PA-TDI duration, a fixed 9x9 
pixel region of interest was placed on the LA lateral wall just above the mitral 
annulus providing the tracing of the mechanical activation in that area (Figure 
1). The PA-TDI duration was assessed by measuring the time interval between 
the onset of the P- -wave on 
the tissue Doppler tracing (Figure 1). A long PA-TDI duration corresponds to a 
long total atrial conduction time.  
 
 
Figure 1. Measurement of the total atrial conduction time (PA-TDI duration). A fixed 9x9 pixel region of 
interest (yellow) was positioned in the left atrial (LA) lateral wall on a tissue Doppler recording to obtain a 
tracing of the mechanical activation in this area (yellow tracing). A simultaneously acquired registration of 
surface electrocardiogram (ECG) lead II (blue tracing) was displayed underneath the tissue Doppler tracing. 
The PA-TDI duration (double arrow) was assessed by measuring the time interval between the onset of the P-
-wave on the tissue Doppler tracing (single arrows). 
 
Bland-Altman analyses were performed in our laboratory to assess the 
inter- and intra-observer reproducibility of PA-TDI duration measurements 
showing minimal biases and tight limits of agreement (1.8 ± 10 ms and 1.7 ± 10 
ms, respectively).12  
Total atrial conduction time to predict recurrence of AF  after RFCA 
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Radiofrequency catheter ablation  
Radiofrequency catheter ablation was aimed at creating circular lesions around 
the left and right pulmonary vein ostia. All patients received intravenous 
heparin to maintain an activated clotting time of 300-400 s. A transseptal 
puncture was performed to gain entrance to the LA. Intracardiac 
echocardiography was used to guide the transseptal puncture. A non-
fluoroscopic electroanatomical mapping system with multi-slice computed 
tomography integration was used to guide the ablation procedure (CARTO 
XPTM, CartomergeTM, Biosense Webster, Diamond Bar, CA, USA). Mapping and 
ablation were performed using a 3.5-mm quadripolar open-loop irrigated 
mapping/ablation catheter (7.5Fr NavistarTM, Biosense Webster). 
Radiofrequency current was applied at 30-35 W with a maximum temperature 
of 45°C and an irrigation flow of 20 ml/min until a bipolar voltage of <0.1 mV 
was achieved, with a maximum of 60 s per point. The end-point of the 
procedure was pulmonary vein isolation as confirmed by recording entrance 
block during sinus rhythm or pacing from inside the coronary sinus.13  
 
Statistical analysis 
All variables were tested for a normal distribution with the Kolmogorov-
Smirnov test. Continuous variables are presented as mean ± SD and were 
-test, paired or unpaired as appropriate. 
Categorical variables are presented as number (percentage) and were 
compared with the chi-square test. Univariable and multivariable Cox 
proportional hazard analyses were performed to investigate clinical and 
echocardiographic predictors of AF recurrence after RFCA. All variables 
mentioned in Table 1 and Table 2 were included in the univariable analyses. 
Variables with a p-value <0.05 in the univariate analysis were included into the 
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multivariate analysis. Multivariate analysis was performed using a backward 
stepwise conditional approach. Variables with a p>0.05 were excluded from 
the model. The receiver-operator characteristics (ROC) curve was calculated to 
evaluate the performance of the strongest independent predictors of AF 
recurrence after RFCA obtained at multivariate analysis. All statistical analyses 
were performed with SPSS software (version 16.0, SPSS Inc., Chicago, IL, USA). A 




The present patient population was prospectively included from an ongoing 
clinical registry.14  Out of 323 consecutive patients undergoing RFCA for 
paroxysmal AF, 213 patients were in sinus rhythm during transthoracic 
echocardiography and comprised the patient population (165 men [77%], 
mean age 55 ± 11 years). Importantly, none of these patients had previously 
undergone RFCA for AF. The procedural end-point of PV isolation was reached 
in all patients and no major procedural complications occurred.  
 After a mean follow-up of 13 ± 3 months, 74 patients (35%) had 
recurrent AF and 139 patients (65%) had maintained stable sinus rhythm. 
Patients with AF recurrence had significantly larger LA volumes compared to 
patients who maintained sinus rhythm (LA maximum volume index: 42 ± 13 
ml/m2 versus 38 ± 11 ml/m2, p=0.014; LA minimum volume index: 22 ± 9 ml/m2 
versus 20 ± 8 ml/m2, p=0.029). Moreover, patients with AF recurrence more 
often had a history of persistent AF than patients who maintained sinus rhythm 
(27 [36%] versus 19 [14%], p<0.001). Persistent AF was defined as AF episodes 
lasting longer than 7 days or requiring termination by cardioversion, according 
to the European Society of Cardiology guidelines definitions.9 More detailed 
comparisons of baseline characteristics and echocardiographic characteristics 
Total atrial conduction time to predict recurrence of AF  after RFCA 
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between patients with AF recurrence and patients who maintained sinus 
rhythm are shown in Tables 1 and 2, respectively. 
 








Clinical characteristics     
Age (years) 55 ± 11 55 ± 9 55 ± 15 0.99 
Male gender, n (%) 165 (77) 108 (78) 57 (77) 0.91 
Body Surface Area (m2) 2.1 ± 0.2 2.1 ± 0.2 2.1 ± 0.2 0.18 
Body Mass Index (kg/m2) 26.5 ± 3.6 26.4 ± 3.4 26.8 ± 3.8 0.41 
CHADS2  15 (7) 13 (9) 2 (3) 0.07 
Duration of atrial fibrillation (months) 67 ± 60 68 ± 56 65 ± 66 0.75 
History of cardioversion, n (%) 114 (54) 68 (49) 46 (62) 0.07 
History of persistent atrial fibrillation, n (%) 46 (22) 19 (14) 27 (36) <0.001 
Failed anti-arrhythmic drugs (n) 3.2 ± 1.3 3.2 ± 1.4 3.2 ± 1.2 0.92 
Hypertension, n (%) 88 (41) 53 (38) 35 (47) 0.20 
Diabetes, n (%) 9(4) 8 (6) 1 (1) 0.13 
     
Medication     
 ACE-inhibitor, n (%) 48 (23) 32 (23) 16 (22) 0.82 
 AT-II receptor blocker, n (%) 58 (27) 34 (24) 24 (32) 0.21 
 Class IC anti-arrhythmic drug, n (%) 75 (35) 54 (39) 21 (28) 0.13 
 Class III anti-arrhythmic drug, n (%) 121 (57) 77 (55) 44 (59) 0.57 
ACE-inhibitor = angiotensin-converting enzyme inhibitor, AT-II = angiotensin-I 
 
Total atrial conduction time 
The mean PA-TDI duration for the overall population was 132 ± 25 ms. There 
was no relation between the use of class 1c or class 3 anti-arrhythmic drugs 
and PA-TDI duration. Patients with AF recurrence during follow-up had a 
significantly longer PA-TDI duration at baseline than patients who maintained 
sinus rhythm (146 ± 20 ms versus 124 ± 23 ms, p<0.001). Moreover, PA-TDI 
duration was significantly longer in patients who had been previously classified 
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as persistent AF (142 ± 21 ms versus 129 ± 25 ms, p=0.002). After 12 months 
follow up there was no significant change in PA-TDI duration in patients who 
maintained sinus rhythm (123 ± 23 ms versus 127 ± 22 ms, p=0.054) nor in 





















Figure 2. Receiver-operator characteristic curve analyses of the total atrial conduction time (PA-TDI duration) 
and left atrial (LA) maximum volume index according to the recurrence of atrial fibrillation during follow-up. 
CI = confidence interval. 
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Table 2. Echocardiographic characteristics 








Volumes     
LA maximum volume index (ml/m2) 39 ± 12 38 ± 11 42 ± 13 0.014 
LA minimum volume index (ml/m2) 20 ± 8 20 ± 8 22 ± 9 0.029 
LA emptying fraction (%) 49 ± 12 49 ± 12 48 ± 12 0.46 
LV ejection fraction (%) 59 ± 5 59 ± 5 58 ± 6 0.10 
     
Pulsed wave Doppler:     
 E-wave (m/s) 0.63 ± 0.16 0.62 ± 0.16 0.64 ± 0.16 0.36 
 A-wave (m/s) 0.54 ± 0.15 0.55 ± 0.14 0.52 ± 0.15 0.21 
 E/A-ratio 1.24 ± 0.48 1.21 ± 0.46 1.31 ± 0.51 0.12 
 Deceleration time (s) 212 ± 67 213 ± 68 207 ± 63 0.56 
Doppler tissue imaging:     
 -wave (cm/s) 9.1 ± 2.4 9.0 ± 2.5 9.2 ± 2.3 0.58 
 -ratio 7.3 ± 2.6 7.3 ± 2.7 7.3 ± 2.3 0.92 
Diastolic function grade:     
 Normal, n (%) 168 (79) 108 (78) 60 (81) 0.57 
 Gr 1: Impaired relaxation, n (%) 45 (21) 31 (22) 14 (19)  
 Gr 2: Pseudo-normalization, n (%) 0 (0) 0 (0) 0 (0)  
 Gr 3: Restrictive filling, n (%) 0 (0) 0 (0) 0 (0)  
Atrial electromechanical interval:     
 PA-TDI duration (ms) 132 ± 25 124 ± 23 146 ± 20 <0.001 
Gr = grade, LA = left atrial, LV = left ventricular, PA-TDI duration = total atrial conduction time 
 
Clinical predictors of atrial fibrillation recurrence 
Univariate and multivariate Cox proportional hazard analyses were performed 
to identify clinical and echocardiographic predictors of AF recurrence after 
RFCA (Table 3). Left atrial maximum volume index (HR per ml/m2: 1.020, 
p=0.030) and PA-TDI duration (HR per ms: 1.035, p<0.001) were identified as 
independent predictors of AF recurrence. Importantly, multivariate analyses 
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demonstrated that there was no interaction between LA maximum volume 
index or PA-TDI duration and a history of AF. This illustrates that both LA 
maximum volume index and PA-TDI duration have a similar prognostic value in 
patients with and without a history of persistent AF. Therefore LA maximum 
volume index and PA-TDI duration can be used to predict AF recurrence in 
both groups of patients. To study the discriminative performance of these 
variables to predict AF recurrence after RFCA, ROC curve analyses were 
performed (Figure 2). The area under the ROC curve (index of discrimination) 
for LA maximum volume was 0.561 (p=0.14), indicating a low discriminative 
power. The PA-TDI duration demonstrated a higher degree of discrimination 
than LA maximum volume index with an area under the ROC curve of 0.765 
(p<0.001). To illustrate the implication of this finding, an example of a patient 
with a relatively small LA and a long total atrial conduction time is shown in 
Figure 3. Despite the relatively small LA size, the prolonged total atrial 
conduction time indicates a high extent of atrial remodeling most likely caused 
by a decreased atrial conduction speed. Consequently, this patient 
experienced AF recurrence during follow-up, illustrating the importance of 
total atrial conduction time to predict AF recurrence after RFCA. To further 
illustrate the impact of PA-TDI duration on the risk for AF recurrence, the 
Kaplan Meier curve for freedom of AF after RFCA according to PA-TDI quartiles 
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Figure 3. Example of a patient with a small left atrial (LA) size and a long total atrial conduction time (PA-TDI 
duration). The LA maximum volume index was obtained from the 2- and 4-chamber parasternal long-axis 
views (2CH-PLAX and 4CH-PLAX, respectively) and measured 31 ml/m2. A tissue Doppler tracing of the LA 
lateral wall demonstrated a PA-TDI duration (arrow) of 180 ms. Despite the small LA size, the long PA-TDI 
duration indicates a large extent of atrial remodeling. This patient has experienced recurrence of atrial 




Figure 4. Kaplan Meier curve for freedom of atrial fibrillation (AF) after radiofrequency catheter ablation 
according to total atrial conduction time (PA-TDI duration) quartiles. 
 
Discussion 
The present study investigated the value of pre-procedural echocardiographic 
assessment of the total atrial conduction time using TDI to predict AF 
recurrence after RFCA in patients with paroxysmal AF. The main finding was 
that PA-TDI duration was an independent predictor of AF recurrence after 
RFCA. Moreover, PA-TDI duration was a stronger predictor of AF recurrence 
than LA maximum volume index and demonstrated a higher degree of 
discrimination to identify patients who will have AF recurrence after RFCA. 
 
Conventional predictors of atrial fibrillation recurrence 
Radiofrequency catheter ablation is considered a reasonable option for 
patients with symptomatic, drug refractory AF.13 However, RFCA for AF is 
associated with a considerable recurrence rate.15 A large number of parameters 
has been related to a high risk for AF recurrence after RFCA, such as age, arterial 
Total atrial conduction time to predict recurrence of AF  after RFCA 
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hypertension, type of AF, LA size and impaired LV systolic function.5,6,16,17 
Interestingly, these parameters all seem to either cause or reflect the presence 
and extent of atrial remodeling. A high extent of atrial remodeling is thought to 
limit the efficacy of RFCA for AF.  
 In the present study a history of persistent AF and a large LA maximum 
volume index were associated with a higher risk for AF recurrence. Moreover, 
multivariate analysis demonstrated that LA maximum volume index was an 
independent predictor of AF recurrence after RFCA. This is in agreement with 
previous studies that have identified LA size as a predictor of AF recurrence 
after RFCA.4-7   Moreover, this finding is in agreement with the assumption that 
significantly dilated atria are associated with a high degree of atrial remodeling 
that may limit the efficacy of RFCA. Nevertheless, LA size may not be the most 
appropriate approach to identify patients who will experience AF recurrence 
after RFCA, as the present study demonstrated (Figure 2). Although LA 
maximum volume index was independently associated with AF recurrence 
after RFCA, the discriminative power of this parameter was low (area under the 
ROC curve of 0.561 [p=0.14]). Therefore, additional parameters are needed to 
improve patient selection. 
 
Total atrial conduction time and atrial fibrillation recurrence 
In addition to atrial dilatation, slow atrial conduction velocity may be another 
consequence of atrial remodeling.18 Atrial enlargement and slowing of the 
atrial conduction velocity can result in a larger number of re-entrant wavelets 
inside the atria. This situation favors the development and perpetuation of 
AF.19 The total atrial conduction time is related to the atrial dimensions and 
conduction speed. Consequentially, compared to LA size, the assessment of 
the total atrial conduction time may provide a more comprehensive estimation 
of the amount of atrial remodeling since this parameter integrates LA 
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dimensions and electrical properties of the LA wall. Recently, Allessie et al. 
underlined the importance of electrical remodeling in the development of 
substrate for AF by demonstrating a substantially higher degree of functional 
reentry during longstanding AF as compared to acute AF.20 Furthermore, Choi 
et al. demonstrated that by decreasing the total atrial conduction time with 
linear triple-site pacing, burst-induction of AF could be prevented in some 
patients with persistent AF.21  
 The PA-TDI duration is an easy, fast and reliable method to estimate the 
total atrial conduction time. This novel echocardiographic parameter has been 
validated against P-wave duration on signal-averaged electrocardiography.8 
Accordingly, PA-TDI duration has been used to identify patients with an atrial 
substrate vulnerable to develop AF.22-24 The present study demonstrated that 
PA-TDI duration was an independent predictor of AF recurrence after RFCA. 
Importantly, PA-TDI duration was a stronger predictor of AF recurrence after 
RFCA than LA size and demonstrated a higher degree of discrimination (area 
under the ROC curve of 0.765 [p<0.001]).  
 
Clinical implications 
Several risk factors for AF recurrence after RFCA have been identified. However, 
the ability to predict which patients will benefit from RFCA for AF based on 
those risk factors remains limited. Left atrial size is one of the most frequently 
used parameters to select patient for RFCA of AF. However, the accuracy of this 
parameter to predict the efficacy of RFCA for AF is suboptimal. Left atrial size 
reflects the amount of structural changes to the LA tissue caused by atrial 
remodelling. In contrast, total atrial conduction time reflect both structural 
changes (LA dimensions) as well as changes in the electrical properties (atrial 
conduction velocity) caused by atrial remodelling and provides a more 
comprehensive estimation of the amount of atrial remodelling. The current 
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study demonstrated that total atrial conduction time had a higher 
discriminative power than LA size and can be used to improve patient 
selection. If further validated, total atrial conduction time may be used during 
pre-procedural consultation to better inform patients about their risk for AF 
recurrence after RFCA. Alternatively, in patients with a prolonged total atrial 
conduction time, the creation of a more extensive lesion set could be 
considered in order to improve the outcome of the procedure. Importantly, 
echocardiographic assessment of the total atrial conduction time using TDI is 




Some limitations of the present study should be acknowledged. First, detection 
of AF recurrence after RFCA was based on ECG recordings acquired on a 
systematic basis and/or 24-hour Holter registration. Importantly, patients were 
encouraged to obtain an ECG registration when experiencing palpitations in 
order to confirm AF as the cause of these complaints. Nevertheless, 
asymptomatic episodes may have been missed. Second, the present study 
comprised a relatively small group of patients. Therefore, the present findings 
need to be validated in a larger group of patients. Finally, TDI does not 
differentiate between active contraction or passive motion of the myocardial 
segments. The advent of 2-dimensional speckle tracking analysis may provide 
additional information by identifying active motion of the LA wall. 






An increased total atrial conduction time assessed with TDI echocardiography 
is an independent predictor of AF recurrence after RFCA for paroxysmal AF. 
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Background: Coronary artery disease (CAD) has been associated with the 
development of atrial fibrillation (AF). However, little is known about the 
impact of CAD on the outcome treatment of AF. The aim of this study was to 
investigate the impact of CAD on the efficacy of radiofrequency catheter 
ablation (RFCA) for AF using multi-detector row computed tomography 
(MDCT). 
Methods: In 125 consecutive patients undergoing RFCA for AF, a pre-
procedural MDCT examination (coronary angiography and/or coronary calcium 
score) was performed to evaluate the presence and severity of CAD. 
Furthermore all patients underwent a comprehensive echocardiographic 
evaluation to measure the left atrial size and to rule out structural heart 
disease. After RFCA all patients were regularly evaluated at the outpatient 
clinic. 
Results: After a mean follow-up of 12 ± 3 months, 78 patients (62%) had 
maintained stable sinus rhythm and 47 patients (38%) had recurrence of AF. 
Left atrial volume index was a significant predictor of AF recurrence after RFCA. 
Presence of CAD on MDCT did not influence the efficacy of RFCA for AF. 
Conclusions: The presence of CAD on MDCT is not associated with a higher 
risk for AF recurrence after RFCA. 
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Introduction 
Coronary artery disease (CAD) is one of the underlying mechanisms of atrial 
fibrillation (AF) in Western countries.1 Coronary artery disease leads to 
myocardial ischemia, left ventricular dysfunction and elevated left atrial 
pressures that may induce ultra-structural changes within the atrial 
myocardium. These changes form the arrhythmogenic substrate for AF.2  
 Radiofrequency catheter ablation (RFCA) is a curative treatment option 
which is currently reserved for patients with symptomatic drug refractory AF.3 
The cornerstone of most RFCA strategies is pulmonary vein isolation.3 However, 
in patients with a high extent of atrial remodeling, in part caused by CAD, 
elimination of pulmonary vein triggers may not be sufficient to cure AF. Little is 
known about the impact of CAD on the efficacy of RFCA for AF.2 
 Multi-detector computed tomography (MDCT) is frequently performed 
prior to RFCA for AF in order to plan and guide the ablation procedure. MDCT 
provides information about the number and location of pulmonary veins 
draining into the left atrium and also permits evaluation of CAD.4,5 Therefore, 
MDCT provides information on one of the underlying mechanisms related to 
AF. The aim of this study was to investigate the impact of significant and non-
significant CAD on the efficacy of RFCA for AF. 
 
Methods 
Patient population and evaluation 
The population comprised a cohort of consecutive patients undergoing RFCA 
for symptomatic drug-refractory non-valvular AF. Prior to the ablation, all 
patients underwent transthoracic echocardiography to assess left atrial size, 
left ventricular systolic function and to exclude valvular heart disease. 
Moreover, all patients underwent, according to the clinical protocol, an MDCT 
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examination in order to obtain anatomical information to guide the ablation 
procedure and to exclude significant CAD. After RFCA, all patients were 
regularly evaluated at the outpatient clinic during a 12 months follow-up 
period. Electrocardiogram (ECG) recordings were acquired each visit and 24-
hour ECG Holter registrations were scheduled after 3, 6 and 12 months follow-
up. Importantly, all patients were encouraged to immediately obtain an ECG 
registration when experiencing palpitations. All medications were continued 
for at least 3 months. Afterwards, anti-arrhythmic drugs were discontinued at 
the discretion of the physician. After a blanking period of 3 months, recurrence 
of AF was defined as any recording of AF on ECG or an episode longer than 30 s 
on 24-hour ECG Holter registration. All clinical, MDCT and echocardiographic 
data were prospectively collected in the departmental cardiology information 




Two-dimensional transthoracic echocardiography was performed using a 
commercially available ultrasound system (Vivid 7 and E9, General Electric 
Vingmed, Milwaukee, WI), equipped with a 3.5-MHz and 5S transducers. All 
patients were imaged in left lateral decubitus position. Two-dimensional and 
color Doppler data were obtained in the parasternal short- and long-axis views 
and the apical 2- and 4-chamber views, adjusting gain settings and depth. All 
images were ECG-triggered and stored in cineloop format for off-line analyses 
(EchoPac 111.0.00, General Electric  Vingmed). Maximum left atrial volume 
was obtained from the apical 4- and 2-
indexed to body surface area.6 Left ventricular ejection fraction was calculated 
from the standard apical 2- and 4-
according to the American Society of Echocardiography guidelines.6 
Impact coronary artery disease on efficacy RFCA for AF 
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Multi-detector row computed tomography 
Data acquisition 
MDCT scanning was performed using a Toshiba Aquilion ONE system (Toshiba 
Medical Systems, Otawara, Japan) with 320 detector rows, each 0.50 mm wide. 
One hour prior to the examination, an oral beta-adrenergic blocking agent 
(metoprolol 50-100 mg) was administered if the heart rate was above 65 beats 
per minute, unless contra-indicated. In patients with a heart rate above 65 
beats per minute on arrival to the scanner an additional bolus of intravenous 
beta-blocking agent was administered (metoprolol 2.5-10 mg), unless contra-
indicated. Before computed tomography angiography (CTA), a non-enhanced 
low-dose scan was performed to measure the coronary calcium score (CCS). 
The CCS-scan was prospectively triggered at 75% of R-R interval using a single-
rotation-wide volume acquisition (slices reconstructed to 3 mm) with a gantry 
rotation time 350 to 500 ms, tube voltage 120 kV, and tube current 200 to 250 
mA. In patients with a heart rate above 65 beats per minute the CCS-scan was 
prospectively triggered at 45% of R-R interval. Next, CTA scanning was 
performed using prospective ECG triggering, imaging the entire heart in a 
single volume with a maximum of 16 cm cranio-caudal coverage. Tube voltage 
was adapted to body mass index (<23 kg/m2: 100 kV, 23 35 kg/m2: 120 kV, >35 
kg/m2: 135 kV) and tube current varied between 400 580 mA, depending on 
body weight. Contrast material was administered in a triple-phase protocol: 
rst a bolus of 60 ml, followed by 30 ml of a 50:50 mixture of contrast and 
saline, followed by saline ush with a ow rate of 5 6 ml/s (Iomeron 400, 
Bracco, Milan, Italy). Automatic detection of the contrast bolus in the left 
ventricle was used to time the start of the scan with a threshold of +180 
Hounsfield units. Scanning was performed during inspiratory breath-hold. If 
the heart rate was stable and <60 beats per minute the phase window was set 
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at 70 80% of R-R interval, if the heart rate was 60 65 beats per minute the 
phase window was set at 65 85% of R-R interval and if the heart rate was >65 
beats per minute the phase window was set at 30 80% of the R R interval 
(using multiple beats). Images were reconstructed in the end-diastolic phase 
(75% of R R interval) with a slice thickness of 0.50 mm and a reconstruction 
interval of 0.25 mm. If motion artefacts were present, multiple phases were 
reconstructed to obtain maximal diagnostic image quality. Afterwards, all 
datasets were exported, post-processed and analysed on a dedicated 
workstation (Vitrea FX 1.0, Vital Images, Minnetonka, MN, USA). 
 
Image analyses 
The CCS was calculated using the Agatston method and patients were 
categorised as CCS=0, CCS=1-400, and CCS>400. Evaluation of the contrast-
enhanced CTA datasets for the presence and severity of CAD was performed by 
2 experienced investigators. All datasets were assessed as recommended by 
the Society of Cardiovascular Computed Tomography guidelines for the 
interpretation and reporting of CTA.7 The coronary anatomy was determined 
using a standardized 17-segments model according to a modified American 
Heart Association (AHA) classification.8 Each segment was scored as normal (no 
CAD), non-significant CAD (<50% luminal narrowing), significant CAD (>50% 
luminal narrowing) or uninterpretable using the axial slices with the assistance 
of multiplanar and curved multiplanar reconstructed images. Subsequently, 
vessel-based and patient-based analyses of the CTA were performed. In the 
vessel-based analysis, the left main was considered part of the left anterior 
descending coronary artery and the intermediate branch was considered part 
of the left circumflex coronary artery. If one segment was uninterpretable, an 
intention-to-diagnose strategy was applied. If more than one segment in a 
single vessel was uninterpretable, the vessel was considered to be of non-
Impact coronary artery disease on efficacy RFCA for AF 
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diagnostic image quality. In the patient-based analysis, each CTA was classified 
as normal, non-significant CAD (<50% luminal narrowing) and significant CAD 
(>50% luminal narrowing). Similarly, if one vessel was uninterpretable, an 
intention-to-diagnose strategy was applied. If more than one vessel was 
uninterpretable, the entire examination was considered to be non-diagnostic. 
 
Radiofrequency catheter ablation  
Radiofrequency catheter ablation was aimed at pulmonary vein isolation. The 
procedure was performed using either a non-fluoroscopic electroanatomical 
mapping system with a 3.5-mm quadripolar open-loop irrigated ablation 
catheter and a decapolar circular mapping catheter (CARTO XPTM, CARTO 
MergeTM, 7.5Fr Navistar, LASSO, Biosense Webster, Diamond Bar, CA, USA) or a 
non-irrigated multi-electrode catheter with a duty-cycled, unipolar-bipolar 
radiofrequency generator that allows independent delivery of energy to each 
of the electrodes (PVACTM, GENiusTM, Medtronic Ablation Frontiers LLC, 
Carlsbad, CA, USA). All patients received intravenous heparin to maintain an 
activated clotting time of 300-400 s. A single or double transseptal puncture 
was performed to gain entrance to the left atrium. Intracardiac 
echocardiography was used to safely guide transseptal punctures.  
Using the CARTO system, circular lesions were created around the 
ipsilateral left and right pulmonary vein ostia. Radiofrequency current was 
applied at 30-35 W with a maximum temperature of 45°C and an irrigation flow 
of 20 ml/min until a bipolar voltage of <0.1 mV was achieved, with a maximum 
of 60 s per point. Using the PVAC system, all pulmonary veins were selectively 
isolated. The RFCA was delivered to the antral side of the pulmonary vein ostia. 
Special care was taken to avoid energy application inside the pulmonary veins. 
Radiofrequency current was applied at a maximum power of 8 W using a 4:1 
bipolar/unipolar ratio and at 10 W using a 2:1 ratio for 60 seconds per 
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application. Power settings were automatically adjusted in order to reach a 
target temperature of 60 °C. The end-point of the procedure was pulmonary 
vein isolation as confirmed by recording entrance block during sinus rhythm or 
pacing from inside the coronary sinus. 
 
Statistical analysis 
All variables were tested for a normal distribution with the Kolmogorov-
Smirnov test. Continuous variables are presented as mean ± SD and were 
-test for paired or unpaired data. Categorical 
variables are presented as number (percentage) and were compared with the 
chi-square test. The cumulative rate of AF recurrence after RFCA according to 
the presence or absence of significant CAD and the CCS were evaluated with 
the Kaplan Meier curves. Comparison of the cumulative event rates was 
performed using the log-rank test. Univariable Cox proportional hazard 
analyses were performed to investigate the impact of coronary artery disease 
and other clinical characteristics on the recurrence of AF after RFCA. All 
statistical analyses were performed with SPSS software (version 16.0, SPSS Inc., 




A total of 125 patients (96 men [77%], mean age 58 ± 9 years) undergoing a 
first  RFCA procedure for drug refractory paroxysmal AF were included from an 
ongoing clinical registry.9 The mean left atrial volume index was 39.5 ± 15.5 
ml/m2 and AF was paroxysmal in 96 patients (77%) and persistent in 29 (23%), 
according to current guidelines definitions.10 In 92 patients RFCA was 
performed using the CARTO-system and in 33 patients the PVAC-system was 
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used. The procedural end point of PV isolation was reached in all patients and 
no major procedural complications occurred. A more detailed description of 
the baseline characteristics is shown in Table 1 and Table 2.  
 
Table 1. Baseline characteristics  
 Population 
(n=125) 
Clinical characteristics  
Age (years) 58 ± 9 
Male gender, n (%) 96 (77) 
Body Surface Area (m2) 2.08 ± 0.20 
Duration of atrial fibrillation (months) 65 ± 53 
Persistent atrial fibrillation, n (%) 29 (23) 
Failed anti-arrhythmic drugs (n) 3.0 ± 1.1 
Left atrial volume index (ml/m2) 39.5 ± 15.5 
Left ventricular ejection fraction (%) 58 ± 7 
  
Medication  
Statin, n (%) 39 (31) 
Angiotensin-converting enzyme inhibitor, n 
(%) 
18 (14) 
Angiotensin II receptor antagonist, n (%) 40 (32) 
Class IC anti-arrhythmic drug, n (%) 47 (38) 
Class III anti-arrhythmic drug, n (%) 64 (51) 
 
 
Prevalence of coronary artery disease assessed with multi-detector row 
computed tomography 
Multi-detector row computed tomography coronary angiography was 
performed in a total of 100 patients. In the remaining 25 patients, CTA was not 
attempted because of AF with a high ventricular rate unresponsive to beta-
adrenergic blocking agent prior to scanning. In 5 patients the CTA examination 
 
 84 
was considered non-diagnostic. Significant CAD (>50% luminal narrowing in at 
least one vessel) was present in 22 patients (23%). A more detailed description 
of the CTA results is shown in Table 3.  
Coronary calcium score was measured in a total of 121 patients. The 
total CCS was 0 in 52 patients (43%), 1-400 in 56 patients (46%) and >400 in 13 
patients (11%). 
 
Table 2. Risk factors coronary artery disease 
 Population 
n=125 
Risk factors coronary artery disease  
Smoking, n (%) 41 (33) 
Hypertension, n (%) 45 (36) 
Hypercholesterolemia, n (%) 36 (29) 
Diabetes Mellitus, n (%) 7 (6) 
Family history, n (%) 38 (30) 
  
Known coronary artery disease, n (%) 8 (6) 
 Percutaneous coronary intervention, n (%) 
5 (4) 
 Coronary bypass surgery, n (%) 
1 (1) 
 Acute myocardial infarction, n (%) 
2 (2) 
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Table 3. Prevalence and extent of coronary artery disease on computed tomography angiography 
 Normal Non-significant Significant Non-diagnostic 
Vessel-based analysis     
Right  55 (55) 34 (34) 4 (4) 7 (7) 
Left anterior descending 45 (45) 41 (41) 11 (11) 3 (3) 
Left circumflex 57 (57) 32 (32) 5 (5) 6 (6) 
Patient-based analysis 32 (32) 41 (41) 22 (22) 5 (5) 
 
 
Coronary artery disease and atrial fibrillation recurrence 
After a mean follow-up of 12 ± 3 months, 47 patients (38%) had experienced AF 
recurrence and 78 patients (62%) had maintained stable sinus rhythm. All 
patients remained stable and no coronary events were recorded during the 
follow-up. A repeat RFCA procedure was performed in 40 patients (32%). There 
was no difference in AF recurrence between patients with or without 
significant CAD on CTA (Figure 1, panel A). Moreover, the CCS on MDCT was 
similar in patients with and without AF recurrence (Figure 1, panel B). Figure 2 
panel A illustrates the cumulative rates of AF recurrences after RFCA in patients 
with significant versus non-significant CAD. At 12 months follow-up, the 
incidence of AF recurrence was 32% in patients with significant CAD compared 
with 32% in patients without significant CAD (log-rank p=0.62). In addition, 
when the patient population was divided according to the CCS, no differences 
were observed in the 12 month AF recurrence rate among the three groups of 
patients: 33%, 39% and 54% for patients with CCS 0, between 1-400 and >400, 
respectively (log-rank p=0.24) (Figure 2 panel B). Univariable Cox proportional 
hazards analyses confirmed that there was no prognostic impact of significant 
CAD and CCS on the risk for AF recurrence after RFCA (Table 4). In contrast, left 
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atrial volume index was the only characteristic associated with a significantly 





Figure 1. Panel A: Illustration of the distribution of normal findings during coronary angiography on multi-
detector row computed tomography, non-significant coronary artery disease (CAD) and significant CAD 
among patients with recurrence of atrial fibrillation (recurrence) and patients that maintained sinus rhythm 
after radiofrequency catheter ablation (non-recurrence). Panel B: Illustration of the distribution of coronary 
calcium score on multi-detector row computed tomography divided into categories among patients with 
recurrence of atrial fibrillation (recurrence) and patients that maintained sinus rhythm after radiofrequency 
catheter ablation (non-recurrence). 
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Figure 2. Kaplan Meier curve for freedom of atrial fibrillation (AF) after radiofrequency catheter ablation 
according to the presence or absence of significant coronary artery disease (CAD)(panel A) and coronary 




Table 4. Cox univariable proportional hazard analyses of clinical and computed tomography characteristic to 
predict atrial fibrillation recurrence after catheter ablation 
 HR 95% CI P-value 
Clinical characteristics    
Age (per year) 1.030 0.993-1.069 0.11 
Male gender 1.381 0.641-2.973 0.41 
Body Surface Area (per m2) 1.740 0.379-7.979 0.48 
Duration of atrial fibrillation (per month) 1.001 0.943-1.064 0.96 
Persistent atrial fibrillation 1.735 0.919-3.275 0.09 
Hypertension 1.693 0.935-3.064 0.08 
Left atrial volume index (per ml/m2) 1.017 1.003-1.032 0.018* 
Left ventricular ejection fraction (per %) 1.006 0.964-1.051 0.77 
    
Multi-detector row computed tomography    
 Significant coronary artery disease on angiography 1.238 0.527-2.903 0.62 
 Coronary calcium score     
 > 0 1.584 0.836-2.999 0.16 
 > 400 1.663 0.739-3.742 0.22 
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Discussion 
The present study investigated the impact of CAD on the efficacy of RFCA for 
AF. The main finding was that the presence of CAD was not a determinant of 
RFCA outcome. Moreover, there was no relationship between the CCS and the 
risk for AF recurrence after RFCA.  
 
Coronary artery disease and atrial fibrillation 
Coronary artery disease has frequently been associated with the development 
of AF. 1,2,5,11-13 Both conditions are commonly present in the same group of 
patients and many risk factors predisposing for CAD are risk factors to develop 
AF.11,12 However, it remains controversial whether there is a causal relationship 
between CAD and the development of AF.14 Ischemic left ventricular 
dysfunction can increase left atrial pressures and eventually cause left atrial 
wall remodeling providing the substrate for AF.2 However, the Manitoba 
follow-up study demonstrated that the impact of symptomatic ischemic heart 
disease on the development of AF was independent of the presence of 
congestive heart failure.13 Importantly, these results imply that CAD can result 
in AF without causing left ventricular systolic dysfunction. Recently, Nishida et 
al. demonstrated that chronic occlusion of an atrial coronary branch in a canine 
model leads to increased atrial ectopy and conduction abnormalities that 
facilitate reentry.15 These results imply that chronic atrial ischemia or an atrial 
infarction can provide the triggers and substrate needed to develop AF. 
However, the impact of CAD on the outcome of rhythm control therapies has 




Coronary artery disease and the efficacy of radiofrequency catheter 
ablation 
Radiofrequency catheter ablation is a curative treatment option for AF and is 
currently performed in an increasing number of patients.3,16 The cornerstone of 
most ablation strategies is electrical isolation of the pulmonary vein region 
thereby preventing the ectopic beats originating from that area to trigger AF.3 
However, pulmonary vein isolation seems to be less effective in patients with a 
high degree of atrial disease (e.g. patients with a large left atrial volume and/or 
a high extent of atrial fibrosis).17-19 In the presence of extensive atrial disease, 
pulmonary vein triggers seem to be less important in the initiation and 
perpetuation of AF than in patients with relatively healthy atria. 
Coronary artery disease can cause myocardial ischemia, resulting in an 
impaired relaxation of the left ventricle and leading to higher pressures in the 
left atrium. High left atrial pressures cause ultrastructural and electrical changes 
in the atrial tissue, potentially limiting the efficacy of RFCA for AF. In the 
present study no relationship was observed between the presence of CAD and 
the risk for AF recurrence after RFCA and therefore, the presence of CAD does 
not limit the efficacy of RFCA for AF. Most likely, in patients without 
symptomatic CAD, other pathophysiological factors such as age and 
hypertension may contribute to left atrial structural remodelling and limit the 
efficacy of RFCA. To our best knowledge this is the first study to investigate the 
impact of CAD on the efficacy of RFCA for AF.  
 
Limitations 
Some limitations of the present study should be acknowledged. First, MDCT 
provides anatomical information of the coronary arteries. However, MDCT does 
not provide information about the presence or absence of myocardial 
ischemia. Second, the present study included patients with symptomatic AF 
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but without complaints of chest pain. Therefore, the present study population 
comprised a low risk population for significant CAD.  
 
Conclusion 
The presence of significant or non-significant CAD on MDCT is not associated 
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Background: Multi-slice computed tomography (MSCT) is commonly acquired 
prior to radiofrequency catheter ablation (RFCA) for atrial fibrillation (AF) in 
order to plan and guide the procedure. Importantly, MSCT allows accurate 
measurement of left atrial (LA) and pulmonary vein (PV) dimensions and 
classification of PV anatomy. The aim of this study was to investigate the 
impact of LA dimensions, PV dimensions and PV anatomy on the outcome of 
circumferential RFCA for AF.  
Methods: One hundred consecutive patients undergoing RFCA for AF 
(paroxysmal 72%, persistent 28%) were studied. Left atrial dimensions, PV 
dimensions and PV anatomy were evaluated three-dimensionally on MSCT. 
Pulmonary vein anatomy was classified as normal or atypical based on the 
absence/presence of a common trunk or additional vein(s).  
Results: After a mean follow up of 11.6 ± 2.8 months, 65 patients (65%) 
maintained sinus rhythm. Enlargement of the LA in anterior-posterior direction 
on MSCT was related to a higher risk for AF recurrence. No relation was found 
between PV dimensions and outcome of RFCA. In addition, normal right-sided 
PV anatomy was related to a higher risk for AF recurrence compared to atypical 
right-sided PV anatomy. Multivariate analysis showed that anterior-posterior 
LA diameter on MSCT (OR=1.083, p=0.027) and normal right-sided PV anatomy 
(OR=6.711, p=0.006) were independent predictors of AF recurrence after RFCA.  
Conclusion: Enlargement of anterior-posterior LA diameter and presence of 
normal anatomy of the right PVs are independent risk factors for AF recurrence. 
No relation was found between PV dimensions and outcome of RFCA.  
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Introduction 
Multi-slice computed tomography (MSCT) is nowadays commonly acquired 
prior to radiofrequency catheter ablation (RFCA) for atrial fibrillation (AF). Multi-
slice computed tomography provides important information about the left 
atrial (LA) and pulmonary vein (PV) anatomy which can be used to plan and 
guide the RFCA procedure.1 Moreover, MSCT allows accurate three-
dimensional assessment of LA and PV dimensions.2,3 It has been demonstrated 
that LA dimensions and PV dimensions are enlarged in patients with AF.4,5 
However, whereas LA size is a well-known risk factor for AF recurrence after 
RFCA,6-9 little is known about the prognostic importance of PV dilatation. 
Similarly, the impact of PV anatomy on the outcome of RFCA has not been 
studied extensively. Potentially, different anatomical drainage patterns could 
be accompanied by different tissue characteristics of the surrounding 
myocardium that may increase the resistance of the PV area to electrical 
isolation. Moreover, certain anatomical variants could pose a technical 
difficulty to achieve stable catheter position during ablation thereby 
compromising effective lesion formation. This study describes the impact of LA 
dimensions, PV dimensions and PV anatomy assessed by MSCT on the outcome 
of circumferential RFCA for AF. 
 
Methods 
Patient population and evaluation 
The patient population comprised 100 consecutive patients with symptomatic 
drug-refractory AF, undergoing circumferential RFCA. After RFCA, all patients 
were evaluated on a regular basis at the outpatient clinic during a 12 months 
follow-up period. Routine electrocardiograms were recorded each visit and 24-
hour Holter registrations were scheduled at 3, 6 and 12 months after the 
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ablation. Importantly, all patients were encouraged to immediately obtain an 
electrocardiogram when experiencing palpitations. All medications were 
continued for at least 3 months. Afterwards, anti-arrhythmic drugs were 
discontinued at the discretion of the physician. After a post-ablation blanking 
period of 3 months, recurrence of AF was defined as any recording of AF on 
electrocardiogram or an episode longer than 30 seconds on 24-hour Holter 
monitoring.10 After 12 months follow-up, the study population was divided into 
two groups: patients with maintenance of sinus rhythm (non-recurrence 
group) and patients who had recurrence of AF (recurrence group). 
  
Multi-Slice Computed Tomography  
Image acquisition 
Prior to RFCA, all patients underwent an MSCT examination in order to guide 
the procedure.1 The MSCT scan was performed with a 64-slice Toshiba Aquilion 
64 system (Toshiba Medical Systems, Otawara, Japan). A bolus of 70 ml 
nonionic contrast material (Iomeron 400, Bracco, Milan, Italy) was infused 
through the antecubital vein at a rate of 5 ml/s followed by 50 ml saline 
solution flush. Automatic detection of the contrast bolus in the descending 
aorta was used to time the start of the scan. Craniocaudal scanning was 
performed during breath-hold, without electrocardiogram-gating. Collimation 
was 64 x 0.5 mm, rotation time 400 ms and the tube voltage 100 kV at 250 mA. 
After acquisition, the raw MSCT data were exported, post-processed and 
analyzed on a dedicated workstation (Vitrea 2, Vital Images, Minnetonka, 
Minnesota, USA).  
 
Quantitative measurements  
Pulmonary vein ostium dimensions were evaluated using a 2-dimensional 
viewing mode. To allow accurate assessment, multiplanar reformatting was 
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used to place two orthogonal planes parallel to the course of the vein (Figure 1, 
panel A and B). The third orthogonal plane, oriented perpendicular to the 
course of the vein, was then used to measure the diameter of the PV ostium in 
anterior-posterior and superior-inferior direction (Figure 1, panel C). The ratio 
between the largest and smallest diameter was calculated in order to obtain 
information on the oval shape of the ostium. Similarly, multiplanar 
reformatting was used to assess LA dimensions in 3 orthogonal directions: 
anterior-posterior, longitudinal and transversal direction (Figure 2). Left atrial 
volume was calculated using the biplane dimension-length formula: LA volume 
= 4/3  × (anterior-posterior diameter/2) × (longitudinal diameter/2) × 
(transversal diameter/2).11 
 
Figure 1. Assessment of pulmonary vein diameters. To assess pulmonary vein diameters, two orthogonal 
planes were placed parallel to the course of the vein (panel A and B). A third orthogonal plane (panel C), 
oriented perpendicular to the course of the vein, was then used to measure the anterior-posterior (AP) and 
superior-inferior (SI) pulmonary vein diameter (white arrows). 
 
Pulmonary vein anatomy 
Pulmonary vein anatomy was analyzed from an external view using a three-
dimensional volume-rendered reconstruction. Pulmonary vein classification 
was based on the presence or absence of a common trunk and/or additional 
vein(s) (Figure 3). A common trunk was defined when the superior and the 
inferior PV joined more than 5 mm before entering in the LA. An additional vein 





Figure 2. Assessment of left atrial dimensions. The left atrial (LA) dimensions (white arrows) were assessed in 
three orthogonal directions by using multiplanar reformatting. Panel A: LA dimensions in anterior-posterior 
(AP) (red line) and longitudinal direction (green line). Panel B: LA dimension in transversal direction (green 
line). Panel B is a cross-section of panel A at the level of the crosshair and parallel to the red line. 
 
 To evaluate the impact of PV anatomy on the outcome of RFCA for AF, 
left- and right-sided anatomy was additionally classified as normal or atypical. 
Atypical anatomy was defined as the presence of a common trunk or an 
additional PV. 
 
Radiofrequency catheter ablation  
The RFCA procedure was aimed at creating two circumferential lesions around 
the left- and right-sided ipsilateral PVs approximately 1 cm outside the ostia. All 
patients received intravenous heparin to maintain an activated clotting time of 
300-400 s. Intracardiac echocardiography was used to guide the transseptal 
puncture. To guide the ablation, a non-fluoroscopic electroanatomical 
mapping system with MSCT integration was used (CARTO XPTM with 
CartomergeTM, Biosense Webster, Diamond Bar, California, USA). Contact 
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mapping and ablation was performed using a 4-mm quadripolar open-loop 
irrigated mapping/ablation catheter (7Fr NavistarTM, Biosense Webster). A 6Fr 
quadripolar diagnostic catheter placed inside the right atrium served as a 
temporal reference. Radiofrequency current was applied at 30-35 W with a 
maximum temperature of 45°C and an irrigation flow of 20 ml/min until a 
bipolar voltage of <0.1 mV was achieved, with a maximum of 60 s per point. 
The end-point of the procedure was PV isolation as confirmed by recording 
entrance block during sinus rhythm or pacing from inside the coronary sinus.10  
 
Statistical analysis 
Statistical analyses were performed with SPSS software (version 16.0, SPSS Inc., 
Chicago, Illinois, USA). A p-value of <0.05 was considered statistically 
significant. Data are presented as mean ± SD or as number (percentage). 
Statistical comparisons for continuous variables were performed with the two 
-test, paired or unpaired as appropriate. Statistical 
comparisons for categorical variables were performed with the Chi-square test. 
Univariate and multivariate logistic regression analyses were performed to 
study the impact of clinical characteristics, LA dimensions and PV dimensions 
and anatomy on the incidence of AF recurrence after RFCA. Variables with a p-




Figure 3. Classification of pulmonary vein anatomy. Panel A: Separate ostia of the left-sided pulmonary veins; 
Panel B: Separate ostia of the right-sided pulmonary veins; Panel C: Common trunk of the left-sided 
pulmonary veins (defined as a joint part of the superior and the inferior pulmonary veins of more than 5 mm, 
before entering the left entering); Panel D: Additional right-sided pulmonary vein (defined as a 
supranumerary vein directly entering the left atrium). Add = additional pulmonary vein, LIPV = left inferior 
pulmonary vein, LSPV = left superior pulmonary vein, RIPV = right inferior pulmonary vein, RSPV = right 
superior pulmonary vein. 
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Results 
Patient characteristics  
One hundred consecutive patients were included (77 men, mean age 56 ± 9 
years), from an ongoing clinical registry.12 Atrial fibrillation was paroxysmal in 
72 patients and persistent in 28 patients according to the American College of 
Cardiology/American Heart Association/European Society of Cardiology 
guidelines definitions.13 None of the patients had previously undergone RFCA 
for AF. Median duration of AF was 48 months (interquartile range: 24-84) and 
the mean number of anti-arrhythmic drugs used was 3.1 ± 1.3 per patient. The 
mean anterior-posterior diameter of the LA was 43 ± 6 mm and the mean left 
ventricular ejection fraction was 58 ± 8% on transthoracic echocardiography 
(Table 1). The procedural end-point of PV isolation was achieved in all patients. 
In 11 patients a repeat procedure was performed due to early recurrence of AF. 
 After a mean follow-up of 11.6 ± 2.8 months, 65 patients (65%) had 
maintained sinus rhythm (non-recurrence group), whereas 35 patients (35%) 
had recurrence of AF (recurrence group). Anti-arrhythmic drug treatment had 
been discontinued in 16 patients (25%) who had maintained sinus rhythm and 
in 12 patients (34%) with AF recurrence (p=0.30). In the recurrence group a 
higher prevalence of persistent AF was found compared to the non-recurrence 
group (14 [22%] vs. 14 [40%], p=0.049).  
 
Left atrial dimensions 
Left atrial dimensions were measured in three orthogonal directions on MSCT: 
anterior-posterior, longitudinal and transversal (Figure 2). Mean anterior-
posterior diameter was 41 ± 7 mm, mean longitudinal diameter was 65 ± 8 mm 
and mean transversal diameter was 59 ± 7 mm. Anterior-posterior LA diameter 
was significantly larger in the recurrence group than in the non-recurrence 
group (43 ± 6 mm vs. 39 ± 7 mm, p=0.02). Interestingly, no differences were 
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found between the recurrence group and non-recurrence group in 
longitudinal (64 ± 7 mm vs. 65 ± 9 mm, p=0.45) and transversal (59 ± 7 mm vs. 
60 ± 7 mm, p=0.57) LA diameter. Mean LA volume was 82 ± 23 ml. Left atrial 
volume was larger in the recurrence group than in the non-recurrence group 
(88 ± 26 ml vs. 78 ± 21 ml, p=0.04). 
 
 
Table 1. Baseline characteristics 
Variable Total  
(n = 100) 
Age (years) 56.4 ± 8.6 
Male/female  77/23 
Body Surface Area (m2) 2.1 ± 0.2 
Type of atrial fibrillation (paroxysmal/persistent) 72/28 
Duration of atrial fibrillation (months) 64 ± 60 
Anti-arrhythmic drugs used per patient 3.1 ± 1.3 
Hypertension 53 (53%) 
Coronary artery disease 8 (8%) 
Diabetes mellitus  8 (8%) 
Echocardiography  
Anterior-posterior left atrial diameter (mm) 43 ± 6 
Left ventricular ejection fraction (%) 58 ± 8 
 
 
Pulmonary vein dimensions 
Pulmonary vein ostial dimensions were assessed in anterior-posterior and 
superior-inferior direction on MSCT (Table 2). Pulmonary vein dimensions were 
larger in superior-inferior direction than in anterior-posterior direction (21.1 ± 
2.3 mm vs. 16.3 ± 2.5 mm, p<0.001). Overall, right-sided PVs had a larger 
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diameter than left-sided PVs (20.0 ± 2.4 mm vs. 16.6 ± 1.6 mm, p<0.001). 
Similarly, superior PVs had a larger diameter than inferior PVs (19.6 ± 3.8 mm vs. 
17.5 ± 3.1 mm, p<0.001). With regard to the shape of the PV ostium, left-sided 
PVs had a more pronounced oval shape than right-sided PV ostia indicated by a 
lower ratio between the largest and smallest PV diameter (ratio 0.65 ± 0.09 vs. 
0.84 ± 0.09, p<0.001). 
 










Right superior pulmonary 
vein 
18.8 ± 4.2 23.3 ± 4.5 21.0 ± 4.0 0.80 ± 0.11 
Right inferior pulmonary vein 17.7 ± 2.9 20.3 ± 3.2 19.0 ± 2.8 0.87 ± 0.10 
Left superior pulmonary vein 14.3 ± 2.6 21.1 ± 3.6 17.7 ± 2.4 0.67 ± 0.13 
Left inferior pulmonary vein 12.1 ± 2.7 18.8 ± 2.5 15.4 ± 2.0 0.65 ± 0.15 
Additional pulmonary vein 8.9 ± 3.1 10.1 ± 2.4 9.5 ± 2.5 0.82 ± 0.11 
Left common trunk 19.5 ± 4.5 33.5 ± 4.7 26.5 ± 3.4 0.59 ± 0.15 
All right  pulmonary veins 18.2 ± 2.5 21.8 ± 2.8 20.0 ± 2.4 0.83 ± 0.08 
All left pulmonary veins 13.2 ± 2.5 19.9 ± 2.0 16.6 ± 1.6 0.66 ± 0.11 
All pulmonary veins 16.3 ± 2.5 21.1 ± 2.3 18.7 ± 2.2 0.77 ± 0.09 
 
 Pulmonary vein dimensions were not related to the recurrence of AF 
during follow-up: no differences were found in mean PV diameter between the 
recurrence and non-recurrence group (18.8 ± 2.2 mm vs.18.6 ± 2.2 mm, 
p=0.74). In addition, a similar oval shape of the PV ostia was found in the both 
groups (non-recurrence group versus recurrence group: ratio 0.77 ± 0.09 vs. 




Pulmonary vein anatomy 
Pulmonary vein anatomy was assessed based on the presence/absence of a 
common trunk and/or additional PV. A total of 174 left-sided PVs and 226 right-
sided PVs were identified on MSCT. Separate ostia of the left superior PV and 
left inferior PV were present in 74 patients (74%) and a common trunk of the 
left PVs was present in the remaining 26 patients (26%). In addition, separate 
ostia of the right superior PV and right inferior PV were observed in 78 patients 
(78%), an additional right-sided PV in 18 patients (18%) and 2 additional right-
sided veins in 4 patients (4%). Accordingly, atypical anatomy of the left-sided 
PVs was present in 26 patients (26%) and atypical anatomy of the right-sided 
PVs was observed in 22 patients (22%). 
 Normal anatomy of the right-sided PVs was associated with a 
significantly higher risk for AF recurrence compared to atypical anatomy of the 
right-sided PVs (unadjusted OR: 7.353, p=0.010). In contrast, the presence of 
normal or atypical anatomy of the left-sided PVs had no significant impact on 
the outcome of RFCA (unadjusted OR: 2.145, p=0.14). 
 
Predictors of AF recurrence  
Univariate logistic regression analyses were performed to study the impact of 
LA dimensions, PV dimensions and PV anatomy, as well as clinical risk factors 
(e.g. type AF, hypertension) on the outcome of RFCA for AF (Table 3). A large 
anterior-posterior LA diameter (unadjusted OR: 1.082, p=0.021) and a large LA 
volume (unadjusted OR: 1.019, p=0.045) were related to a higher risk for 
recurrent AF after RFCA. Similarly, patients with persistent AF had a higher risk 
for AF recurrence (unadjusted OR: 2.429, p=0.049). The presence of normal 
right-sided PV anatomy was related to a higher risk for AF recurrence 
(unadjusted OR: 7.353, p=0.010). Subsequent multivariate analyses 
demonstrated that anterior-posterior LA diameter (OR: 1.083, p=0.027), 
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persistent AF (OR: 3.004, p=0.035) and normal right-sided PV anatomy (OR: 
6.711, p=0.006) were independent predictors of AF recurrence (Table 4). 
 
Table 3. Univariate logistic regression analysis of clinical and anatomical characteristics on multi-slice 
computed tomography as risk factors for recurrence of atrial fibrillation after radiofrequency catheter 
ablation 
Variable OR 95% CI P-value 
Clinical and echocardiographic characteristics    
Age (per years) 1.027 0.978-1.079 0.28 
Male gender  1.012 0.381-2.691 0.98 
AF duration (per months)   1.032 0.952-1.118 0.45 
Failed anti-arrhythmic drugs (per drug) 1.109 0.802-1.532 0.53 
Persistent atrial fibrillation 2.429 0.989-5.963 0.049* 
Hypertension 0.908 0.399-2.067 0.82 
Left ventricular ejection fraction (per %) 0.971 0.920-1.026 0.30 
Multi-slice computed tomography characteristics    
Normal right-sided pulmonary vein anatomy 7.353 1.603-33.333 0.010* 
Normal left-sided pulmonary vein anatomy 2.146 0.771-5.988 0.14 
Mean pulmonary vein diameter (per mm) 1.033 0.856-1.247 0.73 
Left atrial diameter    
Anterior-posterior (per mm) 1.082 1.012-1.156 0.021*  
Longitudinal (per mm) 1.021 0.967-1.078 0.45 
Transversal (per mm) 1.018 0.958-1.082 0.57 
Left atrial volume (per ml) 1.019 1.000-1.038 0.045* 




Table 4. Multivariate logistic regression analysis of clinical and anatomical characteristics on multi-slice 
computed tomography as risk factors for recurrence of atrial fibrillation after radiofrequency catheter 
ablation 
Variable OR 95% CI P-value 
Clinical characteristics    
Persistent atrial fibrillation 3.004 1.082-8.345 0.035 
    
Multi-slice computed tomography characteristics    
Normal right-sided pulmonary vein anatomy 6.711 1.736-26.316 0.006 
Left atrial diameter    
Anterior-posterior (per mm) 1.083 1.009-1.162 0.027 




The present study investigated the impact of LA dimensions, PV dimensions 
and PV anatomy on the outcome of circumferential RFCA for AF. The main 
findings were that enlargement of the LA in direction on MSCT was an 
independent predictor of AF recurrence after RFCA. In contrast, PV dimensions 
were not related to the outcome of RFCA. Finally, atypical anatomy of the right-
sided PVs was independently associated with less recurrences of AF after RFCA.  
 
Left atrial dimensions  
Left atrial enlargement is an important risk factor for the development of AF in 
the general population,14 and has been identified as an independent predictor 
of AF recurrence after RFCA.6-9 Significant dilatation of the LA is thought to be a 
marker of a large extent of atrial remodeling which may limit the efficacy of 
RFCA. In the present study, assessment of LA dimensions was performed in 
three directions on MSCT: anterior-posterior, longitudinal and transversal. 
Anterior-posterior LA diameter was identified as a predictor of AF recurrence, 
whereas longitudinal and transversal LA diameters were not. Moreover, 
anterior-posterior LA diameter was a stronger predictor of AF recurrence than 
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LA volume. Atrial dilatation is thought to be predominantly oriented in 
longitudinal and transversal direction and not in anterior-posterior direction.11 
A potential explanation for our finding is that the dilatation of the LA in 
anterior-posterior direction occurs at a more advanced stage of atrial 
enlargement and reflects a higher extent of atrial remodeling, thereby 
explaining its prognostic value to predict AF recurrence after RFCA. 
Importantly, anterior-posterior LA diameter was an independent predictor of 
AF recurrence even after correction for type of AF. 
 
Pulmonary vein dimensions and anatomy 
The observations by Haïssaguerre et al. that ectopic beats originating from the 
PVs can initiate AF, have led to an increasing interest in the PVs as target for 
RFCA.15 Nowadays, isolation of the PV region is the cornerstone for most 
ablation strategies.10 However, little is known about the impact of PV 
dimensions and PV anatomy on the efficacy of RFCA for AF.  
 Similar to LA enlargement, PV dimensions are enlarged in patients with 
AF.3-5 Previous series have demonstrated that superior PVs have a larger 
diameter compared to inferior PVs.3,16 This finding has been related to a higher 
incidence of ectopic foci initiating AF originating from the superior PVs than 
from the inferior PVs.15,16 In addition, it is suggested that PV dilatation is 
accompanied by different electrophysiological tissue characteristics in a way 
that AF is more likely to persist.4 However, little is known about the prognostic 
significance of PV dilatation in patients undergoing RFCA to predict AF 
recurrence.  
 The present study evaluated the impact of PV ostial dimensions 
assessed by MSCT on AF recurrence after RFCA. No differences were found in 
PV ostial dimensions or shape between patients with AF recurrence and 
patients without AF recurrence during follow-up. These results suggest that PV 
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dilatation has no prognostic value to predict AF recurrence after 
circumferential RFCA. Most likely, PV dilatation is caused by the presence of AF 
and can be best considered an epiphenomenon. 
 The relation between the anatomy of the PV region and the efficacy 
RFCA for AF has not been studied extensively. Several studies have shown that 
large variations in pulmonary venous drainage pattern into the LA exist.3,17-20 
Potentially, certain anatomical variants could pose a technical challenge to 
achieve stable catheter position thereby influencing the outcome of RFCA. 
Moreover, different venous drainage patterns could be accompanied by 
different tissue characteristics of the surrounding myocardium that may 
increase the resistance of the PV area to electrical isolation. 
 In the present study, the relation between PV anatomy and AF 
recurrence after RFCA was studied. Pulmonary vein anatomy was analyzed on 
MSCT and classified according to the presence or absence of a common trunk 
and/or additional PV as either normal or atypical. Normal anatomy of the right-
sided PVs was associated with an increased risk for AF recurrence after RFCA. 
After correction for anterior-posterior LA diameter and type of AF, normal 
right-sided PV anatomy remained as independent predictor of AF recurrence 
after RFCA. These findings may indicate that an atypical PV drainage pattern 
may be accompanied by an increased susceptibility of the surrounding 
myocardial tissue for electrical isolation or a lower likelihood for PV ectopy 
originating from the right-sided PVs. Furthermore an atypical PV drainage 
pattern may pose less technical difficulty to achieve stable catheter position, 
resulting in a more effective lesion formation and a lower risk for electrical 
reconnection. 
 Recently, Hof et al reported on the impact of PV anatomy on the 
efficacy of RFCA in 146 patients.7 Interestingly, no relation was found between 
PV anatomy and AF recurrence after RFCA. However, the definition of outcome 
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used by Hof et al included three categories (failure, improvement of AF burden 
and complete success),7 and may have precluded from obtaining statistically 
significant differences among the different groups. The use of this definition 
may also explain why type of AF, which is a commonly accepted risk factor for 
AF recurrence,10 was not related to AF recurrence after RFCA in their study.7  
 
Limitations 
Some limitations should be acknowledged. The applicability of MSCT as a pre-
procedural patient selection tool is limited by the radiation exposure inherited 
to this technique. However, since MSCT is commonly acquired prior to RFCA to 
plan and guide the procedure, the present results may help determine whether 
additional ablation is needed in patients who are scheduled for circumferential 
RFCA. Furthermore, this study comprised a relatively small group of patients 
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Background: The presence of atrial fibrillation (AF) is related to increased 
levels of natriuretic peptides. In addition, increased natriuretic peptide levels 
are predictive of the development of AF. However, the role of natriuretic 
peptides to predict recurrence of AF after radiofrequency catheter ablation 
(RFCA) is controversial. 
Objective: To investigate the role of natriuretic peptides to predict AF 
recurrence after RFCA for AF. 
Methods: In 87 patients undergoing RFCA for symptomatic drug-refractory AF, 
pre-procedural NT-proANP and NT-proBNP plasma levels were determined. In 
addition, a comprehensive clinical and echocardiographic evaluation was 
performed at baseline. Left atrial volumes, left ventricular volumes and 
function (systolic and diastolic) were assessed. During a 6 months follow-up 
period, AF recurrence was monitored and defined as any registration of AF on 
ECG or an episode of AF longer than 30 seconds on 24-hour Holter monitoring. 
The role of natriuretic peptide plasma levels to predict AF recurrence after 
RFCA was studied.  
Results: During follow-up, 66 patients (76%) maintained sinus rhythm (SR), 
whereas 21 patients (24%) had AF recurrence. Patients with AF recurrence had 
higher baseline natriuretic peptide levels than patients who maintained SR (NT-
proANP: 3.19 nmol/L [2.55-4.28] versus 2.52 nmol/L [1.69-3.55], p=0.030; NT-
proBNP: 156.4 pg/mL [64.1-345.3] versus 84.6 pg/mL [43.3-142.7], p=0.036). 
However, NT-proBNP was an independent predictor of AF recurrence, whereas 
NT-proANP was not. Moreover, NT-proBNP had an incremental value over 
echocardiographic characteristics to predict AF recurrence after RFCA. 
Conclusion: Baseline NT-proBNP plasma level is an independent predictor of 
AF recurrence after RFCA.  
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Introduction 
Radiofrequency catheter ablation (RFCA) is considered a reasonable treatment 
option for patients with symptomatic, drug refractory atrial fibrillation (AF).1 
However, this treatment modality is associated with a considerable recurrence 
rate.2 Several parameters have been related to a high risk for AF recurrence 
such as age, hypertension, type of AF, left atrial (LA) size and impaired left 
ventricular (LV) systolic function.3-6 These risk factors seem to either cause or 
reflect structural changes (i.e. structural remodeling) of the atria that promote 
the perpetuation of AF and, thereby, limit the efficacy of RFCA. Accordingly, 
pre-procedural evaluation of the extent of atrial remodeling could be used to 
identify patients with an increased risk of AF recurrence after RFCA. However, 
at an early stage of atrial remodeling, conventional imaging techniques (e.g. 
two-dimensional echocardiography to assess LA size) may not be sensitive 
enough to predict whether a patient will experience AF recurrence after RFCA. 
Therefore, more sensitive indicators of atrial remodeling are needed. 
 Natriuretic peptides are hormones released from the atria and/or 
ventricles in response to volume or pressure overload.7 In patients with AF, 
natriuretic peptide levels are elevated.8-10 Potentially, plasma levels of 
natriuretic peptides could provide insight into the presence of underlying 
cardiac conditions that cause structural changes to the LA and may limit the 
efficacy of RFCA.  
 The aim of this study was to investigate the prognostic role of 
natriuretic peptides to predict AF recurrence in patients with preserved LV 




Patient population and evaluation 
The study population included patients with drug-refractory symptomatic 
paroxysmal AF and preserved LV systolic function (ejection fraction >50%), 
who were referred for RFCA. Atrial fibrillation was classified as paroxysmal 
when episodes were generally self-terminating and lasted no longer than 7 
days, according to the American College of Cardiology/American Heart 
Association/European Society of Cardiology guidelines definitions.11  At 
admission, a blood sample was obtained to measure natriuretic peptide levels 
and a comprehensive transthoracic echocardiography examination was 
performed. To minimize the effect of AF on plasma natriuretic peptide levels, 
only patients with paroxysmal AF who were in sinus rhythm (SR) during blood 
sampling were studied. After ablation, all patients were evaluated on a 
systematic basis (1, 3 and 6 months after RFCA) at the outpatient clinic during a 
6 months follow-up period. Routine electrocardiograms (ECG) were recorded 
each visit and 24-hour Holter registrations were scheduled after 3 and 6 
months follow-up. Importantly, all patients were encouraged to obtain an ECG 
registration when experiencing palpitations. During follow-up, all medications 
were continued for at least 3 months. Afterwards, anti-arrhythmic drugs were 
discontinued at the discretion of the physician. After a blanking period of 3 
months, recurrence of AF was defined as any recording of AF on ECG or an 
episode longer than 30 s on 24-hour Holter monitoring. Accordingly, the role of 
baseline clinical characteristics, baseline echocardiographic characteristics and 
baseline natriuretic peptide levels to predict AF recurrence after RFCA was 
studied. 
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Biochemical analysis 
Blood samples were obtained from the antecubital vein at admission. An ECG 
recording was made during sampling to determine the heart rhythm. Plasma 
-
terminal-pro-atrial natriuretic peptide (NT-proANP) were determined using a 
radioimmunoassay (ELISA, Biomedica, Vienna, Austria) which has a 
measurement range of 0 10 nmol/L and a detection limit of 0.05 nmol/L. Inter-
assay variation was 4% and intra-assay variability was 2%. Levels of amino-
terminal-pro-B-type natriuretic peptide (NT-proBNP) were measured using an 
automated immunoassay (Elecsys, Roche, Basel, Switzerland). The reference 
range was 0 400 pg/mL and the intra-assay variability was 1.8% at high 




Two-dimensional transthoracic echocardiography was performed using a 
commercially available ultrasound system (Vivid 7, General Electric Vingmed, 
Milwaukee, WI, United States), equipped with a 3.5-MHz transducer at a depth 
of 16 cm. All patients were imaged in left lateral decubitus position. Two-
dimensional and color Doppler data were obtained in parasternal (short- and 
long-axis) and apical (2- and 4-chamber images) views. All images were ECG-
triggered and stored in cineloop format for offline analyses. Offline analyses 
were performed using EchoPac 108.1.5 (General Electric Medical Systems, 
Horten, Norway). 
 
method.12 Left ventricular (LV) end-diastolic and end-systolic volumes were 
obtained from the apical views and LV ejection fraction was calculated 
12 Left ventricular and atrial volumes were 
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indexed to body surface area. Left ventricular diastolic function was evaluated 
using pulsed-wave Doppler recordings of the mitral valve inflow pattern (E-
wave, A-wave, deceleration time of the E-wave) and Doppler tissue recordings 
-wave). In addition, the diastolic function grade 
was classified as either normal, grade 1 (impaired relaxation), grade 2 
(pseudonormalization) or grade 3 (restrictive filling pattern) as recommended 
by current guidelines.13  
 
Radiofrequency catheter ablation 
The ablation was aimed at creating circular lesions around the left and right 
pulmonary vein ostia. All patients received intravenous heparin to maintain an 
activated clotting time of 300-400 s. Intracardiac echocardiography was used to 
exclude a cardiac thrombus and to guide the transseptal puncture. A non-
fluoroscopic electroanatomical mapping system with multi-slice computed 
tomography integration was used to guide the ablation procedure (CARTO 
XPTM, CartomergeTM, Biosense Webster, Diamond Bar, CA, USA). Mapping and 
ablation was performed using a 3.5-mm quadripolar open-loop irrigated 
mapping/ablation catheter (7.5Fr NavistarTM, Biosense Webster). 
Radiofrequency current was applied at 30-35 W with a maximum temperature 
of 45°C and an irrigation flow of 20 ml/min until a bipolar voltage of <0.1 mV 
was achieved, with a maximum of 60 s per point. The end-point of the 
procedure was PV isolation as confirmed by recording entrance block during 
SR or pacing in the coronary sinus.1  
 
Statistical analysis 
All variables were tested for a normal distribution with the Kolmogorov-
Smirnov test. Normally distributed continuous variables are represented as 
mean ± SD and non-normally distributed continuous variables are represented 
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as median (25th - 75th percentile). Categorical variables are presented as number 
(percentage). Statistical comparisons for continuous variables were performed 
-test or with the Mann-Whitney U-test as appropriate. 
Statistical comparisons for categorical variables were performed with the Chi-
square test. Univariable and multivariable Cox proportional hazard analyses 
were performed to investigate the relation between natriuretic peptide levels 
and the risk for AF recurrence after ablation. Multivariable analyses were 
Due to the limited number of events, 
multivariable analyses were limited to three variables. Separate models were 
created to correct for known clinical determinants of natriuretic peptide levels 
(age and gender) and to correct for the strongest univariate predictors of AF 
recurrence in the present population (LA volume index and LV end-systolic 
volume index). The incremental prognostic value of natriuretic peptides to 
predict AF recurrence was studied by calculating the improvement in global 
Chi-square after addition of NT-proANP or NT-proBNP to the model. In 
addition, for each Cox regression model the c-statistic was calculated. All 
statistical analyses were performed with SPSS software (version 16.0, SPSS Inc., 
Chicago, IL, USA). A value of p<0.05 was considered statistically significant. 
 The authors are solely responsible for the design and conduct of this 
study, all study analyses, the drafting and editing of the paper and its final 




The present patient population was prospectively included from an ongoing 
clinical registry.14 Out of 140 consecutive patients undergoing catheter ablation 
for AF, 87 patients were in SR during the baseline blood test and comprised the 
patient population (70 men [80%], mean age 55.0 ± 9.4 years). None of the 
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patients previously underwent RFCA for AF. Mean duration of AF was 65 ± 60 
months and the mean number of anti-arrhythmic drugs used was 3.4 ± 1.4 per 
patient. Mean LA volume index was 42 ± 12 ml/m2 and mean LV ejection 
fraction was 59 ± 6% as assessed by transthoracic echocardiography. The mean 
pre-procedural AF burden on 24-hour Holter monitoring was 8 ± 19%. None of 
the patients had significant valvular heart disease. The procedural end-point of 
PV isolation was reached in all patients. No major peri-procedural 
complications occurred. 
 
Table 1. Clinical characteristics of the patient population 








Age (years) 55 ± 9 55 ± 9 56 ± 11 0.78 
Male gender, n (%) 70 (80) 52 (79) 18 (86) 0.49 
Body Surface Area (m2) 2.1 ± 0.2 2.1 ± 0.2 2.1 ± 0.2 0.93 
Duration of AF (months) 65 ± 60 62 ± 59 73 ± 64 0.48 
History of cardioversion, n (%) 53 (61) 38 (58) 15 (71) 0.32 
History of persistent AF, n (%) 9 (10) 6 (9) 3 (14) 0.50 
Number of failed AAD 3.4 ± 1.4 3.3 ± 1.3 3.7 ± 1.4 0.27 
Pre-procedural AF burden (%)  8 ± 19 8 ± 18 9 ± 20 0.68 
Hypertension, n (%) 37 (43) 27 (41) 10 (48) 0.70 
Medication:     
 -Blocker, n (%) 21 (25) 14 (21) 7 (33) 0.27 
 Ca-channel blocker, n (%) 16 (18) 11 (17) 5 (24 0.46 
 Class IC AAD, n (%) 30 (35) 24 (36) 6 (29) 0.49 
 Class III AAD, n (%) 51 (60) 38 (58) 13 (62) 0.78 
 ACE inhibitor/ATII, n (%) 40 (46) 28 (42) 12 (57) 0.23 
AAD = Anti-arrhythmic drugs, AF = atrial fibrillation, ECV = electrocardioversion, FU = follow-up, LA = left 
atrium, SR = sinus rhythm. * p-value recurrence versus non-recurrence. 
 
 After a mean follow-up of 6.6 ± 3.0 months, 66 patients (76%) 
maintained stable SR (non-recurrence group), whereas 21 patients (24%) had 
recurrent AF (recurrence group). Baseline clinical and echocardiographic 
characteristics are reported in Tables 1 and 2, respectively. In the recurrence 
group significantly larger LV volumes were noted compared to the non-
Natriuretic peptide levels predict recurrence of AF after RFCA 
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recurrence group (LV end-diastolic volume index: 54 ± 9 ml/m2 versus 48 ± 12 
ml/m2, p=0.037; and LV end-systolic volume index: 23 ± 4 ml/m2 versus 20 ± 6 
ml/m2, p=0.027). Importantly, LV systolic function was similar in both groups 
(LV ejection fraction: 57 ± 4% versus 59 ± 6%, p=0.32). Furthermore, in the 
recurrence group a significantly higher E-wave velocity (0.75 ± 0.23 m/s versus 
-ratio (10.1 ± 4.0 versus 8.4 ± 3.1, p=0.049) 
and higher LA volume index (47 ± 12 ml/m2 versus 41 ± 11 ml/m2, p=0.043) 
were observed. However, no differences in diastolic function grade were found 
between both groups, with the majority of the patients showing normal LV 
filling pattern (Table 2).  
 
Table 2. Echocardiographic characteristics of the patient population 








LA maximum volume index (ml/m2) 42 ± 12 41 ± 11 47 ± 12 0.043 
LV end-diastolic volume index (ml/m2) 50 ± 11 48 ± 12 54 ± 9 0.037 
LV end-systolic volume index (ml/m2) 21 ± 5 20 ± 6 23 ± 4 0.027 
LV ejection fraction (%) 59 ± 6 59 ± 6 57 ± 4 0.32 
     
Pulsed wave Doppler:     
 E-wave (m/s) 0.68 ± 0.17 0.65 ± 0.14 0.75 ± 0.23 0.021 
 A-wave (m/s) 0.61 ± 0.16 0.61 ± 0.17 0.61 ± 0.12 0.97 
 E/A-ratio 1.14 ± 0.35 1.12 ± 0.34 1.21 ± 0.40 0.36 
 Deceleration time (s) 252 ± 74 247 ± 70 267 ± 88 0.30 
     
Doppler tissue imaging:     
 -wave (cm/s) 8.3 ± 2.5 8.5 ± 2.6 7.8 ± 2.1 0.30 
 -ratio 8.8 ± 3.4 8.4 ± 3.1 10.1 ± 4.0 0.049 
       
Diastolic function grade:     
 Normal, n (%) 55 (63) 43 (65) 12 (57) 0.51 
 Gr 1: Impaired relaxation, n (%) 32 (37) 23 (35) 9 (43)  
 Gr 2: Pseudo-normalization, n (%) 0 (0) 0 (0) 0 (0)  
 Gr 3: Restrictive filling pattern, n 
(%) 
0 (0) 0 (0) 0 (0)  
AF = atrial fibrillation, FU = follow-up, Gr = grade, LA = left atrium, LV = left ventricle, SR = sinus rhythm. * p-




Natriuretic peptides and AF recurrence after RFCA 
Prior to the ablation procedure, blood samples were obtained to measure 
baseline NT-proANP and NT-proBNP levels. The median level of NT-proANP was 
2.69 nmol/L (1.86-3.60) and the median level of NT-proBNP was 90.9 pg/mL 
(49.9-159.9). No relation was found between baseline NT-proANP and NT-
proBNP levels and pre-procedural AF burden assessed by 24-hour Holter 
monitoring. Baseline NT-proANP and NT-proBNP levels were significantly 
higher in the recurrence group than in the non-recurrence group (NT-proANP: 
3.19 nmol/L [2.55-4.28] versus 2.52 nmol/L [1.69-3.55], p=0.030; NT-proBNP: 
156.4 pg/mL [64.1-345.3] versus 84.6 pg/mL [43.3-142.7], p=0.036) (Figure 1). 
Cox proportional hazard analyses showed that each 100 pg/mL increase in NT-
proBNP level was associated with an approximately 35% increased risk for AF 
recurrence (unadjusted HR: 1.205, p=0.029) (Figure 2). In contrast, each nmol/L 
increase in NT-proANP level was not significantly associated with a higher risk 
for AF recurrence (unadjusted HR: 1.204, p=0.055) (Figure 2). After correction 
for age and gender, the prognostic value of NT-proANP to predict AF 
recurrence improved (HR: 1.292, p=0.029) but was lost after correction for LA 
size and LV size (HR: 1.213, p=0.088) (Figure 2). In contrast, NT-proBNP 
maintained its prognostic value to predict AF recurrence after correcting both 
for age and gender and for LA size and LV size (HR: 1.390, p=0.006; HR: 1.250, 
p=0.023, respectively) (Figure 2). Furthermore, addition of NT-proBNP to a Cox 
model including LA volume index and LV end-systolic volume index resulted in 
a significant improvement of the global Chi-square value (7.0 vs 11.7, p=0.033), 
illustrating the incremental value of NT-proBNP over LA size and LV size to 
predict AF recurrence after RFCA (Figure 3). In contrast, NT-proANP had no 
incremental value over LA volume index or LV end-systolic volume to predict 
AF recurrence after RFCA (global Chi-square 7.0 vs 9.9, p=0.11) (Figure 3). The c-
statistics for each Cox model are shown in table 3. 
Natriuretic peptide levels predict recurrence of AF after RFCA 
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Figure 1. Baseline natriuretic peptide levels in patients with and without recurrence of atrial fibrillation (AF). 
Bar graphs representing median and 75th percentile of amino-terminal-pro-atrial natriuretic peptide (NT-
proANP) and amino-terminal-pro-B-type natriuretic peptide (NT-proBNP) levels measured at baseline in 
patients with AF recurrence and in non-recurrence patients. Baseline NT-proANP and NT-proBNP levels were 
significantly higher in patients with recurrence of AF during follow-up compared to non-recurrence patients. 
 
Discussion 
The present study investigated the role of natriuretic peptides to predict AF 
recurrence after RFCA in patients without signs of structural heart disease. The 
main finding was that pre-procedural NT-proBNP plasma level was an 
independent predictor of AF recurrence after RFCA. Importantly, NT-proBNP 
plasma level had an incremental value over echocardiographic parameters to 
predict the AF recurrence after RFCA. 
 
Conventional echocardiography and AF recurrence after RFCA 
Echocardiography is an important tool to identify patients with a high risk for 
AF recurrence after RFCA. In particular, LA enlargement on echocardiography is 
a well recognized risk factor for AF recurrence after RFCA.4,5,15 In the present 
study, patients with AF recurrence had significantly larger LA than patients 
who maintained SR during follow-up. This finding is consistent with other 
studies.4,5,15 Most likely, a large LA size reflects a high extent of atrial 
remodeling, which is associated with a limited efficacy of RFCA.  
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Figure 2. Cox proportional hazard analyses of baseline natriuretic peptide levels as predictor of atrial 
fibrillation (AF) recurrence. Hazard ratios unadjusted and corrected for age/gender and left atrial (LA) size/left 
ventricular (LV) size to predict AF recurrence after catheter ablation using baseline natriuretic peptide levels. 
Left atrial volume index and LV end-diastolic volume index were used to correct for LA and LV size, 
respectively. NT-proANP = amino-terminal-pro-atrial natriuretic peptide, NT-proBNP = amino-terminal-pro-B-
type natriuretic peptide. 
 
 In addition to being a marker of structural LA remodeling, LA 
enlargement is a morphologic marker of chronic elevation in LV filling pressure 
(i.e. diastolic dysfunction).16 Atrial fibrillation has been associated with LV 
diastolic dysfunction previously.17 Elevated LV filling pressure may result in an 
elevated LA pressure and, consequentially, in LA dilatation. Accordingly, 
diastolic dysfunction may induce ultrastructural changes of the atria which 
facilitate re-entry and play an important role in the progression and 
perpetuation of AF.18,19 In the present study, patients with AF recurrence had a 
significantly larger LA size, increased E- -
ratio, compared to patients who maintained SR. However, in the present study 
these diastolic function parameters were within normal range. Moreover, the 
Natriuretic peptide levels predict recurrence of AF after RFCA 
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majority of patients showed a normal LV filling pattern and the prevalence of 
diastolic dysfunction grade 1 was similar in patients with and without AF 
recurrence. Therefore, at an early stage of the underlying disease, conventional 
echocardiography may not be sensitive enough to identify patients who will 
develop AF recurrence after RFCA from patients who will not. The use of more 




Figure 3. Incremental value of amino-
terminal-pro-atrial natriuretic peptide 
(NT-proANP) and amino-terminal-pro-
B-type natriuretic peptide (NT-
proBNP) to predict atrial fibrillation 
(AF) recurrence after ablation. Bar 
graph illustrating the change in global 
Chi-square value by the addition of 
NT-proANP or NT-proBNP to a Cox 
proportional hazard model 
comprising left atrial volume index 
and left ventricular end-diastolic volume index (Model 1). The addition of NT-proANP to the model did not 
result in significant improvement of the global Chi-square. In contrast, the addition of NT-proBNP 
significantly improved the global Chi-square, thereby demonstrating the incremental value of NT-proBNP to 
predict AF recurrence after RFCA.Natriuretic peptides and AF recurrence after RFCA 
 
The relation between natriuretic peptide levels and AF has been well 
recognized.8-10,20,21 Previous studies have demonstrated that natriuretic peptide 
levels are elevated in patients with AF,8-10 and that natriuretic peptides are a 
predictor of new-onset AF in the general population.20,21 Nevertheless, the role 
of natriuretic peptides to identify patients with a high risk for AF recurrence 
after RFCA remains controversial. Although several studies have demonstrated 
the value of natriuretic peptides to predict AF recurrence after RFCA,22,23 other 
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studies concluded that natriuretic peptides are merely a marker of AF 
burden.24-26 However, most studies comprised a small number of patients and 
were performed without regard of the presence of AF during blood sampling. 
This is important because the presence of AF has a large impact on natriuretic 
peptide levels and can potentially limit its prognostic value.8,27 To minimize this 
potential effect in the present study, only samples acquired during SR were 
analyzed. After statistical correction for known determinants of natriuretic 
peptide levels as well as for echocardiographic risk factors for AF recurrence, 
NT-proBNP was found to be a strong predictor of AF recurrence after RFCA. In 
contrast, NT-proANP levels were only predictive for AF recurrence after 
correction for age and gender. These results most likely reflect the different 
sensitivities of the NT-proANP and NT-proBNP release mechanisms to the 
primary process causing AF.28 Furthermore, the present study demonstrated 
that baseline NT-proBNP had an additional value to baseline 
echocardiographic parameters to predict AF recurrence after RFCA. Most likely, 
NT-proBNP allows detection of subtle cardiac dysfunction/conditions that limit 
the efficacy of RFCA for AF and may not be detected by conventional 
echocardiography alone.  
 
Table 3. Cox proportional hazards models  
 C-statistic 95% confidence interval 
Model 1 0.719 0.601-0.836 
Model 1 + NT-proANP 0.763 0.661-0.864 
Model 1 + NT-proBNP 0.762 0.647-0.877 
Model 1: Left atrial maximum volume index + left ventricular end-diastolic volume index. NT-proANP = 
amino-terminal-pro-atrial natriuretic peptide, NT-proBNP = amino-terminal-pro-B-type natriuretic peptide 
 
Clinical implications 
Pre-procedural assessment of NT-proBNP in addition to echocardiography can 
be used to identify patients with a high risk for AF recurrence after RFCA. In 
Natriuretic peptide levels predict recurrence of AF after RFCA 
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patients with paroxysmal AF and preserved LV systolic function, NT-proBNP 
levels may provide insight into the presence and severity of an underlying 
cardiac dysfunction/condition that may not be detected by echocardiography. 
If further validated, this information may be used during pre-procedural 
consultation to better inform patients about their risk for AF recurrence after 
RFCA. Furthermore, in patients with high NT-proBNP levels, the creation of a 
more extensive lesion set could be considered in order to improve the 
outcome of the procedure. Finally, high NT-proBNP levels should raise the 
 potentially treatable 
underlying condition. In addition, assessment of NT-proBNP is easy and tests 
are widely available. 
 
Limitations 
Some limitations of the present study should be acknowledged. First, detection 
of AF recurrence after RFCA was based on ECG recordings acquired on a regular 
basis and/or 24-hour Holter registration. Importantly, patients were 
encouraged to obtain an ECG registration when experiencing palpitations in 
order to confirm AF as the cause of these complaints. Nevertheless, 
asymptomatic episodes may have been missed. Second, to minimize the 
confounding effect of heart rhythm on natriuretic peptide levels, a selected 
population, comprising only patients with paroxysmal AF that were in SR 
during pre-procedural blood sampling, has been studied. Third, the present 
study comprised a relatively small group of patients. Therefore only a limited 
number of variables could be incorporated into the multivariable analyses. To 
create a valid risk stratification system, the present findings need to be 
validated in a larger group of patients including a risk reclassification analysis. 
Fourth, the continuation and discontinuation of anti-arrhythmic drugs during 
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In patients without signs of overt structural heart disease, baseline NT-proBNP 
plasma level obtained during SR is an independent predictor of AF recurrence 
after RFCA. Plasma levels of NT-proBNP may allow detection of subtle cardiac 
dysfunction/conditions that may not be detected by echocardiography alone. 
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Cardiovascular Catheterisation and Intervention. Chapter 40: Intracardiac echocardiography. 








In the past years intracardiac echocardiography (ICE) has emerged as a 
valuable imaging tool for interventional and electrophysiological procedures. 
Intracardiac echocardiography allows real-time visualization of important 
anatomical structures that cannot be visualized on fluoroscopy, and is not 
associated with radiation exposure to the patient and operator. This imaging 
modality is used to guide and monitor interventional procedures and for early 
detection of complications. Importantly, as an alternative to transesophageal 
echocardiography (TEE), ICE can be performed without general anesthesia. In 




Intracardiac echocardiography is generally performed from within the right 
atrium or the right ventricle. The images acquired with ICE should therefore be 
interpreted from that perspective. Depending on the position and direction of 
the ultrasound catheter, all large cardiac structures, including the atria, 
ventricles, atrioventricular and semilunar valves, coronary sinus and 
pericardium can be visualized with ICE. Awareness of the orientation of the 
scanning plane and a good understanding of the 3-dimensional (3D) cardiac 
anatomy are essential for a correct interpretation.  
 
Equipment 
Currently, two different ICE technologies are available. The first approach 
utilizes a mechanical ultrasound tipped catheter which can also be used for 
endovascular echocardiography. The second uses an electronic ultrasound 
catheter that is equipped with a phased array transducer at its tip. Both are 
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introduced using a retrograde femoral venous approach after the application 
of local anesthesia. The mechanical or rotational system uses a 9 French 
catheter equipped with a 9 MHz single-element transducer incorporated at its 
tip (Ultra ICETM, Boston Scientific, San Jose, CA). A piezoelectric crystal inside the 
transducer is rotated at 1800 rpm in the radial dimension and provides a 2-
dimensional (2D) 360º scanning plane, oriented perpendicular to the catheter 
shaft. To adjust the imaging plane, the catheter can be withdrawn or advanced 
inside the heart. To prepare the catheter for use, the system has to be filled 
with 3-5 ml sterile water and connected to a dedicated ultrasound machine 
(iLabTM System, Galaxy® System, Galaxy2TM system or Clearview® UltraTM system, 
Boston Scientific).  
 The electronic system uses an 8, 9 or 10 French ultrasound catheter 
equipped with a 64-element phased array transducer located at its tip 
(ACUSON AcunavTM, Siemens Medical Solutions, Mountain View, CA and 
ViewFlexTM, St. Jude Medical, West Berlin, NJ) that generates a 90º wedge 
shaped 2D scanning plane, oriented parallel to the catheter shaft. The high 
resolution transducer can be used at multiple frequencies (5-10 MHz) thereby 
allowing depth control and enhancement of tissue penetration to a maximum 
of 15 cm. The flexible catheter can be rotated around its axis, and the tip of the 
catheter can be deflected by manipulating the steering mechanism at the 
handle of the catheter. The flexibility and maneuverability of the catheter 
enable the operator to position it inside the right ventricle or coronary sinus. In 
this way, additional views can be obtained, that cannot be acquired from the 
right atrium. The phased array catheter is connected to a dedicated ultrasound 
machine (SequoiaTM, CypressTM, CV70TM, Siemens Medical Solutions and 
ViewMate®, St. Jude Medical).  
 Several important differences between the two ICE technologies exist. 
The phased array catheter allows adjustment of the ultrasound frequency, 
Intracardiac Echocardiography 
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thereby enabling depth control. Furthermore, the phased array catheter has 
Doppler capabilities, allowing measurement of hemodynamic and physiologic 
variables, and has superior flexibility compared to the rotational catheter. The 
advantages of rotational ICE include a 360º scanning plane instead of 90º and 
the considerably lower costs. In daily clinical practice, phased array ICE is the 
most commonly used technology in the cardiac catheterization laboratory. The 
focus of the present chapter will be on phased array ICE, while, mechanical 
intravascular ultrasound is reviewed in Chapter 28.   
 
Fundamentals 
Intracardiac echocardiography can be used to visualize nearly all cardiac 
structures.1 However, unlike for transthoracic echocardiography and TEE, there 
are no widely accepted standard views for ICE. In the following paragraphs, a 
clinically oriented guide for catheter manipulation and visualization of the 
various cardiac structures is provided. 
 Intracardiac echocardiography is generally performed under conscious 
sedation. Using local anesthesia and a femoral vein approach, the ultrasound 
catheter is inserted through the inferior vena cava into the right atrium. While 
standing at the right side of the patient, the operator can change the 
orientation of the ultrasound beam by advancing or withdrawing the catheter 
and by rotating it around its axis. In this chapter, rotation of the ultrasound 
catheter away from the operator is called clockwise rotation, whereas rotation 
towards the operator is referred to as counter-clockwise rotation. The 
orientation of the ultrasound beam can also be altered by deflecting the tip of 
the ultrasound catheter in two orthogonal planes (anterior-posterior, left-right) 
through manipulation of the two steering knobs at the handle of the catheter.  
 Even though images acquired with ICE are quite similar to TEE, the 
large freedom of ultrasound beam orientation can easily cause a sense of 
 
 142 
disorientation to the inexperienced operator. In order to gain and regain 
as the starting point from which all catheter manipulations are described. To 
reach this position, the ultrasound catheter is positioned in the mid-right 
atrium with the control knobs in a neutral position. The resulting image shows 
the right atrium, tricuspid valve and right ventricle (Figure 1, panel A). The 
operator can use these and other anatomical landmarks to maintain 
orientation, a marker is present on the ultrasound screen corresponding to the 




cava inferior (VCI). Panel B: aortic valve (AoV), cavotricuspid isthmus (*), Eustachian ridge/valve (EuV), right 




the inferior right atrium, the Eustachian ridge can be visualized (Figure 1, panel 
B). The tissue between the Eustachian ridge and the tricuspid valve is known as 
the cavotricuspid isthmus which is targeted during catheter ablation for atrial 
flutter. By advancing the catheter back in 
counter-clockwise the crista terminalis and right atrial appendage are 
Intracardiac Echocardiography 
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reveal the right ventricular outflow tract, the pulmonary artery and the 
ascending aorta (Figure 1, panel B).  
 
 
Figure 2. Panel A: Left atrium (LA) and left atrial appendage (LAA). Panel B: Descending aorta (Desc Aorta), 
LA, left superior pulmonary vein (LSPV) and left inferior pulmonary vein (LIPV). Panel C: Esophagus and 
posterior LA wall. Panel D: Pulmonary artery (PA), right inferior pulmonary vein (RIPV), right superior 
pulmonary vein (RSPV) and transverse sinus. 
 
Left-Sided Structures 
the right ventricle and right ventricular outflow tract, provides a view on the 
left atrium, mitral valve, the interatrial septum and the coronary sinus (Figure 1, 
panel C). By gently deflecting the catheter tip in the left direction, the left atrial 
appendage can be seen (Figure 2, panel A). From this view, clockwise rotation 
will reveal the left-sided pulmonary veins (Figure 2, panel B). The left inferior 
pulmonary vein is visualized at the inferior portion of the ultrasound beam and 
the left superior pulmonary vein at the superior portion. In case of difficulty to 
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distinguish between the left superior pulmonary vein and the left atrial 
appendage, Doppler flow measurements can be used to differentiate between 
the two structures. When further rotating clockwise, the posterior left atrial wall 
and the esophagus can be visualized (Figure 2, panel C). Eventually, continued 
clockwise rotation will provide a cross-sectional view of the right-sided 
pulmonary veins and the right pulmonary artery (Figure 2, panel D). Similar to 
the left pulmonary veins, the right inferior pulmonary vein is visualized at the 
inferior portion of the ultrasound beam and the right superior pulmonary vein 
at the superior portion.  
 
 
Figure 3. Panel A: Long axis view of the left ventricle (LV): interventricular septum (IVS), mitral valve (MV). 
Panel B: Short axis view at the apical level. Panel C: Short axis view at the basal level. 
 
 To acquire a long axis view of the left ventricle and mitral valve from 
slightly into the inferior right atrium 
and the tip of the catheter is deflected in the anterior direction. By advancing 
the catheter through the tricuspid valve into the right ventricle and rotating 
the catheter clockwise, the interventricular septum and left ventricle appear 
(Figure 3, panel A). This long axis view can be very useful to detect pericardial 
effusion during interventional procedures. From the long axis view, a short axis 
view of the left ventricle can be acquired by deflecting the tip of the catheter in 
the left or right direction (Figure 3, panel B). Advancing or withdrawing the 




Indications and clinical applications 
Intracardiac echocardiography can be used in a wide variety of diagnostic and 
interventional procedures. These procedures are summarized in Table 1 and 
will be reviewed in the following paragraphs.   
 
Table 1. Applications of Intracardiac Echocardiography during Interventional and Electrophysiological 
Procedures 
 Detection of intracardiac thrombus 
 Closure of atrial septal defect 
 Transseptal puncture 
 Electrophysiological procedures  
o Atrial fibrillation ablation 
o Complex atrial flutter ablation 
o Ventricular tachycardia ablation 
o Left ventricular lead placement in cardiac resynchronization therapy 
 Other interventional procedures 
o Biopsy of an intracardiac tumor 
o Left atrial appendage closure 
o Closure of ventricular septal defect 
o Alcohol septum ablation in hypertrophic obstructive cardiomyopathy 
o Mitral valve balloon valvuloplasty 
o Percutaneous valve procedures 
 
Detection of Intracardiac Thrombus 
Patients undergoing a left-sided interventional procedure are at a high risk for 
systemic embolism.2,3 Intracardiac echocardiography can facilitate a safe left-
sided procedure by excluding intracardiac thrombus inside the left atrial 
appendage, left atrium and left ventricle.4 Furthermore, ICE can be used to 
assess the presence of spontaneous contrast, thereby identifying patients at a 
high risk for thrombus formation.5 Furthermore, ICE can help to detect the 
formation of thrombi at an early phase and allow for treatment prior to the 
occurrence of embolic events.6,7 
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 The efficacy of TEE to detect intracardiac thrombus has been 
established by the ACUTE trial (Assessment of Cardioversion Using 
Transesophageal Echocardiography).8 Even though ICE provides high quality 
images comparable to TEE, only few studies have compared the sensitivity of 
the two imaging modalities for the detection of intracardiac thrombus. The ICE-
CHIP study (IntraCardiac Echocardiography guided Cardioversion to Help 
Interventional Procedures) was designed to address this issue.9 The preliminary 
results of the ICE-CHIP study show that ICE has a similar sensitivity for the 
detection of spontaneous contrast, as compared to TEE.10 In 100 patients with 
atrial fibrillation, spontaneous contrast of the left atrium was seen in 50% on 
ICE and in 55% on TEE (p=NS) whereas spontaneous contrast of the left atrial 
appendage was seen in 24% on ICE and in 34% on TEE (p=NS). However, the 
results on thrombus detection from the ICE-CHIP study are not yet available. 
Therefore, more studies are needed to determine the exact value of ICE for the 
detection of intracardiac thrombi. 
 
Closure of Atrial Septal Defect 
Percutaneous transcatheter device closure of atrial septal defect or patent 
foramen ovale has proven to be a safe and effective alternative to open heart 
surgery.11,12 While percutaneous closure of patent foramen ovale may be 
performed under fluoroscopy guidance only, closing procedures of atrial septal 
defect are typically guided by TEE and fluoroscopy. However, ICE does not 
require general anesthesia, and may provide similar images as TEE.13,14  It has 
been shown that the use of ICE during transcatheter device closure may result 
in a reduction of fluoroscopy time (9.5 ± 1.6 minutes vs. 6.0 ± 1.7 minutes, 
p<0.0001),13 procedure length (47 ± 8 minutes vs. 35 ± 6 minutes, p<0.001) and 
catheterization laboratory occupation (92 ± 18 minutes vs. 50 ± 12 minutes, 
p<0.001) compared to TEE guided interventions.15 Importantly, the high costs 
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of an ICE catheter may be balanced by the need for general anesthesia during 
TEE guided procedures.16 
 
 
Figure 4. Panel A: Interatrial septum (IAS), left atrium (LA) and right atrium (RA). Panel B: During a Valsalva 
maneuver the patent foramen ovale (PFO) is revealed. Panel C: A large type II atrial septal defect (delineated 
by the two markers). Panel D: Doppler flow delineates the flow across PFO during a Valsalva maneuver. 
 
 To guide the placement of a transcatheter closure device, the 
clockwise to visualize the interatrial septum and fossa ovalis (Figure 4, panel A, 
B and C). By using Doppler capacities, the flow between the left and right 
atrium can be visualized and quantified (Figure 4, panel D). A guiding wire is 
then placed through the atrial septal defect and inside the left atrium. 
Subsequently, the catheter that contains the closure device is advanced 
through the atrial septal defect and the left-sided portion of the occluder is 
deployed. After this step, the position of the device against the interatrial 
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septum is carefully evaluated before deploying the right-sided portion of the 
occluder in order to avoid malposition and the associated risk of migration of 
the device (Figure 5, panel A). Once the operator is convinced that the position 
is correct, the right-sided portion of the occluder is deployed (Figure 5, panel 
B). Once again the position and the stability of the device are checked and 
subsequently the occluder is released. 
 
 
Figure 5. Panel A: A biodegradable closure device is inserted across the interatrial septum (IAS) inside the left 
atrium (LA). Subsequently, the left-sided occluder is deployed. (RA = right atrium). Panel B: After confirmation 
of the position of the device, the right-sided occluder is also deployed. 
 
Transseptal Puncture 
A transseptal puncture provides antegrade access to the left atrium and left 
ventricle during left-sided interventional procedures as an alternative to a 
retrograde approach through the aortic valve and mitral valve. However, a 
transseptal puncture can result in serious complications, such as aortic 
perforation, pericardial tamponade and perforation of the inferior vena cava.17 
The fossa ovalis is considered to be the safest site to perform a transseptal 
puncture in order to avoid these complications. Intracardiac echocardiography 
allows excellent visualization of the fossa ovalis and can be used to detect a 
patent foramen ovale or monitor the transseptal puncture.18 At present, no 
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prospective studies have addressed the question whether ICE may improve the 
safety of transseptal punctures. 
 
 
Figure 6. Panel A: Fossa ovalis, left atrium (LA), left inferior pulmonary vein (LIPV). Panel B: Tenting of the 
transseptal sheath against the fossa ovalis. (RA = right atrium). 
 
 To visualize the interatrial septum, the catheter is gently rotated 
thicker part (limbus) and thin part (fossa ovalis) (Figure 6, panel A). To detect a 
patent foramen ovale, saline/contrast is injected through the femoral vein 
inside the right atrium and the patient is instructed to perform the Valsalva 
maneuver (Figure 7, panel A). In the presence of a patent foramen the contrast 
will cross the interatrial septum, into the left atrium (Figure 7, panel B). In the 
absence of a patent foramen ovale, a transseptal sheath with a concealed 
Brockenbrough transseptal needle is inserted through the femoral vein inside 
the right atrium. Using fluoroscopy and ICE, the transseptal sheath is 
positioned against the fossa ovalis. In case of a stable position of the sheath 
panel B). The transseptal puncture can now be performed by pushing the 
needle out from the sheath, through the fossa ovalis. Successful transseptal 
puncture can be confirmed on ICE by injecting saline/contrast through the 




Figure 7. Panel A: Contrast inside the right atrium (RA) during Valsalva, in a patient with a closed foramen 
ovale. Panel B: Contrast crosses the interatrial septum (IAS) from the RA to the left atrium (LA) during Valsalva 
in a patient with a patent foramen ovale. 
 
Electrophysiological Procedures 
Intracardiac echocardiography has become an important imaging tool during 
electrophysiological procedures. In addition to thrombus detection and 
guidance of a transseptal puncture, ICE can be used to identify key anatomical 
structures to facilitate complex procedures like atrial fibrillation ablation and 
atrial flutter ablation.19-21 Intracardiac echocardiography can visualize the exact 
location of the mapping catheter and confirm stable contact of the catheter 
against the myocardium. Moreover, ICE can be used to visualize morphological 
changes in the myocardium, such as increased echo density, wall thickening 
and crater formation as a sign of effective lesion formation,22 and the 
development of micro bubbles as a sign of tissue heating and potential char 
formation.23,24 In the following paragraphs, the specific role of ICE in various 
electrophysiological procedures will be reviewed.  
 
Atrial fibrillation ablation 
Radiofrequency catheter ablation targeting the pulmonary veins is a potential 
curative treatment option for patients with drug-refractory atrial fibrillation.25,26 
However, it is associated with long procedure times and a small risk for severe 
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complications, including pulmonary vein stenosis, systemic embolism, cardiac 
tamponade and esophagus injury.2 Intracardiac echocardiography can 
facilitate these complex procedures by visualization of the pulmonary veins 
and monitoring of the location of the ablation catheter, and may help in 
avoiding complications by visualization of the esophagus and other important 
surrounding structures.19,23,27  
 Several studies have shown that pulmonary vein anatomy is highly 
variable.28-30 Application of radiofrequency current inside a pulmonary vein 
ostium may cause pulmonary vein stenosis and pulmonary hypertension.31 
Accurate visualization of the pulmonary vein region is therefore of utmost 
importance to safely and effectively perform catheter ablation. A head-to-head 
comparison between ICE and multi-slice computed tomography (MSCT) 
demonstrated that ICE enables accurate assessment of pulmonary vein 
anatomy and mean ostial diameters (ICE 1.51 ± 0.22 mm vs. MSCT 1.45 ± 0.29 
mm, p=NS). However, less additional pulmonary veins were detected using ICE, 
as compared with MSCT (ICE 2 (8%) vs. MSCT 5 (21%)).29 This was confirmed by 
Jongbloed et al who detected less additional pulmonary veins with ICE, as 
compared with MSCT (ICE 7 (17%) vs. MSCT 13 (32%)).30 In addition, an 
underestimation of the ostial diameter on ICE compared to the ostial diameter 
in superior-inferior direction on MSCT was noted (14.9 ± 4.0 mm vs. 18.4 ± 3.4 
mm, p<0.01).30 This finding suggests the need for 3D imaging to accurately 
visualize the shape and dimensions of the pulmonary vein ostia. Nevertheless, 
in a group of 259 patients, Marrouche et al demonstrated that anatomical 
guidance of radiofrequency catheter ablation with ICE is both safe and 
effective.23 Importantly, the use of ICE in addition to a circular catheter resulted 
in an improved outcome compared to a circular catheter alone.23  
 The esophagus and left atrial posterior wall are very closely related. 
With the use of ICE, Ren and colleagues demonstrated that the mean distance 
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between the left atrial posterior wall and the esophagus was 5.8 ± 1.2 mm 
(range 3.2-10.1 mm) and that the left atrial posterior wall and the esophagus 
were contiguous over a mean length of 36.0 ± 7.7 mm (range 18-59 mm).27 As a 
consequence, the temperature inside the esophagus may increase significantly 
during left atrial ablation.32 Heating of the esophagus can result in esophageal 
injury varying from transient erythematous changes to tissue necrosis and the 
development of an atrioesophageal fistula.27,33,34 While monitoring the relation 
between the esophagus and the ablation catheter with ICE, the ablation power 
and duration can be adjusted in order to reduce esophageal damage.27 
Monitoring lesion development and the occurrence of micro bubbles as an 
indication of an increased esophageal temperature, allows the operator to 
perform additional energy titration, thereby further minimizing the risk of 
esophageal damage.27,32  
 As an alternative to anatomical guidance with ICE, image integration 
with MSCT or magnetic resonance imaging integration is commonly used to 
guide radiofrequency catheter ablation for AF.35 A 3D image of the left atrium 
can be integrated with an electroanatomical map by performing a semi-
automatic registration process. However, the validity of this technique is 
largely dependent on the quality of the registration.36-38 An inaccurate 
registration process can result in a large shift of landmark points up to of 5-10 
mm, thereby compromising the safety and efficiency of lesion placement.36,37 
Adjunctive real-time imaging with ICE can be used to confirm the accuracy of 
the registration process in order to ensure an accurate delivery of 
radiofrequency energy.37  
 Recently, an electroanatomical mapping system (CARTO Sound, 
Biosense Webster, Diamond Bar, CA) has been released that allows the  
integration of ICE and electroanatomical mapping.39 By integrating ICE and 
electroanatomical mapping, an accurate 3D anatomical shell of the left atrium 
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and pulmonary veins can be acquired without performing a registration 
process.40 A modified phased array ultrasound catheter with an imbedded 
navigation sensor at its tip (Soundstar, Biosense Webster) is positioned inside 
the right atrium. The mapping system can detect the position and direction of 
the ICE catheter, thereby enabling the projection of the scanning plane inside 
its 3D environment. By gently rotating the ultrasound catheter, ECG-gated 
images of the left atrium and pulmonary veins are acquired. On each image, 
the endocardial borders (contours) are traced manually and are thereafter 
assigned to a designated map (Figure 8, panel A). Separate maps are created 
for the left atrial body and each of the pulmonary veins. All contours within a 
map are used to create a 3D shell of the structure (Figure 8, panel B). By 
combining all maps, the 3D geometry of the whole left atrium and pulmonary 
veins is visualized, which can be merged with a MSCT image in order to 
facilitate the ablation procedure (Figure 8, panel C).  
 
 
Figure 8. Panel A: After acquisition of an ECG-gated ultrasound image, the endocardial contours (green) of 
the left atrium (LA) and pulmonary veins are manually traced and are thereafter assigned to a corresponding 
map. Panel B: By systematically collecting images of the whole LA and marking the endocardial borders, a 
registered three-dimensional (3D) reconstruction of the LA anatomy is created. Panel C: The acquired 3D 




Complex atrial flutter ablation 
A common atrial flutter is an organized tachycardia with a reentry circuit inside 
the right atrium and a protected isthmus between the tricuspid valve and the 
inferior vena cava (cavo-tricuspid isthmus).20 Ablation of a common flutter is 
performed by creating a linear line of block across the cavo-tricuspid isthmus.41 
Even though it is considered unnecessary to use special imaging or mapping 
during a standard procedure, during complex cases ICE may be used to 
facilitate the procedure.21 Intracardiac echocardiography can identify the cavo-
tricuspid isthmus and other anatomical structures that can act as electrical 
barriers during atrial flutter, like the crista terminalis and Eustachian ridge.20 
Ablation of an atrial flutter can be complicated by complex anatomy, for 
example in patients previously operated for congenital heart disease. 
Particularly in these patients, ICE can facilitate the ablation procedure by 
visualizing important anatomical structures and guiding catheter placement.42 
 
Ventricular tachycardia ablation 
Ablation of ventricular tachycardia is usually limited to inducible and tolerated 
arrhythmias.43,44 Techniques to identify the arrhythmogenic substrate without 
inducing the tachycardia are being developed in order to treat patients who do 
not meet these criteria. Intracardiac echocardiography allows identification of 
akinetic and dyskinetic (aneurysmatic) myocardial segments in patients with 
ischemic ventricular tachycardia, thereby visualizing the exact location and 
extent of the substrate.45,46 Furthermore, ICE can be used to visualize small 
aneurysms of the right ventricle in patients with (suspected) arrhythmogenic 
right ventricular dysplasia, thereby detecting the arrhythmogenic substrate in 
these patients.46 
 Recently, the feasibility of the integration of ICE and electroanatomical 
mapping to guide ischemic ventricular tachycardia ablation was 
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demonstrated.47 By creating a 3D geometry of the left ventricle and marking 
the akinetic and dyskinetic segments as seen on ICE, the ischemic substrate 
could be mapped and the ablation procedure could be performed successfully.  
 
Left ventricular lead placement in cardiac resynchronization therapy 
Cardiac resynchronization therapy (CRT) has a beneficial effect on clinical 
symptoms, exercise capacity and left ventricular systolic function in selected 
patients with drug-refractory heart failure.48-50 Moreover, CRT is associated with 
an increased survival and a reduction in the number of re-hospitalizations for 
heart failure, as compared to optimal medical treatment.48 However, 
implantation of a CRT device ─ usually performed under fluoroscopic and 
angiographic guidance ─ can be challenging due to venous anatomy, resulting 
in a failure to place the left ventricular pacing lead in up to 8% of the patients.48-
50 A number of case studies report on the use of ICE to visualize the coronary 
sinus in order to guide left ventricular lead placement.51,52 However, at present 
no prospective studies have reported a beneficial effect of ICE guidance on the 
success rate for left ventricular lead placement.  
 
 
Figure 9. Panel A: An intracardiac mass originating from the superior vena cava is extending into the right 
atrium (RA) and tricuspid valve. (RV = right ventricle). Panel B: Intracardiac echocardiography is used to 




Other Interventional Procedures 
Biopsy of intracardiac mass. Intracardiac echocardiography can be used to 
visualize the origin and extent of an intracardiac mass (Figure 9, panel A). 
Therefore, ICE may be used to guide biopsies (Figure 9, panel B) and to monitor 
associated complications such as perforation or bleeding as suggested by few 
preliminary reports.53,54  
 
Left atrial appendage closure. Implantation of a left atrial appendage 
occlusion device has been advocate as strategy to reduce the risk for systemic 
embolism in patients with atrial fibrillation and contraindications for 
anticoagulation and the procedure is typically guided by TEE. Recently, in a 
small group of patients the feasibility of ICE guidance as an alternative to TEE 
was reported.55 Intracardiac echocardiography provided similar visualization of 
the left atrial appendage and similar assessment of the left atrial appendage 
orifice diameter compared to TEE (ICE 22.6 ± 3.4 mm vs. TEE 19.5 ± 1.5 mm, 
p=NS). Importantly, the degree of accuracy with respect to exclusion of a 
thrombus inside the left atrial appendage, the exact positioning of the delivery 
sheath and the verification of the location and stability of the occlusion device 
using ICE were was comparable to TEE.  
 
Ventricular septal defect closure. Intracardiac echocardiography can be used 
to guide transcatheter closure of a perimembranous ventricular septal defect.56 
This imaging modality allows identification and visualization of the defect and 
monitoring the placement of a guiding wire through the defect and the 
deployment of the left sided occluder. Subsequently, ICE is used to confirm the 
correct position of the left sided occluder against the interventricular septum 
before the deployment of the right sided occluder. After deployment of the 
second occluder, ICE can be used to assess any residual shunt and valvular 
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regurgitation that may have resulted from the procedure. In 12 patients, Cao et 
al documented that ICE may be used as a safe and effective alternative for TEE 
to guide closure of a ventricular septal defect.56 
 
Alcohol ablation in hypertrophic obstructive cardiomyopathy. Alcohol septal 
ablation is an effective treatment to reduce the intraventricular gradient in 
patients with hypertrophic obstructive cardiomyopathy.57 However, the 
efficacy and safety of the procedure is dependent on the identification of the 
correct septal artery. In order to identify this branch, echocontrast is commonly 
injected into a septal artery at the time of coronary angiography and 
transthoracic echocardiography is used to detect the extent and localization of 
the corresponding myocardial territory. Intracardiac echocardiography allows 
high quality visualization of the entire interventricular septum and may be a 
useful tool to guide alcohol septal ablation.58 In 9 patients, Pedone et al 
demonstrated that the use of ICE to guide the procedure was feasible .59 
However, more studies are needed to define the role of ICE in alcohol septal 
ablation in patients with hypertrophic obstructive cardiomyopathy. 
 
Mitral valve balloon valvuloplasty. Percutaneous balloon valvuloplasty is an 
accepted alternative to surgical commissurotomy in selected patients with 
symptomatic mitral stenosis. In this setting, ICE can be used to exclude 
thrombus formation at the level of the left atrium, assess the morphology and 
function of the mitral valve, guide the transseptal puncture, monitor the 
positioning of the balloon and assess any residual valvular gradient or 
postprocedural mitral regurgitation.60 In addition it may allow an early 




Percutaneous valve procedures. Intracardiac echocardiography may provide 
online anatomical information useful to guide percutaneous valve repair or 
replacement.61,62 Accordingly, this imaging modality may be used to determine 
the appropriate size and site of deployment of the percutaneous valve as well 
as to monitor the anatomical and functional result of the procedure.62 Studies 
are needed to define the role of ICE during percutaneous valve procedures. 
 
Intrapericardial use of intracardiac echocardiography. Positioning the ICE 
catheter inside the pericardium has the potential to provide valuable 
information during complex ablation procedures. Recently, the safety and 
feasibility of this approach was demonstrated in both experimental and clinical 
setting.63,64 In 10 patients, endocardial structures could be visualized in great 
detail from various angles.64 The ability to visualize cardiac anatomy from 
different angles could benefit catheter navigation. However, this invasive 




Although phased array ICE enables adjustment of the ultrasound frequency, 
tissue penetration remains a limiting factor in visualizing cardiac anatomy. The 
use of a lower ultrasound frequency would result in a higher degree of tissue 
penetration allowing visualization of structures further away from the 
transducer, but at the cost of a lower image resolution. In addition, the costs of 
phased array ICE are relatively high as compared to TEE and these expensive 
catheters are for single use only. However, the costs of ICE are somewhat 
balanced by the need for general anesthesia and an echocardiographist during 
TEE. Moreover, intracardiac echocardiography provides 2D monoplane images. 
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This limitation can be partially overcome by the flexibility of the catheter 
enabling to visualize the same structure from another angle. Nevertheless, 
operators who are used to multiplane TEE may still have difficulty obtaining the 
same views. Finally, there are no widely accepted standard views for ICE, in 
contrast to TEE and transthoracic echocardiography. This may be difficult, in 
particular for the inexperienced operator. Standard manipulation of the 
landmark structures may be helpful. 
 
Special issues 
Intracardiac echocardiography is an invasive imaging modality and its use is 
usually confined to patients undergoing a percutaneous interventional 
procedure. In general, the contraindications for ICE are similar to other right-
sided cardiac catheterization procedures using a transfemoral access. In 
pediatric patients, the use of ICE is limited by the respective diameters of the 
femoral vein and the ultrasound catheter. 
 
Conclusions 
Intracardiac echocardiography is a valuable imaging tool for a wide variety of 
interventional and electrophysiological procedures. This imaging modality 
allows real-time visualization of anatomical structures, catheters and devices 
thereby enabling the monitoring and guidance of complex procedures like 
catheter ablation for atrial fibrillation and placement of a transcatheter closure 
device for atrial or ventricular septal defects. Since it provides images of quality 
comparable to TEE, ICE may be used ─ in the hands of an experienced operator 
─ as an alternative to TEE during closure of an atrial septal defect or ventricular 
septal defect and during percutaneous occlusion of the left atrial appendage. 
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Background: Multi-slice computed tomography (MSCT) integration is 
commonly used to guide radiofrequency catheter ablation (RFCA) for atrial 
fibrillation (AF). MSCT provides detailed anatomical information but lacks the 
ability to provide real-time anatomy during RFCA. Intracardiac 
echocardiography (ICE) allows real-time visualization of cardiac structures. 
Objective: The purpose of this study was to investigate the feasibility of three-
dimensional (3D) anatomical mapping of the left atrium (LA) with ICE and 
integrating the 3D map with MSCT to facilitate RFCA for AF.  
Methods: In seventeen patients undergoing RFCA for AF, 3D mapping of the 
LA was performed with ICE using a new mapping system (CARTOSOUNDTM, 
Biosense Webster) which allows tracking of a new ICE probe. On each ICE 
image endocardial contours were traced and used to generate a 3D map of the 
LA and pulmonary veins (PVs). A preprocedural acquired MSCT image of the LA 
was then integrated with the 3D map. Additionally, PV assessment with ICE was 
compared with MSCT. 
Results: Accurate 3D mapping could be performed in all patients with a mean 
number of 31.1 ± 8.5 contours. Integration with MSCT resulted in a mean 
distance between MSCT and ICE contours of 2.2 ± 0.3 mm for the LA and PVs 
together and of 1.7 ± 0.2 mm around the PV ostia specifically. Agreement in 
assessment of PV anatomy and diameters between ICE and MSCT was 
excellent.  
Conclusion: 3D ICE mapping of the LA is feasible. The 3D map created with ICE 
can be merged with MSCT to facilitate RFCA for AF. 
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Introduction 
Ectopic beats originating from the pulmonary veins (PVs) can initiate atrial 
fibrillation (AF) 1. Radiofrequency catheter ablation (RFCA) is considered a 
reasonable option in the treatment of patients with AF, when at least one anti-
arrhythmic drug has failed 2. Ablation strategies targeting the PVs are the 
cornerstone of these RFCA procedures 2. To plan and guide these ablation 
procedures, non-invasive three-dimensional (3D) imaging modalities like 
magnetic resonance imaging and multi-slice computed tomography (MSCT) 
are available to visualize the left atrium (LA) and PVs 3,4. Electrophysiological 
navigation systems allowing the integration of MSCT with electroanatomical 
maps, combine accurate real-time navigation with detailed anatomical 
information thereby facilitating the ablation procedure 5 and reducing 
fluoroscopy time and procedural duration 6.   
 However, a limiting factor of using MSCT to guide the ablation 
procedure is the time interval between image acquisition and the ablation 
procedure which may result in differences in heart rhythm, heart rate and fluid 
status potentially causing an inaccurate registration process. Because the 
quality of the registration process determines the accuracy of navigating 7, this 
could result in less accurate lesion placement during RFCA. Recently, a new 
electroanatomical mapping system has been released that allows integration 
of 3D mapping and real-time intracardiac echocardiography (ICE). Using this 
system, a registered 3D shell of the LA and PV anatomy can be generated from 
two-dimensional (2D) ICE images.  
 The aim of this study was to investigate the feasibility of creating a 3D 
map of the LA and PVs with ICE and integrating this map with a MSCT surface 
image in order to facilitate RFCA for AF. In addition, a direct comparison 





Study population and protocol 
The study population comprised 17 consecutive patients with symptomatic 
drug refractory AF, who underwent RFCA in our institution. In all patients a 
MSCT was acquired two days before the ablation. Prior to the procedure, the 
raw MSCT data was loaded into an electroanatomical mapping system (CARTO 
XPTM, Biosense Webster, Diamond Bar, California) equipped with a newly 
developed image integration module (CARTOSOUNDTM, Biosense Webster). 
During the ablation procedure 3D maps of the LA and PVs were created using 
an ICE catheter with an imbedded CARTO navigation sensor (10Fr SoundstarTM, 
Biosense Webster) allowing the mapping system to detect its position and 
generate a registered 3D shell from the recorded two-dimensional (2D) images. 
After completion of the mapping procedure a registration process was 
performed to integrate the MSCT image with the 3D map made with ICE. 
Thereafter the merged MSCT image and 3D maps were used to guide the RFCA 
procedure. 
 
Multi-Slice Computed Tomography 
In all patients MSCT data were acquired two days before the ablation 
procedure. The MSCT examination was performed with a 64-slice Toshiba 
Aquilion 64 system (Toshiba Medical Systems, Otawara, Japan) (7 patients) or a 
320-slice Toshiba Aquilion One system (Toshiba Medical Systems) (10 patients). 
Craniocaudal scanning was performed during breath holding. For the Aquilion 
64 system collimation was 64 x 0.5 mm, rotation time 400 ms and tube voltage 
between 100 and 135 kV at 250 to 400 mA. For the Aquilion One system 
collimation was 320 x 0.5 mm, rotation time 350 ms and tube voltage 120 kV at 
400 to 500 mA. In all patients nonionic contrast material (Iomeron 400, Bracco, 
Milan, Italy; 105 ml for Aquilion 64 and 50 ml for Aquilion One scanning) was 
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infused through the antecubital vein at a rate of 5 ml/s followed by 50 ml saline 
solution flush. Automatic detection of the contrast bolus was used to time the 
start of the scan. Before the ablation procedure, all MSCT data were analyzed 
on a dedicated workstation (Vitrea 2; Vital Images, Minnetonka, Minnesota).  
 
Image processing and segmentation 
Prior to the ablation procedure, the raw MSCT data were loaded into the image 
integration module of the mapping system (CartoMergeTM, Biosense Webster) 
and a segmentation process was performed. The segmentation process 
consisted of three phases as described previously 5. The first step was to 
delineate the borders of interest on the MSCT (LA and PVs) by manually setting 
the threshold intensity range. A 3D volume was subsequently created of all 
structures within the set threshold range. The second step was to segment this 
3D volume into different structures by placing markers in the middle of the 
different areas. An algorithm was used to automatically depict the different 
structures based on the placement of the markers and the border of the 3D 
volume. Finally, the segmented surface images were exported to the mapping 
system. 
  
Anatomical mapping with intracardiac echocardiography 
During the catheter ablation procedure, a 3D anatomical map was created with 
ICE images. A new mapping system was used, equipped with a new image 
integration module that allows the integration of ICE and 3D mapping 
(CARTOSOUNDTM). This system is able to detect the position and direction of a 
specifically designed ICE catheter with an imbedded CARTO navigation sensor 
located at its tip (SoundstarTM). By positioning the ICE catheter inside the right 
atrium, ECG gated images of the LA and PVs were acquired. To provide ECG 
gating, either a quadripolar electrophysiological catheter placed inside the 
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right atrium or the body surface ECG was used as a reference signal in patients 
with sinus rhythm or AF, respectively. In order to correct for respiratory phase, 
all ICE images were acquired during expiratory breath hold.  
 
Figure 1. Three-dimensional (3D) mapping with intracardiac echocardiographic (ICE). Ultrasound images of 
the left atrium (LA) are acquired. The endocardial contour of the LA is traced on the ultrasound viewer of the 
mapping system. After assigning the contour to a map, it appears on the map viewer (A). By acquiring more 
contours and reconstructing them into a registered 3D shell (B), the shape of the LA and pulmonary veins 
(PVs) is depicted. Systematically, the LA and PVs are visualized (C) until a complete 3D map of the LA and PVs 
is acquired (D). Add PV = additional pulmonary vein, LCO = left common ostium, RIPV = right inferior 
pulmonary vein, RSPV = right superior pulmonary vein. 
 
Intracardiac echocardiography was performed using a Sequoia 
ultrasound system (Siemens Medical Solutions USA, Mountain View, California) 
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which transferred real-time ICE data to the mapping system. On the mapping 
system, the endocardial contours were traced manually after which they were 
assigned to a map (Figure 1A). All contours within a map were used to generate 
a registered 3D shell (Figure 1B and 1C). For each map a separate shell was 




Figure 2. After three-dimensional (3D) mapping with intracardiac echocardiography, the 3D map and multi-
slice computed tomography (MSCT) image are displayed next to each other (A). Then a manual registration 
process was performed. This resulted in the integration of the 3D map and the MSCT image in order to 




Figure 3. The quality of the registration process was reviewed at the level of the pulmonary vein ostium by 
measuring the distance between multi-slice computed tomography and three-dimensional map at 5 
representative points.  
 
Registration 
After creating a map with ICE, a registration process was performed to 
integrate the MSCT surface image and the 3D map. First, the MSCT surface 
image was displayed next to the anatomical map (Figure 2A). A landmark was 
placed at a distinct anatomical structure on the anatomical map and at a 
performed by minimizing the distance between both landmarks. Next, the 
maps created during the mapping procedure were each assigned to the 
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During this process the ICE contours were represented as a line of adjacent 
mapping points. An internal algorithm was used to minimize the distance 
between these points and the MSCT surface image (Figure 2B). 
The accuracy of the registration process was then reviewed. The mean 
value, standard deviation and range of the distance between the points along 
the ICE contours and the MSCT surface were provided by the algorithm. The 
accuracy of the registration process at the level of the PVs was evaluated by 
measuring the distance between the contours and MSCT surface at 5 
representative points around each PV ostium (Figure 3). 
 
Pulmonary vein anatomy and quantitative measurements 
After an accurate registration had been acquired the PVs and their atrial 
insertion were evaluated on both MSCT and ICE. Pulmonary vein anatomy was 
classified according to the presence or absence of a common ostium/trunk 
and/or additional veins. As described previously, a common ostium was 
defined as a PV carina located outside the extrapolated endocardial border of 
the LA 4. A common trunk was defined as a clearly recognizable common part 
in which both superior and inferior PV drain before emptying into the LA 8. An 
additional vein was defined as a supranumerical vein entering the LA with a 
separate ostium. The same criteria for PV classification were used for MSCT and 
ICE evaluation. 
Pulmonary vein diameters on MSCT were measured in anterior-
posterior (AP) and superior-inferior (SI) direction inside the PV ostium, as 
previously described 4. Pulmonary vein diameters on ICE were measured at the 
widest point. Left atrial diameter was measured in AP direction on both MSCT 





Figure 4. After registration the three-dimensional map created with intracardiac echocardiography and 
integrated multi-slice computed tomography image were used to facilitate the ablation procedure. 
Circumferential lesions were created outside the pulmonary vein ostia. Red tags represent the sites of 
radiofrequency current application. 
 
Radiofrequency catheter ablation 
Radiofrequency catheter ablation was performed by creating two 
circumferential lesions around the left and right PV antrum (Figure 4). 
Additional lesions consisting of a roofline, a mitral valve isthmus line or sites 
exhibiting fractionated activity were created if deemed necessary. After 
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excluding an intracardiac thrombus, and in the absence of a patent foramen 
ovale, a transseptal puncture was performed under ICE guidance. All patients 
received a bolus of intravenous heparin (5000 IU) with an additional bolus to 
maintain an activated clotting time between 300-400 s. The ablation procedure 
was guided by the 3D map created with ICE and integrated with the MSCT 
image. An open loop irrigated 4-mm tip quadripolar mapping/ablation 
catheter (7Fr NavistarTM, Biosense Webster) was introduced in the LA and used 
to apply radiofrequency current outside the ostia of all PVs. At each point, 
radiofrequency current was applied at 30-35 W (maximum tip temperature 45 




Data are presented as mean ± SD or as number (percentage). Statistical analysis 
was performed using SPSS 14.0 software (SPSS Inc., Chicago, Illinois). Statistical 
comparisons were performed w -test, paired or 
unpaired as appropriate. Kappa analysis was used to quantify the level of 
agreement in PV anatomy classification with MSCT and ICE. Bland-Altman 
analysis was used to quantify the level of agreement between measurements 





Seventeen patients were studied (13 men, mean age 56 ± 8 years). Atrial 
fibrillation was paroxysmal in 11 patients and persistent in 6 according to the 
ACC/AHA/ESC Guidelines definition 9. Mean duration of AF was 72 ± 58 months 
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and the mean number of anti-arrhythmic drugs used was 3.7 ± 1.3 per patient. 
Mean LA size measured by transthoracic echocardiography was 41.8 ± 5.3 mm; 
mean left ventricular ejection fraction was 58 ± 7 %. Four patients had 
undergone another radiofrequency catheter ablation procedure for AF 
previously. 
 
Table 1. Result of the registration process per patient 
    Distance between contours and MSCT surface image 
(mm) 
Patient Age (years) Gender  No. of 
contours 
Mean SD Range 
1 46 F 20 2.1 1.6 0.00-8.45 
2 55 M 19 1.9 1.4 0.00-8.91 
3 61 M 27 2.3 1.6 0.00-8.82 
4 72 M 23 2.5 1.9 0.01-10.27 
5 57 M 18 2.1 1.7 0.01-10.17 
6 40 F 36 1.8 1.4 0.01-7.19 
7 58 M 39 2.6 1.9 0.00-9.99 
8 48 M 38 2.0 1.5 0.00-7.68 
9 61 F 29 1.9 1.4 0.15-6.45 
10 47 M 42 1.7 1.4 0.00-7.44 
11 68 M 22 2.3 1.5 0.01-7.03 
12 50 M 40 2.1 1.6 0.01-9.15 
13 53 F 38 1.9 1.7 0.00-12.50 
14 58 M 31 2.8 1.9 0.02-11.56 
15 60 M 43 2.5 1.8 0.00-8.57 
16 54 M 30 2.5 1.7 0.01-8.36 
17 58 M 34 2.3 1.6 0.01-8.38 
Mean 55.6  31.1 2.2 1.7  
SD 8.0  8.5 0.3 0.2  
MSCT = multi-slice computed tomography, No. = number, SD = standard deviation. 
 
Mapping and registration accuracy 
In order to acquire a good geometry of LA and PVs a mean of 31.1 ± 8.5 ICE 
contours were drawn per patient (range 18-43 contours). The mean time 
needed to make a 3D map with ICE was 76 ± 27 minutes (range 25-126 
minutes). It was noted that the time needed to make a map significantly 
decreased from 97 ± 20 minutes during the first 4 procedures to 39 ± 10 
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minutes during the last 13 procedures (p<0.001). After the registration process 
the mean distance between the drawn ICE contours and the MSCT surface 
image ranged from 1.7 to 2.8 mm (mean 2.2 ± 0.3 mm). The standard deviation 
of the ICE-MSCT difference ranged from 1.4 mm to 1.9 mm (mean 1.7 ± 0.2 
mm). Individual results of the registration process are given in Table 1. 
The accuracy of the registration process at the level of the PVs was 
evaluated by calculating the mean value of the distance between the contours 
and MSCT surface at 5 representative points around each PV ostium. The mean 
distance between the drawn contours and the MSCT surface image at the level 
of the PV ostia ranged from 0.7 to 4.4 mm (mean 1.7 ± 1.1 mm) and was 
smallest around the left inferior PV (mean 1.5 ± 1.1 mm) and largest around the 
left superior PV (mean 2.1 ± 1.3 mm) (Table 2). 
 
Classification pulmonary vein anatomy 
An equal number of 70 PVs were visualized with MSCT and ICE (4.12 ± 0.49 per 
patient). The most common PV variant consisted of 2 left sided PVs with 
separate ostia and 2 right sided PVs with separate ostia (7 patients, 41%). A 
common ostium of the left PVs was noted in 8 patients (47%) with MSCT and in 
10 patients (59%) with ICE. A common trunk of the left superior and left inferior 
PV was recognized in 3 patients (18%) with both MSCT and ICE. An additional 
PV was identified in 5 patients (29%). All additional PVs were located at the 
right side of the LA. Using kappa analysis, an excellent agreement between 
MSCT and ICE for the classification of the left-sided PVs (kappa = 0.77) and the 




Table 2. Result of the registration process at pulmonary vein ostia  
 Distance between contours and MSCT surface image 
(mm) 
 
Pulmonary vein Mean SD Range 
RSPV 1.7 1.0 0.8-3.2 
RIPV 1.6 1.0 0.7-3.2 
LSPV 2.1 1.3 0.8-4.4 
LIPV 1.5 1.1 1.0-2.4 
LCT 1.7 1.2 1.3-1.9 
Both RPV 1.7 1.0 0.7-3.2 
Both LPV 1.8 1.2 0.8-4.4 
All PV 1.7 1.1 0.7-4.4 
MSCT = multi-slice computed tomography, LCT = left common trunk, LIPV = left inferior pulmonary vein, LPV 
= left pulmonary veins, LSPV = left superior pulmonary vein, PV = pulmonary vein, RIPV = right pulmonary 




Pulmonary vein diameters were measured in two directions on MSCT (AP and 
SI) and in the direction of the largest diameter possible on ICE, as previously 
described 4. Superior-inferior diameters measured on MSCT were significantly 
larger for all PVs compared to the diameters measured on ICE (Table 3). The AP 
diameters of the right superior PV, left superior PV and additional veins 
measured on MSCT were not significantly different from the diameters 
measured on ICE. In contrast, the AP diameters of the right inferior PV on MSCT 
were significantly larger than the PV diameters on ICE (Table 3). Bland-Altman 
analysis demonstrated that there was a good overall agreement between ICE 
and MSCT for the assessment of the PV ostium diameter (Figure 5). 
Left atrial diameter was measured in AP direction on both MSCT and 
ICE. Mean AP diameter of the LA on MSCT was 39.6 ± 7.2 mm compared to 35.9 
± 7.2 mm on ICE. The mean difference between AP diameter on MSCT and ICE 
was 3.7 ± 5.0 mm (p<0.01) and ranged from 0.3 to 15.6 mm.  
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Table 3. Measurements of pulmonary vein ostium diameter MSCT versus ICE 
 MSCT SI (mm) MSCT AP (mm) ICE (mm) SI diameter 
MSCT vs ICE 
(p-value) 
AP diameter 
MSCT vs ICE 
(p-value) 
RSPV 24.0 ± 3.5 19.2 ± 3.3 18.3 ± 3.3 <0.01 NS 
RIPV 20.8 ± 3.0 17.9 ± 3.3 15.3 ± 2.4 <0.01 <0.05 
LSPV 21.6 ± 3.9 15.4 ± 3.0 15.2 ± 2.2 <0.01 NS 
LIPV 19.0 ± 2.1 11.9 ± 2.3 14.6 ± 2.4 <0.01 <0.05 
LCT 38.2 ± 3.8 22.4 ± 1.0 28.2 ± 0.4 <0.05 <0.05 
ADD 9.6 ± 1.9 8.5 ± 2.4 8.5 ± 0.9 <0.05 NS 
All PV 21.5 ± 5.7 16.2 ± 4.5 16.0 ± 4.3 <0.01 NS 
ADD = additional pulmonary vein, AP = anterior-posterior, ICE = intracardiac echocardiography, LCT = left 
common trunk, LIPV = left inferior pulmonary vein, LSPV = left superior pulmonary vein, MSCT = multi-slice 
computed tomography, PV = pulmonary vein, RIPV = right pulmonary vein, RSPV = right superior pulmonary 
vein, SI = superior-inferior 
 
Radiofrequency catheter ablation 
Transseptal puncture was performed under ICE guidance in 13 patients. A 
patent foramen ovale existed in 4 patients. The mean ablation time was 80 ± 34 
minutes and mean fluoroscopy time was 35 ± 6 minutes. Radiofrequency 
catheter ablation was targeted at the PVs in all patients. No differences 
between heart rhythm during MSCT acquisition and ablation procedure were 
observed. No complications occurred during and after the ablation procedure.  
 
 
Figure 5. Bland-Altman analysis of measurements performed with multi-slice computed tomography and 






The present study is the first to report on the feasibility of creating a 3D map of 
the LA and PVs with ICE and integrating this map with MSCT in order to 
facilitate RFCA for AF. This study has three main findings: 1) It is feasible to 
create an anatomical map of the LA and PVs using ICE contours; 2) The 
anatomical map created by ICE can accurately be merged with a MSCT surface 
image and 3) Anatomical ICE mapping is a sensitive imaging modality to 
visualize PVs and classify LA and PV anatomy. 
 
3D mapping with ICE and MSCT integration 
In the present study a novel mapping system was used that enables detection 
of a specifically designed ICE catheter with an imbedded CARTO navigation 
sensor. This mapping system allows acquisition of ECG gated ICE images and 
reconstructs them into a registered 3D shell. With this new technology, it has 
become possible to acquire accurate real-time anatomical information of the 
LA and PVs without entering the left side of the heart. Khaykin et al first 
reported on the use of 3D mapping with ICE during the ablation of a right free 
wall accessory pathway 10. Okumura et al demonstrated the accuracy of 
navigation based on 3D mapping with ICE in animal experiments 11. Both 
groups subsequently demonstrated the feasibility of creating a 3D map with 
ICE to guide RFCA for AF 11-13. The present study supports these findings and 
additionally demonstrates the accuracy of creating a 3D map of the LA and PVs 
with ICE by comparing LA and PV geometry on the 3D ICE map with MSCT. 
In addition, the current study is the first to demonstrate the feasibility 
of integrating a 3D map created with ICE and a MSCT image. Integration of 
MSCT images with conventional electroanatomical mapping is commonly used 
to guide RFCA for AF 14. In an animal study, Dong et al 15 demonstrated that the 
integration of MSCT and electroanatomical mapping allows accurate 
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placement of anatomically guided ablation lesions in all cardiac chambers. 
Furthermore, several studies demonstrated the feasibility of the integration of 
MSCT and electroanatomical mapping to guide RFCA for AF 5,16-18. Importantly, 
Kistler et al 6 showed that the integration of a MSCT image to guide RFCA for AF 
is associated with reduced fluoroscopy time and an improved outcome of the 
procedure.  
However, the time interval between the MSCT data acquisition and the 
ablation procedure is a limitation of MSCT image integration. This delay may 
result in differences in heart rhythm, heart rate and fluid status which may 
cause errors in the image integration process, thereby compromising the 
accuracy of lesion placement. By integrating real-time ICE, MSCT and 
electroanatomical mapping, it has become possible to combine real-time 
anatomical and electrophysiological information with highly detailed 
anatomical information, thereby potentially increasing the accuracy of the 
placement of ablation lesions. The present study demonstrates the accuracy of 
integrating a MSCT image with a 3D map created with ICE. This was illustrated 
by a mean distance of only 2.2 mm between the MSCT image and the ICE 
contours, which is comparable with the integration results between an 
electroanatomical map and MSCT 5,16-18.  However, despite acquiring a 
good overall match between ICE and MSCT, the distance between the 
represented points along the ICE contours and MSCT ranged from 0.00 to 12.50 
mm (Table 1). Similar ranges have been reported for the integration of 
electroanatomical maps and MSCT 5,16. This wide range may be related to 
differences in reconstructed LA and PV anatomy between MSCT and ICE in 
areas that are strongly influenced by cardiac and respiratory movement. 
 
Pulmonary vein visualization  
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Left atrial and PV anatomy are highly variable 3,4,19. Importantly, accurate 
visualization of the PV ostia during RFCA for AF is required to avoid ablation 
within the PVs 2. In the present study, the PV ostia were visualized with ICE and 
MSCT. Both imaging modalities recorded an equal number of PVs, which 
suggests that 3D mapping with ICE has a high sensitivity for detecting PVs. 
Furthermore, there was good agreement between ICE and MSCT for 
classification of the PV anatomy.  
In the present study, ICE slightly underestimated PV diameter, as 
compared with MSCT. This observation is in agreement with a study by 
Jongbloed et al 4 who found that ICE underestimated PV diameter for all PVs by 
3.5 mm in SI direction and 0.2 mm in AP direction. An explanation for the 
underestimation of left sided PV diameters on ICE may be the fact that these 
PVs are visualized in longitudinal cross-sections thereby potentially missing the 
middle and widest part of the PVs. In contrast, the underestimation of the right 
sided PV diameters may be due to the fact that the exact PV-LA junction can be 
challenging to visualize in transversal cross-sections. However, since 
radiofrequency current is typically applied outside the PVs, this should have 
little implications for the safety of the ablation procedure.  
The present study shows that 3D mapping with ICE provides an 
accurate visualization of PV ostia and PV anatomy with a high sensitivity for 
detecting additional PVs and gives a good estimation of PV dimensions, as 
compared with MSCT. 
 
Clinical implications 
The integration of MSCT with electroanatomical mapping allows accurate 
placement of ablation lesions 15 and has improved the outcome of anatomically 
guided RFCA targeting the PVs 6. However, it is reported that the accuracy of 
navigating with MSCT integration depends on the quality of the registration 
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process 7. With the release of a new electroanatomical mapping system that 
allows integration of ICE it has become possible to acquire calibrated real-time 
3D anatomical information without performing a manual registration process. 
The ablation procedures in this study were guided by a 3D map made 
with ICE, integrated with a MSCT surface image. Importantly, this study 
demonstrates that 3D mapping with ICE alone provides accurate visualization 
of the LA geometry and PV ostia which is required to safely perform RFCA for 
AF targeting the PVs. Therefore it should be possible to perform an 
anatomically guided ablation procedure targeting the PVs on 3D mapping with 
ICE alone. This may result in a considerable reduction in radiation exposure for 
the patient. Further studies are therefore needed to fully explore the value of 
this promising new technique. 
 
Limitations 
This study represents an initial experience with 3D mapping using ICE to guide 
RFCA for AF. The time necessary to make a map with ICE was therefore 
relatively long. However, due to a clear learning curve, this time decreased in 
the later procedures. Therefore, it can be expected that the time needed to 
make a 3D ICE map can be shortened significantly.  
 In this study RFCA was guided by the 3D map made with ICE and 
integrated with the MSCT image. As a consequence no data has been acquired 
on guidance by 3D ICE mapping alone. Furthermore, at present no data is 
available on the outcome of the ablation procedures.  
 Intracardiac echocardiography allows real-time visualization of 
important cardiac structures. However, some areas of the LA may be 
challenging to visualize with ICE due to their parallel orientation to the 
ultrasound beam. Examples of these areas are the right sided PV-LA junction 
and the left side of the anterior wall. By positioning the ICE catheter inside the 
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right ventricle these structures can be visualized from another angle thereby 
providing more insight in LA and PV anatomy. Additionally, conventional 
electroanatomical mapping can also be used to acquire anatomical 
information in these and other areas. 
Three-dimensional mapping with ICE is very sensitive to respiratory 
phase. Small differences in respiratory phase during image acquisition may 
result in contours situated outside the interpolated continuity of the other 
contours of the 3D map. However, by acquiring all ICE images during 
expiratory breath hold, consistent sets of contours could be acquired in all 
patients.  
Three-dimensional mapping with ICE is a very promising but expensive 
technique. The ICE catheters used in this study are single-use only and a 
dedicated mapping system with image integration modules is needed to 
integrate ICE with the electroanatomical mapping and MSCT images. 
Furthermore this technology is only available on one electroanatomical 
mapping system (CARTO XP) and on limited echocardiographic machines 
(Sequoia ultrasound system and Cypress ultrasound system, Siemens Medical 
Solutions). Nonetheless, integration of ICE provides accurate anatomical 
information that could potentially replace MSCT integration in RFCA for AF. 
Replacing MSCT would render the use of ICE cost-efficient and would reduce 
radiation exposure to the patient. Furthermore, the ability to acquire registered 
real-time anatomical information of important structures with ICE has a 
significant additional value compared to MSCT integration. 
 
Conclusions 
Using a novel mapping system that allows integration of ICE and 
electroanatomical mapping it is feasible to create a real-time registered 3D 
Integration of ICE and MSCT to guide RFCA for AF 
 187 
shell of LA and PV anatomy. Furthermore, the 3D map created with ICE can 
accurately be integrated with a MSCT surface image. This approach combines 
real-time anatomy with high detailed anatomy potentially providing highly 
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Introduction 
This case-report concerns a 10-year-old boy who previously underwent a 
Senning operation for transposition of the great arteries with an intramural 
course of the coronary arteries. The patient suffered from recurrent episodes of 
atrial tachycardia (AT) with 1:1 atrioventricular conduction which caused, in 
combination with dysfunction of the systemic right ventricle, hemodynamic 
instability. Unresponsive to antiarrhythmic drug treatment, the patient was 




Figure 1. A three-dimensional shell of the cardiac anatomy created with intracardiac echocardiography (ICE). 
Positioning the ICE catheter inside the systemic venous atrium (SVA), anatomical and surgical lines of 
conduction block were identified such as caval veins, tricuspid valve annulus and atrial baffle suture line. ICV 
= inferior caval vein, LPV = left pulmonary veins, PA = posterior-anterior view, PVA = pulmonary venous 
atrium, RAO = right anterior oblique view, RIPV = right inferior pulmonary vein, RSPV = right superior 
pulmonary vein, RV = right ventricle, SCV = superior caval vein. 
 
Electrophysiological examination and ablation 
The procedure was performed under general anesthesia. Because the AT 
caused hemodynamic instability, the mapping procedure was aimed at 
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identification of the arrhythmogenic substrate and critical isthmus of a 
presumed macro-reentrant circuit with only brief episodes of induced 
tachycardia. First, a registered three-dimensional (3D) shell of the cardiac 
anatomy was created on an electroanatomical mapping system (Cartosound, 
Biosense Webster, Diamond Bar, California, USA) using intracardiac 
echocardiography (ICE). By positioning the ICE catheter inside the systemic 
venous atrium, the entire cardiac anatomy could be visualized including 
structures that form a potential area of conduction block such as the caval 
veins, the tricuspid valve annulus and surgical suture lines (e.g. atrial baffle 
suture line)(Figure 1). Second, bipolar voltage mapping of the systemic venous 
atrium was performed during sinus rhythm to further evaluate the 
arrhythmogenic substrate and to confirm areas of conduction block caused by 
surgical incisions (Figure 2). An area of low voltages (>0.5 mV) and persistent 
double potentials was found near the inter-atrial septum, confirming the 
location of the atrial baffle suture line. Based on these findings and the current 
literature on tachycardia ablation in Senning patients,1 a selection of potential 
reentry circuit isthmus sites was made (Figure 2). Subsequently, the AT was 
induced and reentry was confirmed as the underlying mechanism by 
entrainment mapping at the selected sites. The responses to entrainment are 
given in figure 2. Pacing near the cavotricuspid isthmus (CTI) from inside the 
pulmonary venous atrium resulted in identical flutter-wave (F-wave) 
morphology in all 12 electrocardiogram leads and a post-pacing interval similar 
to the intraatrial reentrant tachycardia (IART) cycle length (Figure 2), indicating 
a CTI dependent flutter. Most likely, the reentrant circuit involved the posterior 
wall of the systemic venous atrium with the atrial baffle suture line acting as 
the posterior barrier, the anterior septal remnant and the CTI. A linear lesion 
was created between the tricuspid valve annulus and inferior caval vein (Figure 
3). During ablation, the IART cycle length progressively prolonged until finally 
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the IART terminated. Importantly, in Senning patients the CTI is divided into a 
systemic venous part and a pulmonary venous part by the atrial baffle. To 
assure a complete line of block, applications were delivered on both sides of 
the CTI. At the end of the procedure the IART was no longer inducible. During 
the 5-month follow-up period no recurrences have been observed.  
 
 
Figure 2. Bipolar voltage map of the systemic venous atrium (SVA) integrated with the three-dimensional 
shell of the cardiac anatomy created with intracardiac echocardiography in a posterior view. Bipolar voltages 
displayed in pink. Green dots represent sites with double potentials. Black dots represent sites selected for 
entrainment pacing during intraatrial reentrant tachycardia (IART). For each selected site the difference 
between post-
to entrainment pacing at the cavotricuspid isthmus is given (white box). The tracing includes surface 
electrocardiogram leads III, aVF, V1, V6 and intracardiac recordings from the reference catheter inside the 
SVA and the mapping catheter (p = proximal, m = mid and d = distal). Pacing was performed from the distal 
electrodes of the mapping catheter (first two beats on each tracing). ICV = inferior caval vein, MAP = 





Figure 3. Map containing voltage data of the systemic venous atrium (SVA) and anatomical data acquired 
with intracardiac echocardiography (seen from a right posterior oblique view; color coding similar as in figure 
2). The ablation catheter was positioned inside the pulmonary venous atrium using a retrograde approach. A 
linear radiofrequency (RF) lesion connecting the tricuspid valve annulus and inferior caval vein resulted in 
prolongation of the intraatrial reentrant tachycardia (IART) cycle length and eventually in IART termination 
(red dots represent RF ablation sites, white arrow indicates site of termination). Insets: catheter position 




Intra-atrial reentry is the most common mechanism for supraventricular 
tachycardia in patients with a Mustard or Senning baffle.1,2 Image integration 
(e.g. Multi-Slice Computed Tomography and electroanatomical mapping) can 
facilitate the ablation of these tachycardias by visualizing the complex cardiac 
anatomy and its relation to the position of the ablation catheter.3 However, the 
accuracy of image integration is limited by the quality of the registration 
process.4 Differences in heart rate, heart rhythm and fluid status can negatively 
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influence this process. In the present report, a new anatomical mapping 
technique is used to create a 3D anatomical map of the cardiac anatomy with 
ICE. This technique does not require a registration process and allows 
visualization of landmark structures with minimal radiation exposure. The 
anatomical information acquired with ICE in combination with rough voltage 
mapping enabled us to identify and confirm the critical isthmus by limited 
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A case of radiofrequency catheter ablation of atrioventricular (AV) nodal re-
entry tachycardia, in a patient with transposition of the great arteries after 
venous rerouting according to Mustard, is described. An electroanatomical 
map of the His and AV nodal region was created from inside the systemic 
venous atrium. Retrograde mapping of the pulmonary venous atrium was 
performed and the arterial catheter retracted to a position in close proximity to 
the venous catheter inside the intra-atrial baffle. This position was chosen to 
deliver radiofrequency current. 
Anatomical perspective on RFCA of AV NRT  after Mustard correction for transposition of the great arteries 
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Introduction 
Transposition of the great arteries (TGA) is a congenital cardiac malformation 
characterized by concordant atrioventricular (AV) and discordant ventriculo-
arterial connections that accounts for approximately 2.4% of all congenital 
heart diseases.1 Currently, anatomical correction of TGA by performing an 
arterial switch procedure is the treatment of first choice. This operation is 
regularly performed since the 1980s, before which surgical treatment consisted 
of physiological correction with venous rerouting of blood according to 
Mustard or Senning (Figure 1).2,3 Thus, the majority of adults with TGA have 
undergone either a Mustard or Senning procedure. Common complications 
following Mustard and Senning procedures include conduction disorders and 
arrhythmias, often of atrial origin. The mechanism most commonly described is 
intra-atrial re-entry based on scar tissue,4 whereas AV nodal re-entry is far less 
common. In patients with normal cardiac anatomy, radiofrequency catheter 
ablation (RFCA) is highly effective.5 Literature on RFCA in patients after venous 
switch procedures is, however, limited.4,6-8 
In this paper, we describe a case of RFCA of AV nodal re-entry 
tachycardia (AVNRT) performed in a patient with TGA treated by venous 
rerouting according to Mustard, with focus on the anatomical situation 
following this operation and implications for the ablation procedure. 
 
Case presentation 
A 24-year-old man was referred for recurrent episodes of narrow complex 
tachycardia, despite the use of different antiarrhythmic drugs. The patient was 
born with TGA, for which a Mustard operation was performed 2 weeks after 
birth. Tachycardia events had a sudden onset and its clinical signs were 
palpitations and laryngeal discomfort. Chemical cardioversion using adenosine 
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was necessary to terminate events. On physical examination, blood pressure 
was 140/85 mmHg and heart rate 65 beats per minute (bpm). The 
electrocardiogram showed right ventricular (RV) hypertrophy, consistent with a 
systemic RV after the Mustard procedure. Laboratory tests were normal. 
Transthoracic echocardiography showed a dilated RV with reasonable function 
(tricuspid annular plane systolic excursion 14 mm) and minor AV leakage. Given 
the frequent symptomatic recurrences, it was decided to perform an 
electrophysiological examination and subsequent ablation. 
 
Electrophysiological examination and ablation 
The procedure was performed under local anaesthesia and guided by 
fluoroscopy and a three-dimensional (3D) non-fluoroscopic mapping system 
-F ablation catheter 
(Navistar, Biosense Webster) and two 6-F quadripolar electrophysiological 
catheters were introduced through the right femoral vein into the systemic 
venous atrium (His position, systemic venous atrium, and left ventricle, 
respectively). A second 7-F ablation catheter was later inserted through the 
right femoral artery and guided via the aorta, RV, and tricuspid valve to the 
pulmonary venous atrium, containing the AV node. A bolus of intravenous 
Heparin (7,500 IU) was administered. 
At the beginning of the electrophysiological study, the patient was in 
sinus rhythm (cycle length [CL] 1,100 ms, AV 82 ms, His ventricular 40 ms). The 
antegrade Wenckebach point was at 300 ms and a significant A-His jump (53 
ms) was observed. The retrograde Wenckeback point was at 340 ms and there 
was concentric decremental ventriculoatrial (VA) conduction, suggesting that 
retrograde conduction occurred through the AV node. During catheter 
manipulation, there were spontaneous episodes of tachycardia with a cycle 
length of 370 390 ms and a short VA interval of 58 ms. Atrial and ventricular 
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extrastimulations could not reset the tachycardia and it was consistently noted 
that the tachycardia started with a prolongation of the atrial-to-His interval, all 
of this being compatible with the diagnosis common-type AVNRT.7 
Importantly, the tachycardia could reproducibly be induced by atrial electrical 




Figure 1. (panel A) Induction of the tachycardia by atrial programmed stimulation (100 mm/s). The tracing 
includes surface electrocardiogram leads I, V1, V6, and intracardiac recordings from electrophysiological 
catheters inside the systemic venous atrium (SVA) and left ventricle apex (LVa). In this tracing electrical 
stimulation with 400 ms (S1) and extrastimulation with 300 ms (S2) and 270 ms (S3) resulted in a critical 
prolongation of the atrioventricular (AV) time (190 240-446 ms) after which the tachycardia started (*). The 
tachycardia cycle length (CL) was 387 ms and the ventriculoatrial (VA) time was 58 ms. (panel B) Tracing of 
the tachycardia including a His registration (400 mm/s). The tracing includes surface electrocardiogram leads 
I, V1, V6, and intracardiac recordings from electrophysiological catheters inside the SVA, LVa, as well as from 
the mapping catheter, which was placed in His position. On the distal electrodes of the mapping catheter 




Next, to obtain a 3D reconstruction of the complex atrial anatomy, an 
electroanatomical map of the His and AV nodal region was created from inside 
the systemic venous atrium using the CARTO system. Anatomical references 
(including His position and AV node) were marked on the map (Figure 2). Well-
defined His signals as well as fragmented signals could be obtained from inside 
the intra-atrial baffle. However, since these signals were most likely derived 
from the AV node positioned in the posterior wall of the pulmonary venous 
atrium on the other side of the baffle, ablation at this site would mean that 
radiofrequency current had to be applied through the baffle. Although this was 
considered as an option, a direct approach via the pulmonary venous atrium 
was preferred to minimize the risk of injury to the baffle. Subsequently, 
retrograde mapping of the pulmonary venous atrium was performed by 
inserting the catheter through the femoral artery, passing the aorta, RV, and 
tricuspid valve into the pulmonary venous atrium. The arterial catheter was 
retracted to a position in close proximity to the venous catheter inside the 
intra-atrial baffle (Figure 2). This position was chosen to deliver radiofrequency 
current. Radiofrequency current was applied at 60 W with a maximum of 30 
seconds on each ablation site. Location markers were placed at each ablation 
site on the electroanatomical map to obtain optimal insight in catheter 
positions in relation to the AV node and His bundle. During ablation of the slow 
pathway, an accelerated junctional rhythm consistently occurred. After 
ablation, AVNRT could no longer be induced with induction pacing even after 
intravenous administration of isoprenaline. The patient remained free of 
tachycardia during follow-up (3 months), without antiarrhythmic medication. 
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Figure 2. Three-dimensional electroanatomical map of the atrioventricular junction. Left anterior (A) and 
right anterior (B) oblique views. Anatomical maps were obtained from the systemic venous atrium (SVA) and 
pulmonary venous atrium (PVA). Red dots implicate ablation points in the area of the AV node, posterior in 
the PVA, inferior to the intraatrial baffle. Yellow dots indicate the His position. (C) Fluoroscopy. A reference 
catheter (RC) is located high in the SVA and a mapping catheter (SVC = systemic venous catheter) inferiorly in 
the intraatrial baffle pointing in the direction where the AV node is located just inferior to the baffle. The 
arterial catheter has been inserted in a retrograde fashion via the aorta, right ventricle, and tricuspid valve 
into the pulmonary venous atrium (PVC = pulmonary venous catheter) that contains the AV node. This 
catheter was retracted to a position in close proximity to the catheter in the SVA, close to the AV node, as 
indicated by the yellow arrow. At this location, radiofrequency current was applied. (D) Scheme of the 
anatomy. The AV node is indicated as a yellow oval. LIPV = left inferior pulmonary vein; LSPV = left superior 
pulmonary vein; LVC = left ventricular catheter; MV = mitral valve; TV = tricuspid valve; VCI = inferior caval 




This report describes RFCA of AVNRT in a patient after venous rerouting 
according to Mustard. In patients with normal cardiac anatomy, ablation of 
AVNRT is usually performed by a transvenous approach. In patients with TGA, 
the location of the AV node inside the right atrium is similar to patients with 
normal cardiac anatomy. However, after venous rerouting the caval veins drain 
into the systemic venous atrium/intra-atrial baffle, connected to the LV. As a 
consequence, the AV node is localized inside the pulmonary venous part of the 
atria and cannot be reached through a transvenous approach. Although a 
transbaffle approach to ablate AVNRT has been described,8 this approach 
constitutes the risk of damaging the intra-atrial baffle, thereby creating a shunt 
between the systemic venous and pulmonary venous atria with the risk of 
hemodynamic overload or paradox embolism. Cryoablation is an alternative; 
however, there are reports indicating that this approach may be more time 
consuming with higher recurrence rates.9 Still, its application might prove safer 
in terms of catheter stability in patients with complex anatomy. In the current 
situation, we preferred the arterial, retrograde approach. A disadvantage of this 
approach may be the difficult positioning of the catheters. Therefore, optimal 
insight and knowledge of the anatomy is mandatory. In the present report, we 
describe this procedure using intraoperative fluoroscopy and CARTO mapping. 
A disadvantage of the retrograde arterial approach in ablation of 
AVNRT in Mustard patients is the relatively sharp angle that the ablation 
catheter must make in order to reach the location of the AV node. The venous 
catheter in the baffle toward the mitral valve (below which the AV node is 
located) can be used to guide the arterial catheter in the pulmonary venous 
atrium, as was described in our case. Also, the use of multidirectional steerable 
catheters may facilitate ablation using the arterial approach. 
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Samenvatting en conclusie 
De algemene introductie van deze thesis geeft een overzicht van het belang 
van pre-procedurele diagnostiek bij patiënten die in aanmerking komen voor 
radiofrequente catheter ablatie (RFCA) voor atriumfibrilleren (AF). Nieuwe 
echocardiografische technieken om atriale remodelering op te sporen worden 
besproken, alsmede de plaats van de cardiale computed tomography (CT) en 
natriuretische peptiden binnen de pre-procedurele evaluatie. Daarnaast wordt 
een overzicht gegeven van het gebruik van beeldvormende technieken tijdens 
RFCA van complexe atriale ritmestoornissen en worden de voor- en nadelen 
van de meest gebruikte modaliteiten besproken. Ten slotte wordt de integratie 
van verschillende beeldvormingsmodaliteiten besproken met als doel de 
individuele beperkingen van de verschillende technieken te compenseren. 
 
Deel I: Pre-procedurele evaluatie voorafgaand aan radiofrequente 
catheter ablatie voor atriumfibrilleren 
Het eerste deel van deze thesis richt zich op de rol van echocardiografie, 
cardiale CT en natriuretische peptiden om patiënten te identificeren met een 
hoge kans op sinus ritme na RFCA voor AF. 
 Hoofdstuk 1 betreft een editoriaal commentaar over de beperkingen 
van linker boezem grootte als voorspeller van recidief AF na RFCA. De grootte 
van de linker boezem wordt over het algemeen bepaald door de anterior-
posterior diameter te meten gebruikmakend van twee-dimensionele 
echocardiografie. Echter de vergroting van de linker boezem kan asymmetrisch 
zijn en daarom zou een drie-dimensionele evaluatie wellicht een beter 
weergave geven van de werkelijke grootte. Een drie-dimensionele meting van 
de linker boezem grootte kan worden verkregen middels cardiale CT, drie-
dimensionele echocardiografie en magnetische resonantie imaging. 
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 In Hoofdstuk 2 wordt calibrated integrated backscatter gebruikt om 
echocardiografisch de mate van linker boezem fibrosering (verlittekening) in te 
schatten en dit te relateren aan de effectiviteit van RFCA voor AF. Calibrated 
integrated backscatter is een echocardiografische techniek waarmee 
weefselkarakterisering kan worden verricht op basis van de weerkaatsing van 
ultrasoon geluid. In een groep van 170 patiënten bleek een hoge mate van 
fibrosering van de linker boezem voorspellend te zijn voor een AF recidief na 
RFCA (OR 1.217 per dB, p<0.001). Daarnaast bleek dat het gecombineerd 
inschatten van de hoeveelheid linker boezem fibrosering en linker boezem 
grootte een significante verbetering gaf van de precisie waarmee patiënten 
met een grote kans op een succesvolle ablatie konden worden geïdentificeerd. 
  Hoofdstuk 3 beschrijft de invloed van de totale atriale geleidingstijd 
op de effectiviteit van RFCA voor AF. De totale atriale geleidingstijd geeft een 
indruk van de mate waarin er zowel elektrische als structurele remodelering 
van de boezems heeft plaatsgevonden waardoor AF kan ontstaan en in stand 
wordt gehouden. De totale atriale geleidingstijd wordt gemeten middels tissue 
Doppler imaging door de tijd te meten tussen het begin van de p-golf in 
-golf op de tissue 
Doppler opname van de laterale wand van de linker boezem (PA-TDI tijd). De 
PA-TDI tijd bleek beter in staat om een recidief AF na RFCA te voorspellen dan 
conventionele maten zoals linker boezem grootte (receiver-operator 
characteristics analyses: area under the curve 0.765 vs. 0.561, respectievelijk). 
 In Hoofdstuk 4 wordt de invloed onderzocht van coronarialijden op de 
effectiviteit van RFCA voor AF. In een populatie van 125 patiënten werd de 
aanwezigheid en uitgebreidheid van coronarialijden bepaald door middel van 
een cardiale CT scan (coronair angiografie en/of calcium score) en dit werd 
gerelateerd aan het optreden van een recidief AF. De aanwezigheid en de 
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uitgebreidheid van coronarialijden had geen invloed op de effectiviteit van 
RFCA voor AF. 
 Naast informatie over de aanwezigheid en uitgebreidheid  van 
coronarialijden biedt cardiale CT ook informatie over de anatomie van de 
pulmonaal venen en de linker boezem grootte. In Hoofdstuk 5 wordt de 
invloed van pulmonaal venen anatomie, pulmonaal venen dimensies en linker 
boezem dimensies op de effectiviteit van RFCA voor AF bestudeerd. Een 
atypische configuratie van de rechtzijdige pulmonaal venen, gedefinieerd als 
een extra uitmondende pulmonaal vene, was aanwezig bij 17% van de 
patiënten en was geassocieerd met een lager risico op een AF recidief. Er werd 
geen relatie gevonden tussen linkszijdige pulmonaal venen anatomie en de 
effectiviteit van RFCA voor AF. Pulmonaal venen dimensies waren eveneens 
niet voorspellend voor de effectiviteit van RFCA. Linker boezem grootte 
gemeten met CT bleek een grotere voorspellende waarde te hebben voor een 
AF recidief dan linker boezem grootte gemeten met twee-dimensionele 
echocardiografie.  
In Hoofdstuk 6 wordt de waarde van natriuretische peptiden (NT-
proANP en NT-proBNP) bestudeerd in de evaluatie van patiënten voorafgaand 
aan RFCA voor AF. In theorie kunnen natriuretische peptiden een aanwijzing 
geven over de aanwezigheid van een cardiaal lijden dat de effectiviteit van 
RFCA voor AF beperkt. Bij 87 patiënten met symptomatisch medicatie-resistent 
AF werden voor de procedure de bloedspiegels van NT-proANP en NT-proBNP 
bepaald. Alle bloedmonsters werden afgenomen tijdens sinus ritme om een 
potentieel vertroebelend effect van het AF op de natriuretische peptide 
spiegels te voorkomen. Na een follow-up van 12 maanden bleek het pre-




Het eerste deel van deze thesis suggereert dat uitgebreide evaluatie 
van het aritmogene substraat van de boezems, daarin meenemende de 
hoeveelheid fibrosering en de elektromechanische eigenschappen, een betere 
patiënt selectie mogelijk maakt dan aan de hand van linker boezem grootte 
alleen. Daarnaast suggereren de uitslagen dat het pre-procedureel meten van 
de natriuretische peptiden een sensitief middel biedt voor het bestaan van een 
aritmogeen substraat buiten de tijdens RFCA aangepakte pulmonaal venen 
regio. 
 
Deel II: Beeldvormende technieken ter ondersteuning van radiofrequente 
catheter ablatie van complexe atriale ritmestoornissen 
Het tweede deel van deze thesis beschrijft de rol van beeldvormende 
technieken en de integratie hiervan tijdens RFCA voor complexe atriale 
ritmestoornissen. Om dit soort procedures uit te kunnen voeren is een 
nauwkeurige beeldvorming van de intracardiale catheters in relatie tot de 
cardiale anatomie noodzakelijk. Daarnaast is, gezien de aanzienlijke stralen 
belasting voor zowel de patiënt als de operateur, de behoefte aan niet-
ioniserende beeldvormende modaliteiten groot. 
 Hoofdstuk 7 beslaat een overzicht van de verschillende toepassingen 
van intracardiale echocardiografie tijdens interventie en elektrofysiologische 
procedures. Intracardiale echocardiografie wordt verricht met een speciale 
catheter, uitgerust met een ultrasone transducer op de punt, die in de rechter 
boezem of de rechter ventrikel wordt gepositioneerd. Intracardiale 
echocardiografie verstrekt real-time anatomische informatie zonder 
stralingsbelasting en kan gebruikt worden tijdens RFCA procedures. Echter, op 
dit moment is intracardiale echocardiografie een twee-dimensionele modaliteit 
en is het niet in staat de hoge mate van detaillering te leveren die cardiale CT 
wel heeft. 
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 In Hoofdstuk 8 wordt de integratie tussen intracardiale 
echocardiografie, elektroanatomisch mappen en cardiale CT beschreven om 
RFCA voor AF mee te faciliteren. Hiervoor wordt een nieuw elektroanatomisch 
mapping system gebruikt dat in staat is om de positie te bepalen van een 
speciaal ontworpen echocardiografie catheter en daarmee het twee-
dimensionele echo beeld in de drie-dimensionele mapping omgeving kan 
projecteren. Door het markeren van de endocardiale contouren van de linker 
boezem en pulmonaal venen op de verschillende echo beelden werd er een 
drie-dimensionele kaart gecreëerd van de linker boezem op het 
elektroanatomische mapping systeem. Daarna werd een CT scan van de linker 
boezem in het mapping systeem geladen en geïntegreerd met de verkregen 
drie-dimensionele kaart. In een groep van 17 patiënten bleek het mogelijk om 
een drie-dimensionele kaart te creëren van de linker boezem door middel van 
intracardiale echocardiografie met een gemiddelde van 31.1 ± 8.5 contouren. 
De integratie met cardiale CT resulteerde in een gemiddelde afstand tussen 
kaart en CT reconstructie van 2.2 ± 0.3 mm. Drie-dimensioneel mappen met 
intracardiale echocardiografie liet een hoge sensitiviteit zien om de pulmonaal 
venen te detecteren en visualiseren. 
 Hoofdstuk 9 bestaat uit een case-report over de integratie van 
intracardiale echocardiografie en elektroanatomisch mappen om de ablatie 
van een atriale tachycardie te faciliteren bij een jonge patiënt die in het 
verleden een Senning operatie heeft ondergaan vanwege een transpositie van 
de grote vaten. De ritmestoornis leidde tot hemodynamische instabiliteit 
waardoor de mogelijkheid tot activatie mapping tijdens tachycardie werd 
beperkt. Door de anatomische informatie verkregen met intracardiale 
echocardiografie in combinatie met het grof in kaart brengen van de atriale 
voltages bleek het mogelijk om de kritische isthmus te identificeren door 
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middel van entrainment mapping op een beperkt aantal geselecteerde posities 
en tijdens slechts korte episodes van tachycardie. 
 Hoofdstuk 10 beschrijft de casus van een 24-jarige man die in het 
verleden een Mustard operatie onderging vanwege een transpositie van de 
grote vaten. Hij werd verwezen vanwege recidiverende tachycardieën. Het 
elektrofysiologisch onderzoek toonde een AV-knoop re-entry tachycardie aan. 
Daaropvolgend werd elektroanatomische mapping verricht om de complexe 
cardiale anatomie in beeld te brengen en vervolgens succesvol RFCA te 
verrichten van het langzame pad. Afsluitend wordt een beschouwing gegeven 
van de veranderde anatomische situatie na een Mustard operatie.   
 
Conclusies 
De implementatie van nieuwe echocardiografische technieken om atriale 
remodelering te meten alsmede het gebruik van natriuretische peptiden in de 
beoordeling van patiënten voorafgaand aan RFCA voor AF, verbetert de 
identificatie van diegenen met een hoge kans om sinus ritme te verkrijgen na 
de procedure. De integratie van verschillende beeldvormende modaliteiten 
tijdens RFCA van complexe atriale ritmestoornissen stelt de operateur in staat 
om belangrijke cardiale structuren te herkennen, reduceert logischerwijs de 
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Summary and conclusion 
The general introduction outlines the role and importance of pre-procedural 
evaluation of patients undergoing RFCA for AF. Novel echocardiographic 
techniques to estimate atrial remodelling are discussed as well as the role of 
MSCT and natriuretic peptides during the pre-procedural evaluation. In 
addition, the use of imaging and image integration during RFCA for complex 
atrial arrhythmias is discussed. An overview of the advantages and limitations 
of the most common used imaging modalities is provided and the benefit of 
image integration to overcome these limitations is discussed. 
 
Part I: Pre-procedural evaluation of patients undergoing radiofrequency 
catheter ablation for atrial fibrillation 
The first part of this thesis discusses the role of echocardiography, MSCT and 
natriuretic peptides in the pre-procedural evaluation to identify patients with a 
high likelihood to maintain sinus rhythm after RFCA for AF.  
Chapter 1 comprises an editorial comment about the limitations of left 
atrial size as a predictor of AF recurrence after RFCA. Left atrial size is commonly 
estimated by measuring the anterior-posterior left atrial diameter on two-
dimensional echocardiography. However as left atrial enlargement may not be 
symmetrical, a 3-dimensional evaluation provides a more accurate estimate of 
true left atrial size. Three-dimensional measurement of left atrial size can be 
performed MSCT, 3-dimensional echocardiography and magnetic resonance 
imaging. 
 In Chapter 2, echocardiography derived calibrated integrated 
backscatter is used to estimate the extent of left atrial fibrosis and to relate this 
to the outcome of RFCA for AF. Calibrated integrated backscatter is an 
echocardiographic technique that allows tissue characterisation based on 
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ultrasound reflectivity. In a group of 170 patients undergoing RFCA for AF, a 
high extent of left atrial fibrosis was an independent predictor of AF recurrence 
(OR 1.217 per dB, p<0.001). Moreover, the combined assessment of left atrial 
fibrosis and left atrial size significantly improved the accuracy to identify 
patients with a high likelihood to maintain sinus rhythm. 
 Chapter 3 describes the impact of total atrial conduction time on the 
efficacy of RFCA for AF. Total atrial conduction time reflects the extent of both 
electrical and structural remodelling of the atria and can be assessed using 
tissue Doppler imaging by measuring the time delay between the onset of the 
P- -wave on the tissue Doppler 
tracing of the left atrial lateral wall (PA-TDI duration). The PA-TDI duration 
demonstrated a superior accuracy to predict AF recurrence after RFCA 
compared to left atrial size (receiver-operator characteristics analyses: area 
under the curve 0.765 vs. 0.561, respectively).  
 In Chapter 4, the impact of coronary artery disease on the efficacy of 
RFCA for AF is studied. In a population of 125 consecutive patients MDCT is 
used to determine the presence and extent of coronary artery disease 
(coronary angiography and/or coronary calcium score) prior to RFCA for AF. 
The presence and extent of coronary artery disease had no negative impact on 
the efficacy of RFCA for AF.  
 In addition to information about the presence of coronary artery 
disease, multi-slice computed tomography provides information about the 
pulmonary veins and left atrial dimensions. Chapter 5 studies the impact of 
pulmonary vein anatomy and dimensions, as well as left atrial dimensions, on 
the efficacy of RFCA for AF. Atypical anatomy of the right-sided pulmonary 
veins, defined as an additional right pulmonary vein, was present in 17% of 
patients and was associated with a lower risk for AF recurrence after RFCA. Left 
sided pulmonary vein anatomy as well as pulmonary vein dimensions were not 
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predictive for AF recurrence after RFCA. Left atrial size measured by MSCT 
demonstrated a superior accuracy to predict AF recurrence compared to left 
atrial size on two-dimensional echocardiography. 
Finally, Chapter 6 describes the role of natriuretic peptides (NT-proANP 
and NT-proBNP) in the pre-procedural evaluation of patients undergoing RFCA 
for AF. Theoretically, natriuretic peptides can provide information about the 
presence and severity of a previously undetected cardiac condition limiting the 
efficacy of RFCA for AF. In 87 patients with symptomatic drug-refractory AF, 
pre-procedural serum levels of natriuretic peptide levels were determined. 
Importantly, all samples were collected during sinus rhythm to avoid the 
potentially obscuring effect of AF on the natriuretic peptide levels. After a 
follow-up of 12 months, pre-procedural NT-proBNP was an independent 
predictor of AF recurrence after RFCA.  
The first part of this thesis suggests that comprehensive evaluation of 
left atrial substrate, taking into consideration the extent of atrial fibrosis and 
electromechanical properties, may provide a better identification of patients 
who will benefit from RFCA for AF than measurement of left atrial dimensions. 
Furthermore, measurement of natriuretic peptides levels may provide a more 
sensitive marker for the presence of non-pulmonary vein related 
arrhythmogenic substrate to develop AF. 
 
Part II: Imaging to facilitate radiofrequency catheter ablation of complex 
atrial arrhythmias 
The second part of this thesis describes the role of imaging and image 
integration to facilitate RFCA of complex atrial arrhythmias. To perform these 
procedures, accurate visualization of the intracardiac catheters in relation to 
the cardiac anatomy is crucial. Furthermore, as these procedures are associated 
 
 222 
with a high radiation exposure to both patient and operator, the need for non-
fluoroscopic imaging modalities has increased. 
 Chapter 7 comprises an overview of the use of intracardiac 
echocardiography during interventional and electrophysiological procedures. 
Intracardiac echocardiography is performed using a catheter with an 
ultrasound transducer at its tip which is typically positioned inside the right 
atrium or right ventricle. Intracardiac echocardiography provides real-time 
information about the cardiac anatomy without radiation exposure and can be 
used to guide RFCA procedures. However, currently intracardiac 
echocardiography is a 2-dimensional imaging modality and does not provide 
the highly detailed anatomical information that multi-slice computed 
tomography does. 
 In Chapter 8 the integration of intracardiac echocardiography, 
electroanatomical mapping and MSCT to guide RFCA for AF is described. A 
novel electroanatomical mapping system was used that allows tracking of a 
specifically designed ultrasound catheter thereby allowing to project the 2-
dimensional ultrasound image into its 3-dimensional mapping environment. 
By tracing the endocardial contours of the left atrium and pulmonary veins on 
these ultrasound images a 3-dimensional map was created on the 
electroanatomical mapping system. Finally, a pre-procedurally acquire MSCT 
image of the left atrium was uploaded to the mapping system and integrated 
with the 3-dimensional map. In a group of 17 patients, 3-dimensional mapping 
of the left atrium using intracardiac echocardiography was feasible with a 
mean of 31.1 ± 8.5 contours. Integration with multi-slice computed 
tomography resulted in a mean distance of 2.2 ± 0.3 mm between the map and 
the multi-slice computed tomography image. Three-dimensional mapping 
using intracardiac echocardiography demonstrated a high sensitivity to detect 
and visualize the pulmonary veins. 
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 Chapter 9 comprises a case-report about the integration of 
intracardiac echocardiography and electroanatomical mapping to facilitate 
ablation of an atrial tachycardia in a young patient who previously underwent 
a Senning operation for transposition of the great arteries. The arrhythmia 
caused hemodynamic instability thereby limiting activation mapping of the 
presumed macro-reentrant circuit during on-going tachycardia. However, the 
anatomic information acquired with intracardiac anatomy in combination with 
rough voltage mapping enabled the identification and confirmation of the 
critical isthmus by limited entrainment mapping at selected sites during only 
brief episodes of tachycardia. 
 Finally, Chapter 10 describes the case of a 24-year-old male who 
previously underwent a Mustard operation for transposition of the great 
arteries and suffered from recurrent episodes of tachycardia. The 
electrophysiological examination revealed an atrioventricular nodal re-entry 
tachycardia. Subsequently, electroanatomical mapping was performed to 
visualize the complex cardiac anatomy and successfully guide RFCA of the 
slow-pathway. In addition, an anatomical perspective is provided about the 
cardiac anatomy following a Mustard operation. 
 
Conclusions 
Implementation of novel echocardiographic techniques to measure atrial 
remodelling as well as natriuretic peptide levels in the assessment of patient 
undergoing RFCA for AF improves the identification of those with a high 
likelihood to maintain sinus rhythm after the procedure. Moreover, integration 
of multiple imaging modalities during RFCA of complex atrial arrhythmias 
allows for an improved identification of important cardiac structures, reduced 
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